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Abstract
Microglia, the resident macrophages of the central nervous system (CNS), 
are the primary cell to respond to injury in the brain, both in inflammation e.g. in multiple 
sclerosis (MS), and in trauma. Microglia can be activated in vitro by proinflammatory 
cytokines such as IFNy and TNFa and respond by secretion of cytokines, chemokines, 
proteases, nitric oxide and superoxide radicals
As MS is a putative autoimmune disease of the CNS, chemokines 
(chemotactic cytokines), secreted by many cell types including T cells and macrophages 
in MS lesions, have been postulated as key players in the orchestration of the 
inflammatory response by recruitment and activation of inflammatory cells.
As potential mediators of microglial cell recruitment to sites of injury, the ability of 
microglia to migrate in response to a  and p chemokines was assessed. All chemokines 
tested demonstrated the ability to induce migration and changes in the distribution of 
filamentous actin in adult rat microglia and a human microglial cell line, CHME3, in 
vitro. This study indicates that chemokines secreted by activated T cells in the CNS may 
attract microglia to areas of central nervous system inflammation where they could exert 
their well documented effects.
Proteases are also found in close proximity to MS plaques in increased 
amounts as agents of myelin breakdown in MS. Matrix metalloproteinases (MMPs) are 
zinc-dependant enzymes, capable of degrading extracellular matrix proteins and are 
known to be produced by microglia. The control of MMP activity by plasmin, as well as 
the balance between MMP and levels of their natural inhibitors, TIMPs, may determine 
lytic or anti-lytic activity in MS. The in vitro control of MMPs 2 and 9, TIMPs 1 and 2 
and urokinase type plasminogen activator (uPA) by microglia was examined in response 
to several chemokines using ELISA and zymography techniques. The chemokines tested 
were all found to significantly increase the secretion of MMPs and TIMPs by CHME3 
cells after 24 hours stimulation. The chemokines, MCP1, MIPlp and Fractalkine were 
also shown to increase MMP9 secretion by rat microglia with little or no effect on 
MMP2. Interestingly, MCP1, MIPla/p and RANTES significantly decreased the 
secretion of uPA by CHME3 cells which may indicate an increase in uPAR expression. 
These results suggest that chemokine mediated control of MMP activity in the 
breakdown of the blood brain barrier could allow further recruitment of immune cells 
into the CNS and also cause demyelination of axons by lysis of myelin basic protein.
Since chemokines, as well as cytokines, are possible candidates for 
microglia activation, microglia were tested in their response to several chemokines by 
measurement of nitrite production, superoxide secretion and Fc receptor expression. The 
majority of the chemokines tested were able to increase superoxide and nitrite 
production as well as Fc receptor expression with the exception of the J3 chemokine, 
RANTES, whereby only CHME3 cells produced a significant increase in superoxide 
production and Fc receptor expression above unstimulated levels suggesting a difference 
in chemokine receptor expression or a difference in the binding affinity and signal 
transduction in different cell types.
The present study has led to a further understanding of the possible 
chemokine control of microglial migration, proteinase production and effector function in 
CNS diseases, as well as their well documented role in recruitment of lymphocytes. 
Targetting these chemokines in MS patients, with specific antibodies or use of synthetic 
inhibitors to block their receptors may lead to downregulation of the immune response 
and a decrease in the severity of the disease.
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CHAPTER 1
1. GENERAL INTRODUCTION
1.1 Cells of the central nervous system
The cell types of the central nervous system (CNS) include neuronal and non 
neuronal cell types, or glial cells. Glial cells include microglia, astrocytes and 
oligodendrocytes. In the mammalian CNS, astrocytes and oligodendrocytes outnumber 
neurons (Perry, 1994). The myelin sheaths which surround and insulate nerve axons are 
synthesised by oligodendrocytes. The functions of astrocytes are numerous and include 
production of growth factors, metabolism of neurotransmitters and maintenance of 
homeostasis (Savchenko etal, 1997). The major cytoskeletal protein of astrocytes is glial 
fibrillary acidic protein (GFAP) which allows the identification of these cells by 
immund cyto chemi stry. Microglia are the resident phagocytic cells of the CNS.
1.1.1 IVticroglia
It was once thought that the CNS was an immunologically privileged site, based 
on observations that the CNS was not able to reject allografts. However it has now 
become clearer that the CNS is not defenceless and that microglia, the resident brain 
macrophages, provide the brain’s immune defence (Gremo et al, 1997, Carson and 
Sutcliffe, 1999, Kreutzberg, 1996). Del Rio-Hortega, in 1932 established the basic 
characteristics of microglial cells using silver staining methods and light microscopy 
(Theele and Streit, 1993). Their existence was questioned by some scientists until the 
advent of antibodies which allowed reproducible visualisation of these cells in tissue
l
sections. Multiple forms of this cell type have now been characterised and termed 
amoeboid, ramified and reactive microglia (Thomas, 1992). Amoeboid microglia are 
present in developing brain tissue and are typical of macrophages whereas ramified 
microglia are found in normal adult tissue and possess a small cell body with many 
branches (Thomas, 1992, Perry and Gordon, 1988). Reactive microglia arise in adult 
tissue after injury or infection and are characterised by their lack of ramified processes 
e.g. following facial nerve transection, experiments show retraction of these long delicate 
branches into the oval reactive form (Streit and Graeber, 1993). These parenchymal 
microglia differ from another subset of macrophage like cells found in the perivascular 
space in close association with the vascular endothelium and the blood brain barrier 
(Hickey and Kimura, 1988). These cells are capable of antigen presentation and could be 
considered as a distinct macrophage population which undergo constant replacement by 
bone marrow precursor cells.
1.1.2 Distribution of microglia
Studies of microglia in situ using various specific antibodies has allowed their 
distribution to be identified. Microglia in the cortex of rats were shown to be fairly 
uniformly distributed but with higher densities in the frontal lobe. The lowest densities of 
microglia were found in the cerebellum and medulla oblongata and overall the density 
was lower in the gray matter than the white matter (Savchenko et al, 1997). The 
numbers of microglia in normal appearing white matter of the human brain have been 
estimated at 13-15% of all cells (Hayes et al, 1987). Although densities vary throughout 
the brain, the distribution within particular structures are normally highly regularly 
spaced, each with its own territory and when more microglia are present, the territory of 
each is smaller (Perry, 1994).
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1.1.3 The origin of microglia
The origin of microglia is not conclusive although evidence suggests that 
microglia have more in common with peripheral macrophages than with other cells of the 
CNS (Perry, 1994, Altman, 1994). It is believed that cells of bone marrow origin, 
colonise the CNS and this colonisation is finished in the early postnatal period. These 
amoeboid microglia, later develop into the adult ramified microglia (Leong and Ling, 
1992, Ling and Wong, 1993). An important difference between parenchymal microglia 
and other macrophage populations, is that most macrophages have a relatively short 
lifespan whereas parenchymal microglia can live as long as the organism (Carson and 
Sutcliffe, 1999). Resident tissue macrophages are involved in homeostatic control and 
defence of the organism against infection and injury and brain microglia share these 
functions.
1.1.4 Markers expressed bv microglia
Microglia, like other macrophages, express a wide range of surface and 
cytoplasmic markers which make them distinct. Hayes et al, 1988 used a panel of 
monoclonal antibodies to characterise isolated human and rat adult microglia. Both rat 
and human microglia were found to express the complement receptor C3b which is 
involved in the binding of complement opsonised particles. Adult human (Williams et al 
1992) and neonatal rat microglia expressed macrophage cytoplasmic antigens (EBM-11 
and EDI antibodies respectively). Complement receptor C3b was also found to be 
expressed and intensely stained in amoeboid microglia in the early postnatal rat although 
the staining intensity diminished in the late postnatal period as the cells became ramified 
(Ling et al, 1990). Human microglia express MHC (major histocompatibility complex) 
class II antigens (Hayes et al, 1987) which is an important molecule in the presentation
of antigen to T cells in the immune response. This is in contrast with rat microglia which 
express little or no MHC II constitutively although expression can be induced by 
stimulation with interferon gamma (IFNy) (Woodroofe et al, 1989). Markers for non­
specific esterase are often used to identify monocytes which is also present in amoeboid 
microglia but not in the adult ramified microglia (Hayes et al, 1988, Thomas, 1992). 
Other commonly used markers for microglia expressed on both the ramified and 
amoeboid forms are the plant lectins, B4 isolectin and agglutinin-120. These lectins bind 
to the microglia recognising D- galactose and within the brain parenchyma, do not label 
neurons, astrocytes or oligodendrocytes showing their selectivity for microglia (Thomas,
1992).
Fc receptors are found on developing and adult rodent microglia (Perry and 
Gordon, 1988) and adult human microglia (Hayes et al 1988) and like the complement 
receptors, are important in binding of antibody opsonised particles. Microglia, like other 
macrophages are phagocytic which is proven by their ability to ingest antibody coated 
erythrocytes (Hayes et al, 1988, Hall et al 1997) and the ability of amoeboid microglia to 
phagocytose opsonised and non opsonised latex beads (Bocchini et al 1988).
1.1.5 The role of microglia in the normal CNS
During development of the CNS, immature microglia invading the tissue are 
thought to phagocytose dying cells and selectively eliminate certain axonal projections in 
the cerebral cortex (Thomas, 1992) as well as stimulating astrocyte proliferation by the 
secretion of interleukin l(IL-l) (Giulian et al 1988a+b) It is more difficult to elucidate 
the homeostatic function of ramified microglia in the adult CNS. One proposal is that 
they play an important role in ‘fluid cleansing’ of extracellular fluid in their 
microenvironments due to observations on their high levels of motility and pinocytosis in
4
living cerebral cortical cultures (Booth and Thomas, 1991). This is thought to contribute 
to tissue maintenance by the removal of cellular metabolites.
1.1.6 The effects of Interferon y on microglia
Cytokines found in the normal and diseased CNS have a wide range of effects on 
microglia demonstrated mainly by in vitro experiments. MHC class II expression can be 
greatly increased on rat microglia by stimulation with IFNy (Woodroofe et al, 1989). 
This effect on rat microglia has been shown to be inhibited by interferon beta (IFNP) 
although it had no effect on basal levels of MHC class II expression (Hall et al, 1997). 
The upregulation of MHC class II by IFNy was also confirmed in experiments using 
human microglia (Williams et al, 1992). The Fc receptor expression by rat microglia can 
also be upregulated by IFNy (Woodroofe et al, 1989, Hall et al, 1997) and IFNP (Hall et 
al 1997).
1.1.7 Microglia in CNS disease
It is apparent that microglia contribute to a wide range of CNS pathologies and 
are often the first cell type to respond to an insult, although they can be the targets of 
infection for example in HIV infection of the CNS (Dickson et al, 1993). They appear to 
be detrimental in many diseases but can also be beneficial to repair. Giliad and Giliad 
(1995), describe evidence of the accumulation of nerve growth factor by microglia but 
not astrocytes, which may be important after CNS trauma for nerve cell survival. A 
model of facial nerve axotomy in the rat has been used extensively to study the response 
of microglia to injury. Microglia proliferate at the site of injury within 24 hours and 
produce macrophage colony stimulating factor (M-CSF) just 24 hours after the injury. 
One week after axotomy a small proportion of microglia in the vicinity express MHC
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class II which was seen to last for up to 15 weeks (Streit and Graeber, 1993). Microglia 
produce a similarly rapid response to inflammation within the CNS. Microglia isolated 
from inflamed rat brain, 7 days after induction by a viral infection, showed an 
upregulation of MHC II (Sedgewick et al, 1991). In an experimental glioma model 
produced in rats, there was a massive infiltration into the tumour by activated microglia 
(Morioka et al, 1992). Furthermore, amoeboid microglia in culture have been shown to 
be cytotoxic to tumour cells by production of tumour necrosis factor alpha (TNFa) (Frei 
etal, 1987).
Microglia are implicated in the pathogenesis of neurodegenerative diseases such 
as Alzheimer’s disease and amyotrophic lateral sclerosis, due to observations on their 
state of activation in tissue sections and upregulation of cell surface markers including 
MHC II and Fc receptors (McGeer et al, 1993) Furthermore, they have been shown to 
accumulate on Alzheimer’s plaques in vitro (Joshi and Crutcher, 1998). N9 cells, a 
murine microglial cell line has been demonstrated to bind to beta amyloid fibrils, the 
major components of senile plaques, through the expression of a scavenger receptor, 
SRA (El Khoury et al, 1998) this is proposed as a trigger for the secretion of 
neurotoxins. A mouse model of Parkinson’s disease demonstrated an increased number 
of MHC class II expressing microglia associated with the induced neurodegeneration, 
which were less branched in morphology when compared to control brain (Kurkowska- 
Jastrzebska et al, 1999). Giese et al (1998), found that accumulation of microglia as well 
as cellular expression of prion proteins (PrP) in vitro was necessary for the neurotoxicity 
of prion protein in mouse brain cultures. A chemical (L-Leucine Methyl Ester) that 
selectively kills microglia, blocked the neurotoxicity of PrP. Activated microglia were 
also shown to be present in vivo in prion infected mice with the time course of activation 
and distribution closely resembling the pattern of PrP deposition. Immunocytochemical
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studies on CNS tissue from the human prion disease, Creutzfeld-Jacob disease (CJD), 
also showed a high density of microglia associated with PrP deposits although microglia 
did not appear to be involved in PrP processing (Muhleisen et al, 1995). More recent 
studies have shown that the activated microglia expressing increased MHC II associated 
with spongiform degeneration, show cytoplasmic vacuolation suggesting they may also 
be targets of CJD (Eitzen et al, 1998). Microglia have also been shown to be present at 
an increased density in the temporal and frontal cortex of chronic schizophrenics possibly 
indicating changes in the architecture of the cortex (Radewicz et al, 1998).
1.1.8 The role of microglia in MS
The most widely studied CNS disease in relation to the involvement of microglia 
is multiple sclerosis (MS) and also the animal model of MS, experimental autoimmune 
encephalomyelitis (EAE) (Benveniste, 1997). Microglia appear to play a key role in the 
pathogenesis of MS due to their rapid activation upon a number of insults, their 
inducibility in the expression of MHC class II molecules, their motility and phagocytic 
abilities and close proximity to perivascular cuffs (Gehrmann et al, 1995).
Several groups have described the distribution of macrophages and microglia in 
MS plaques (Woodroofe et al, 1986, Esiri and Reading, 1987, Li et al 1993). The 
macrophages in the active MS lesion often have ingested myelin fragments and stain 
strongly for MHC II, suggesting that the myelin processing may be responsible for 
activation of these cells. Microglia are present in an activated state throughout the 
normal appearing white matter which surround active plaques. In some cases, microglia 
in normal appearing white matter are stained by oil red O, demonstrating the presence of 
neutral lipids, resulting from the degradation of myelin (Li et al, 1993) This suggests that 
microglia are involved in very early myelin processing events, which may then lead on to
activation of specific immune responses. Demyelination occurs as the lytic dissolution of 
myelin from axons close to macrophages. Myelin phagocytosis by macrophages is 
brought about by attachment of myelin debris to clathrin coated pits on macrophages of 
monocytic and microglial lineage (Hartung, 1995, Raine, 1994). This process also occurs 
in the experimental model of EAE in rabbit, mouse and guinea pig (Raine, 1994). A 
review by Smith et al, 1999, suggests that damage to myelin by macrophage secreted 
proteases, externalising the phosphatidyl serine component of the myelin, would allow 
the scavenger receptors present on activated microglia, which have a high affinity for 
phosphatidyl serine, to interact with this ligand for phagocytosis to occur. The 
importance of macrophages infiltrating the CNS in EAE was demonstrated by 
eliminating macrophages in the liver and spleen of rats before the appearance of any 
clinical signs, which markedly suppressed the appearance of clinical signs compared to 
control animals (Huitinga et al, 1990).
1.1.9 The products of activated microglia
Many of the effects of microglial cells can be attributed to the large array of 
substances they can synthesise and secrete, in response to a wide variety of stimuli. A 
summary by Minghetti and Levi, 1998, lists some of the products which include growth 
factors, cytokines, complement factors, prostanoids, proteolytic enzymes and free 
radicals. The list is ever increasing and should now include chemokines (Hayashi et al, 
1995, Calvo etal, 1996, Peterson etal, 1997).
Cytokines released by activated microglia include: Tumour necrosis factor a  
(TNFa) (Sawada et al, 1989), Interleukin l a  (IL-la) (Yao et al, 1992), Interleukin ip 
(IL-ip), Interleukin 6 (IL-6) (Woodroofe et al, 1991, Raine, 1994, Gehrmann et al, 
1995, Lukas and Hohlfeld, 1995) TGF-pi (Kiefer et al, 1998) as well as Interleukin ip
converting enzyme (ICE) which is responsible for processing IL-1 to its mature 
biologically active form (Yao and Johnson, 1997). Microglia are also found to express 
the 3 chemokines monocyte chemotactic protein 1 (MCP1), macrophage inflammatory 
proteins 1 a  and 3 (MEPla and MIP13) (Hayashi et al, 1995, Calvo et al, 1996, 
Peterson et al, 1997, McManus et al, 1998b) and the interferon inducible, a  chemokine, 
IP-10 (Ren et al, 1998). More recent studies have shown microglial expression of 
interleukin 12 (IL-12) (Aloisi et al, 1997, Suzumura et al, 1998) and interleukin 18 (IL- 
18) (Conti et al, 1999). These two cytokines synergise in the induction of IFNy 
production by T helper 1 cells (Conti et al, 1999). IL-18 also stimulates the in vitro 
production of IL-13 by astrocytes (Culhane et al, 1998). IL-13 produced by microglia 
has been shown to induce astrocytic proliferation and neovascularisation in brain trauma 
(Gehrmann et al, 1995), TNFa has a cytotoxic effect on myelinating oligodendrocytes 
(Gehrmann et al, 1995, Banati et al, 1993) and is expressed by microglia in 
demyelinating lesions (Dickson et al, 1993). The effect of IL-6 treatment of microglia 
using a microglial cell line (Nil), showed that chronic exposure to IL-6 augmented the 
LPS induced production of TNFa and IL-6 ( Di Sianto et al, 1996) suggesting a role in 
the orchestration of fiither cytokine production. Over-expression of human IL-6 in the 
CNS in transgenic mice also increased the production of TNFa, IL-13 and IL-6 in the 
CNS, after LPS injection intraperitoneally or intracerebroventricularly (Di Santo et al
1996). Findings by Woodroofe and Cuzner (1993) using in-situ hybridisation techniques, 
also show production of IL-6 and TNFa as well as IFNy in perivascular inflammatory 
cuffs from postmortem MS brain tissue. Ren et al (1999) have shown that there is 
differential expression of TNFa in microglia isolated from different regions of the rat 
CNS, with detection of high levels from microglia isolated from the hippocampus and
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suggest that microglial gene expression may depend on the interaction with other neural 
cell types in the microenvironment. Expression of TGF-pl by microglia was observed 
during the recovery phase of EAE which may serve to downregulate activated T cells 
and contribute to recovery (Kiefer et al, 1998).
1.2 Multiple Sclerosis
Multiple Sclerosis (MS) is a demyelinating disorder affecting the white matter of 
the brain and spinal cord. The disease is characterised pathologically by inflammation and 
demyelination of axons within the CNS giving rise to symptoms ranging from double 
vision to paraplegia. Most cases present between 20 and 40 years of age (Kurtzke,
1993). MS is now widely accepted as an autoimmune disorder (Raine, 1994) for which 
there is no known cure. The disease follows a characteristic relapsing and remitting 
course and recovery from each episode of demyelination is usually incomplete leading to 
progressive clinical deterioration. Some patients follow a rapidly progressive course 
while others may survive for over 20 years with only minor disability.
1.2.1 Epidemiology of MS
MS is most prevalent in populations living furthest from the equator e.g. the 
prevalence is particularly high in Northern Europe with 1 in 800 of the population in the 
UK being affected (Kurtzke, 1993). Within the United Kingdom, there is also a striking 
difference in the prevalence between the North of Scotland and Southern England with 
regions in Northern England having a higher prevalence than that found in the Southern 
regions (Compston, 1997). It is also interesting to note that studies on migrants moving 
from Northern Europe to Southern Africa as adults, took with them the high prevalence 
rate of their country of origin whereas those migrating below the age of 15 years took on
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the frequency of native Africans (Compston, 1997). This suggests that the disease 
process is established in childhood. MS is also more common in females than in males 
with a ratio of 2:1 irrespective of ethnicity (Compston, 1997). Studies on MS in 
pregnancy show a slight decrease in relapse rate during pregnancy when compared with 
non pregnant periods of the same patients and control women (Runmarker and 
Anderson, 1995). The reasons for this are undefined although it may be due to the 
selective immunosupression during pregnancy to allow the foetus to survive as an 
allograft. Studies on experimental autoimmune uveitis (EAU) show that pregnant animals 
are less susceptible to induction of EAU or experience a less severe course (Agarwal et 
al, 1999).
1.2.2 Histology of MS
Patients with MS show numerous demyelinated plaques in the brain and spinal 
cord often closely related to venules. Histological observations generally show myelin 
breakdown and phagocytosis by macrophages. There is perivascular cuffing with 
inflammatory cells including T cells, B cells and macrophages in the acute plaque. As 
myelin breakdown subsides, a reactive gliosis is established leading to a chronic plaque. 
(Adams et al, 1989).
1.2.3 Animal models of multiple sclerosis
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory disease of 
the CNS that is commonly used as an animal model for MS (Bradl and Linington, 1996, 
Hulkower et al, 1993, Huitinga et al, 1990). It can be induced in a number of genetically 
susceptible animals, including primates by injection of an emulsion of homogenised 
myelin, whole brain homogenate, myelin basic protein (MBP) or proteolipid protein
(PLP) in adjuvant (Owens and Sriram, 1995, Hulkower et al, 1993, Huitinga et al, 
1990). In the Lewis rat, sub-cutaneous injection of homogenised myelin induces an acute 
paralytic disease about 10-12 days after sensitisation (Hulkower et al, 1993, Huitinga, et 
al 1990). There is full recovery usually over the next few days but in some animals, 
mainly females, a short relapse may occur (Hulkower et al 1993). Since EAE is a T cell 
mediated disease, it may also be induced by passive transfer of MBP or PLP reactive T 
cells. Changing the immunisation protocol results in the chronic form of EAE in which 
animals enter a series of relapses and remissions similar to MS. CNS tissue of sensitised 
animals shows perivascular inflammation with lymphocytes and macrophages/monocytes 
being the major cell types. Breakdown of the blood brain barrier can also be observed. 
The observation that MS is an autoimmune disease stems partly from the similarities with 
EAE, which a is T cell mediated disease, and it is proposed that MS is also T cell 
mediated (Sriram and Rodriguez, 1997). Although similar, there is a major difference 
between EAE and MS and that is, EAE is known to be a T cell mediated autoimmune 
disease as it can be induced with specific antigens whereas in MS, the inducing antigen 
remains undefined. Nevertheless, much understanding of MS has come from studying 
EAE which remains the closest animal model. Theiler’s murine encephalomyelitis virus 
(TMEV) induced demyelinating disease in mice, is also considered a good model for MS 
as infection leads to a chronic demyelinating disease with similarities to MS (Oleszak et 
al, 1995).
1.2.4 Viruses and multiple sclerosis
Epidemiological evidence suggests that MS involves an infectious agent (Kurtze, 
1993) encountered probably between the ages of 5-15 years (Calder et al, 1989). This 
may involve molecular mimicry where the immune system is presented with stretches of
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amino acids that resemble 'self. For example, Adenovirus Type 2 contains amino acid 
sequences similar to those in the crucial encephalitogenic fragment of myelin basic 
protein (MBP). MBP is the major constituent of the myelin sheath and is produced by 
oligodendrocytes. A number of different viruses have been proposed as the causative 
agents in MS including: rabies, measles, mumps, rubella, herpesviruses, chimpanzee 
cytomegalovirus and retroviruses, however no definitive viral agent has been found as 
yet and it may be that different viruses are involved in different patients. This would 
depend on their genetic background (Monteyne et al, 1998), since a genetic 
predisposition also determines a person’s susceptibility to MS (Kurtze, 1993).
1.2.5 Genetics of MS
There is no single known factor responsible for the cause of MS, although family 
and twin studies have shown that genetic factors exert a significant influence of 
autoimmune disease predisposition (Theofilopoulos, 1995). Individuals with a greater 
genetic loading (i.e. with an affected parent) have been shown to have a lower age of 
onset and increased susceptibility suggesting that MS is at least in part, under genetic 
control (Sadovnick et al 1998). Concordance rates for monozygotic and dizygotic twins 
with MS range from 20-30% and 3-4% respectively (Ebers et al, 1995). Although 
concordance in monozygotic twins with MS is lower than expected for a purely genetic 
disease, suggesting environmental factors may be involved, the role of genomic 
imprinting (ie gene silencing by methylation) and non-identity of immune repertoires 
cannot be ruled out (Theofilopoulos, 1995).
It is widely accepted that a genetic association exists between MS and the HLA 
region in Caucasian populations and this has been shown to be the single most prevalent 
susceptibility locus in genome wide genetic screens in familial MS (Sawcer et al, 1996,
Haines et al 1996, Ebers et al 1996). This genetic association with the HLA region has 
been demonstrated to be due to the HLA-DR2 allele in familial and sporadic cases, 
however a minority of familial cases do not segregate with HLA-DR2, suggesting that 
multiple genetic loci are involved (Haines et al, 1998).
A number of additional putative MS susceptibility loci have been identified, 
including the (3 chain of the T cell receptor (Theofilopoulos, 1995), myelin basic protein 
(Tienari etal, 1992, Barcellos etal, 1997) and Intercellular adhesion molecule 1 (ICAM- 
1) (Mykco et al, 1998). Also, genetic polymorphisms have also been shown to affect the 
clinical course of MS, whereby, patients with both IL-1RA allele 2+ and IL-1(3 allele2' had 
an increased rate of disease progression (Schrijver et al, 1999).
1.3 The blood brain barrier
The blood brain barrier (BBB) separates the CNS environment from the systemic 
blood circulation to maintain homeostasis essential for optimal brain functioning. Under 
normal circumstances it protects the CNS from water soluble, blood borne components. 
The BBB is formed by endothelial cells, astrocytes, perivascular microglia and a basal 
lamina (De Vries et al, 1997). The endothelial cells of the CNS are held together by tight 
junctions formed by proteins in the tight junction complex and also the adherens junction 
complex. The proteins in the tight junction complex are zonula occludens 1 (ZOl) and 
occludin, and the adherens junction complex contains vascular endothelial cadherin and 
vinculin (Perry et al, 1997). Astrocytes project their end feet to the endothelial cells and 
are embedded in the basal lamina along with the perivascular macrophages. The BBB 
also has a metabolic barrier provided by the constitutive expression of the enzymes, 
monoamine oxidase A and B and catechol-o methyltransferase which are involved in the 
degradation of neurotransmitters and some blood borne compounds that may have
14
entered the CNS (de Vries et al, 1997). The transport of hydrophilic essential substances 
such as glucose, across the BBB is by selective carrier mechanisms and diffusion of 
compounds depends on their lipid solubility (de Vries et al, 1997).
1.3.1 Breakdown of the blood brain barrier
When inflammation occurs in the CNS, as in MS, the BBB can be changed 
significantly with the influx of inflammatory cells and plasma proteins. The cytokines 
released by inflammatory cells in MS, TNFa, IL-ip and IL-6 can lead to an increase in 
the permeability of endothelial tight junctions. Free radicals, which are produced by 
activated macrophages and microglia have also been shown to increase the permeability 
of the BBB (Hallenbeck, 1996, de Vries et al, 1997). Increased permeability of the BBB 
is also caused by the effects of proteases including the matrix metalloproteinases and 
serine proteases (Perry et al, 1997, Hallenbeck, 1996). Under normal conditions, small 
numbers of leukocytes cross the BBB for immune surveillance of the CNS. In the 
inflammatory response the expression of adhesion molecules such as ICAM-1 and 
vascular cell adhesion molecule 1 (VCAM-1) is upregulated on the endothelium, 
allowing greater influx of cells expressing the correct ligands (Archaelos and Hartung, 
1997).
1.3.2 Cell migration into the CNS
Autoreactive T cells recognising MBP circulate in the blood of MS patients and 
upon encountering antigen they may become activated (Hartung, 1995). Activated self 
reactive T cells cross the BBB and initiate an immune response within the CNS. Slow 
flowing leukocytes attach weakly to the endothelium through the actions of selectins. 
Adhesion molecule expression by endothelial cells is greatly upregulated by cytokines
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generated in the course of an inflammatory response. Interaction with the endothelium is 
strengthened on encountering specific chemoattractant or activating factors. In the final 
step, T cells change in morphology and are able to migrate through the endothelium in 
response to chemotactic signals (Figure 1.1) such as complement component C5a, 
platelet activating factor and chemokines, the chemotactic cytokines (Hartung, 1995).
Figure 1.1 The multistep model of leukocyte transmigration.
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1. Endothelial cells are activated by inflammatory cytokines to increase expression of 
adhesion molecules e.g. ICAM-1, VCAM-1 and P selectins.
2. Circulating leukocytes attach via selectins.
3. Attatched leukocytes then roll along the endothelium.
4. Leukocyte integrin activation occurs through G protein linked chemokine receptors
The leukocyte endothelium interaction is strengthened by LFA-1/ICAM-1 and 
VLA4/VCAM-1 pairings, leading to firm adhesion, flattening and transmigration. Once
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in the CNS autoreactive T cells undergo local reactivation if they encounter antigen 
presenting cells that display two signals, namely, processed respective autoantigen on 
their surface with MHC class II gene products and the costimulatory molecules B7-1 
(CD80) or B7-2 (CD86). In MS lesions activated microglia express MHC II as well as 
B7 (Windhagen et al, 1995, Benveniste, 1997). Autoantibodies directed to MBP 
antigens may also cross the BBB once opened by activated T cells, or they may be 
produced locally by B cells that have been activated to do so by cytokines released by T 
helper (Th) cells. These autoantibodies activate the complement cascade and this leads 
ultimately to demyelination of axons by antibody and complement mediated 
phagocytosis. The complement component C5a also acts as a chemoattractant for 
inflammatory cells.
1.3.3 The role of macrophages in the pathogenesis of MS plaques
Macrophages and microglia, are involved in the demyelination process in MS. 
Primed Th cells, on entering the CNS are further activated by antigen presenting cells 
e.g. macrophages (Perry 1994, Hartung 1995), microglia (Hartung 1995, Gehrmann et al 
1993, Hickey and Kimura 1988, Gehrmann et al 1995) and astrocytes (Hartung 1995, 
Fontana et al 1984). Thl cells release IFNy and TNFa as well as other factors which 
activate macrophages and microglia which then release inflammatory mediators such as 
proteases, TNFa, reactive oxygen species, nitric oxide (NO) metabolites and activated 
complement components (Hartung 1995). These molecules act at short range to damage 
the myelin sheath. Furthermore, activated macrophages and microglia participate in late 
'cleaning up' events by phagocytosis, following inflammation in the CNS
It is hypothesised that microglia are able to migrate to areas of inflammation 
under the influence of chemokines and once at the site of damage, they become activated
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and recruit other microglia and inflammatory cell types to the site of inflammation by 
release of chemokines such as Monocyte chemotactic protein 1 (MCP1), Macrophage 
inflammatory protein l a  (MTPla) and MIP1J3 (Hayashi et al, 1995, Calvo et al, 1996, 
P e terso n ^al, 1997). (See figure 1.2).
Figure 1.2 Schematic diagram of possible mechanism of cell recruitment and activation in 
the central nervous system by microglial secretion of chemokines at the site of CNS 
inflammation.
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1.4 Chemokines
Recruitment of leukocytes in inflammation is a complex process and involves 
adhesive interactions with the endothelium and secretion of cytokines. Chemokines are a 
rapidly expanding superfamily of chemotactic cytokines of which the majority were 
described in the last decade (Oppenheim et al, 1991, Schall, 1991, Baggiolini et al, 1994, 
Schall and Bacon, 1994, Miller and Krangel, 1992, Taub and Oppenheim, 1994, Petrek 
et al, 1995, Taub, 1996). They are low molecular weight proteins (7-14 kD in their 
monomeric form) and most are around 70 amino acid residues in length. Many of the
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chemokines form dimers, trimers and tetramers upon secretion (Taub, 1996) although 
the monomers have been determined as the major species at physiological concentrations 
and are the functional ligands (McFadden and Kelvin, 1997) Studies on M IPla, showed 
the high molecular weight aggregates of M IPla to disaggregate under assay conditions 
and function as monomers (Graham et al, 1994).
1.4.1 Chemokine Subfamilies
Chemokines are divided into 4 groups according to a conserved cysteine motif 
and their chromosomal location. The first two groups to be characterised, the CXC or a  
chemokines and C-C or p chemokines, have 4 conserved cysteine residues. In the C-C 
chemokines, the first two cysteines are adjacent whereas they are separated by an 
intervening amino acid in the CXC chemokines. X ray crystallography has shown the 
monomeric form of CXC and CC chemokines to have a similar three dimensional 
structure (McFadden and Kelvin, 1997). More recently, the third group, 'C or y 
chemokines have been described, similar in structure to the C-C and CXC chemokines, 
but they lack two of the four cysteine residues. There are only two members of this 
group to date namely murine lymphotactin (Kelner et al, 1994) and its human homologue 
single cysteine motif-1 (SCM-1) (Yoshida et al, 1995). The most recent addition to the 
chemokine subgroups is the CX3C chemokine (Bazan et al, 1997) of which the only one 
discovered to date has been named fractalkine (also known as neurotactin, Pan et al,
1997) and has been found to be membrane bound with a ‘mucin like stalk’ on top of the 
molecule. It has been found to be upregulated on the endothelium, induces adhesion of 
monocytes and T cells in vitro and can be cleaved and released from cell membranes as a 
shed glycoprotein that chemoattracts monocytes and T cells in vitro (Schall, 1997). 
Fractalkine expression has also been shown in the CNS by neurons and microglia
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(Harrison et al, 1998). Lungkine is the most recently discovered CXC chemokine and 
was found to be expressed in mouse lung epithelial cells (Rossi et al, 1999).
In humans, the genes for CXC chemokines have been mapped to chromosome 
4q 12-21 and the C-C chemokines, 17ql 1-21. Lymphotactin is located on mouse 
chromosome 1 and the human homologue, SCM-1 is also mapped to chromosome 1 
(Petrek et al, 1995). Many of the CXC chemokines possess an ELR amino acid motif 
(glutamic acid-leucine-arginine) near the N terminus. These include interleukin-8 (IL-8), 
neutrophil activating peptide-2 (NAP-2), epithelial cell derived neutrophil activating 
protein-78 (ENA-78), growth related peptide a  (GROa/p), GROP and granulocyte 
chemotactic protein-2 (GCP-2), and all induce neutrophil chemotaxis in vitro and in 
vivo. The non ELR containing CXC chemokines including stromal cell derived factor-1 
(SDF-1), monokine induced by gamma interferon (MIG), interferon inducible protein-10 
(IP-10) and platelet factor-4 (PF-4) are not able to chemoattract neutrophils unless the 
ELR motif is inserted into the amino acid sequence (Taub, 1996). Because of their 
chemotactic properties on immune cells, chemokines are clearly involved in leukocyte 
trafficking. They have been extensively studied in vitro for their potent chemoattractant 
activities for various white blood cell populations although their chemotactic potential is 
not limited to immune cells e.g. IL-8 is chemotactic for melanoma cells in vitro (Ming 
Wang et al, 1990). In general CXC chemokines chemoattract neutrophils (with the 
above exceptions) whereas C-C chemokines attract mainly monocyte and lymphocyte 
populations. The p chemokines also have specificity for T cells subsets where M IPla 
preferentially attracts CD8+ T cells and MEPip preferentially attracts CD4+ T cells 
(Taub et al, 1993), even though the MtP proteins share 70% homology. Leukocyte 
trafficking is now only a small part of the discovered roles played by chemokines. Other 
known biological functions include angiogenesis and haematopoiesis (Taub, 1996).
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Stimulation of angiogenesis by CXC chemokines appears to depend on the presence of 
the ELR motif and in fact the non ELR CXC chemokines, IP-10 and MIG inhibit the 
angiogenic response (Keane et al, 1998). As a group, these molecules function in the 
recruitment and activation of leukocytes and other cells at sites of inflammation and 
therefore are important inflammatory mediators.
1.4.2 Chemokine Receptors
As the array of discovered chemokines has expanded, so has the discovery of 
their receptors. The chemokine receptors are a family of seven transmembrane spanning 
glycoproteins (Figure 1.3) that are structurally related, the lowest amino acid similarity 
between 2 receptors being 30%.
Figure 1.3. Schematic diagram of chemokine receptor CCR1 (Adapted from Bertini et 
al, 1994).
extracellularN terminus
Cell membrane
C terminus
The receptor traverses the cell membrane seven times to form 6 loops.
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The structure is based upon the distribution of their conserved sequences and the 
known structure of the seven transmembrane receptor for rhodopsin. The N termini of 
the receptors are extracellular and the C termini intracellular with the seven hydrophobic 
domains passing as a  helices through the membrane, forming 6 loops (Murphy, 1996).
The chemokine receptors are mainly divided into a  and p chemokine receptors 
but there is also the Duffy antigen on erythrocytes (see table 1.1) which is a promiscuous 
chemokine binding protein, with a  and p chemokine ligands (Murphy, 1996, Premack 
and Schall, 1996, Wells et al, 1998). The fourth type of chemokine receptor are the 
virally encoded receptors found in the gamma herpesviruses and these have multiple 
shared ligands (Premack and Schall, 1996).
The P chemokine receptors are located on human chromosome 3 whereas the a  
chemokine receptors, CXCR1, CXCR2 and CXCR4 are clustered on chromosome 2 
(Premack and Schall, 1996). There is also now identified, a receptor for the CX3C 
chemokine, fractalkine and as both chemokine and receptor are membrane bound, it is 
thought they may act as adhesion molecules as well as mediators of leukocyte 
chemotaxis (Imai et al, 1997, Wells et al, 1998). Some receptors identified to date, 
appear to bind only one chemokine whereas others e.g. CCR3 and CCR4 bind many 
different chemokines. This suggests that in the inflammatory response, cells expressing a 
particular receptor may respond to many different chemokines expressed at the inflamed 
site. The fact that some chemokines can bind to more than one type of receptor may have 
come about by the use of chemokine receptors by viruses to infect cells and the 
overlapping ligand specificities may reflect host adaptation to viral infection (Premack 
and Schall, 1996). Displacement experiments in vitro have shown that receptors show a 
preference for one chemokine over another. CCR1 was transfected into a human 
embryonic kidney cell line and was shown to bind the chemokines, MCP1, MIPlot/p and
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Table 1.1 Chemokine receptor families. (Taken from Wells et al, 1998)
a  Chemokine receptors
RECEPTOR LIGAND
CXCR-1 IL-8 GCP 2
CXCR-2 IL-8, GROa P y, ENA-78, NAP-2
CXCR-3 IP-10, MIG
CXCR-4 SDF-lp
CXCR-5 BCA-1
P Chemokine Receptors
RECEPTOR LIGAND
CCR-1 MIPla, P, MCP-3, RANTES, MCP-1
CCR-2 MCP-1-5
CCR-3 Eotaxin, RANTES, MCP-3, MCP-4
CCR-4 MIP-la, RANTES, MCP-1, TARC,
MDC
CCR-5 MIP-la, P, RANTES
CCR-6 MIP-3a
CCR-7 MIP-3p, SLC
CCR-8 1-309
CCR-9 CC chemokines
Erythrocyte chemokine receptors
RECEPTOR LIGAND
DARC (Dufly antigen) RANTES, MCP-1, IL-8, GRO, NAP-2
CX3C chemokine receptor
RECEPTOR LIGAND
CX3CR-1 Fractalkine
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RANTES. All the chemokines tested were able to displace radiolabelled M IPla from 
receptors even though M IPla was the chemokine that bound with the highest affinity 
(Neot eetal, 1993).
It may seem impossible to believe that a chemokine could cause directed 
migration in vivo with such a confusing array of chemotactic signals but it is thought that 
leukocytes can prioritise their responses. The proposed mechanism for this, is receptor 
crosstalk with an agonist hierarchy, and was demonstrated by chemotaxis experiments 
where the migration of neutrophils in response to IL-8 was suppressed by the presence 
of a different chemoattractant peptide, f-met-leu-phe (fMLP) (which binds to a different 
receptor), but IL-8 could not suppress migration of neutrophils towards fMLP (Campbell 
et al, 1997). Furthermore, neutrophils have been shown to migrate up a concentration 
gradient to one chemoattatractant and then migrate down that concentration gradient to 
migrate towards a distant chemoattractant showing ‘multistep navigation’ of cells in a 
complex environment (Foxman et al, 1997).
1.4.3 Chemokine receptor signalling
Binding of the ligand to its receptor on a cell causes the release of intracellular 
second messengers, inositol 1,4,5-trisphosphate and diacylglycerol, via G protein 
complexes. This in turn causes an increase in intracellular free calcium within the cell, 
resulting in reorganisation of the actin cytoskeleton, formation of focal adhesions and 
pseudopod extension, which ultimately leads to movement of the cell. Chemokine 
signalling also involves activation of the GTP binding proteins, Rac and Rho (Premack 
and Schall, 1996). Rac is involved in actin reorganisation events such as membrane 
ruffling and Rho activation induces formation of stress fibres and focal adhesions 
(Machesky and Hall, 1996).
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The suggestion of chemokine receptors being linked to G proteins is confirmed 
by experiments showing Pertussis toxin sensitivity of chemokine signalling in vitro 
(Youngs et al, 1997, Cross et al, 1997).
1.4.4 Chemokines in disease.
Chemokines have been implicated in a range of acute and chronic pathological 
inflammatory conditions. There is a complex cascade of inflammatory events in many of 
these disorders mediated by various leukocytes expressing chemokine receptors attracted 
into the inflamed site by the effects of chemokines (Baggoilini, 1998). A number of CC 
and CXC chemokines including IL-8, ENA-78, MCP1, M IPla and RANTES, have been 
found in joint fluid in rheumatoid arthritis (RA). RA is characterised by joint 
inflammation and experimentally induced joint inflammation in animals could be reduced 
by immunisation with anti MDPla antibodies (Strieter et al, 1996). Upregulation of IL-8 
and MCP1 expression in histological sections of lung and broncheolar lavage fluid has 
been found in a number of respiratory disease states including idiopathic pulmonary 
fibrosis, active sarcoidosis and bronchial carcinoma, with increased numbers of 
monocytes and neutrophils being present (Taub and Oppenheim, 1994). An increase in 
chemokines that chemoattract eosinophils, MIPla, RANTES and MCP3 have also been 
identified in bronchoalveolar lavage fluids from asthma sufferers (Keita and Gleich,
1996). Chemokines are also thought to be involved in atherosclerosis as high levels of 
MIPla, MIPlp and RANTES have been found in atherosclerotic lesions (Taub and 
Oppenheim, 1994) and in vitro studies demonstrate that minimally modified low density 
lipoprotein induces MCP1 production in endothelial and smooth muscle cells, 
components of the arterial wall (Edgington, 1993). The acute and chronic inflammatory 
conditions involving high levels of chemokine expression also include gout, glomerular
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nephritis, endometriosis and psoriasis (Petrek et al, 1995). Diseases associated with 
chemokine involvement also include many CNS conditions.
1.4.5 Chemokines in CNS disease
Because of the role of chemokines in inflammatory conditions, it is now well 
documented that they also have a role in inflammation in the CNS (Ransohoff et al, 
1996, Ransohoff and Tani, 1998). Increased cerebrospinal fluid (CSF) levels of M IPla 
have been detected in patients with the neurological inflammatory disorders, neuro- 
Behcets disease, HTLV-1 associated myelopathy and aseptic meningitis, compared to 
controls with non inflammatory neurological diseases (Miyagishi et al, 1995). Cerebral 
ischaemia is followed by leukocyte accumulation and following occlusion of the middle 
cerebral artery in the rat, levels of IP-10 mRNA were elevated with a peak level at 6 
hours suggesting a role in leukocyte recruitment after stroke (Wang et al, 1998). MCP1 
and GROa have also been found to be expressed in response to cerebral ischaemia, 
consistent with a role in neutrophil and macrophage chemoattraction to lesions 
(Ransohoff and Tani, 1998). The inflammation that occurs after CNS trauma may also be 
due to the expression of chemokines, as demonstrated by brain stab wound injury in the 
rat which showed increased MIPlp and RANTES expression 3 days after injury and 
correlated with the influx of monocytes and lymphocytes (Ghimikar et al, 1996). MCP1 
expression was found just 3 hours after mechanical CNS injury before the appearance of 
inflammatoiy leukocytes and co-localised to reactive astrocytes, which may be involved 
in the monocyte recruitment following trauma (Ransohoff and Tani, 1998).
M IPla expression by glial cells in the human brain has been shown to be present 
in patients with schizophrenia but not in patients with other neuropsychiatric disorders 
including manic depressive illness and cerebral vascular dementia (Ishizuka et al, 1997)
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which may account for the increased density of microglia in the temporal and frontal lobe 
of chronic schizophrenics (Radewicz et al, 1998). Others have shown increased M IPla 
expression in neurons and MLPip expression in reactive astrocytes in Alzheimer’s 
disease brain compared to control brain, as well as elevated IP-10 expression by some 
reactive astrocytes (Xia and Hyman, 1999).
1.4.6 Chemokines in multiple sclerosis and experimental autoimmune encephalomyelitis
Inflammatory cell recruitment into the CNS is a major feature of MS and 
chemokines are thought to be major chemoattractants in the CNS, due to the discovery 
of their expression and in vitro activities on CNS cell types. T cell migration into the 
CNS has been suggested to be due to chemokines activating integrin-mediated adhesion 
of leukocytes to the endothelium (Karpus et al, 1995). This suggestion is supported by 
observations that chemokines bind to glycosaminoglycan sub-populations on endothelial 
cells which may present the chemokine molecules to selectin bound leukocytes ( Witt and 
Lander, 1994, Taub, 1996) (see figure 1.4).
One of the characteristics of EAE is mononuclear cell infiltration into the CNS 
and studies on mice by Karpus et al, (1995) show that MDPla but not MCP1 production 
correlates with increasing disease severity. However, at the height of clinical disease in a 
rat EAE model induced by guinea pig spinal cord myelin, MCP1 was shown to be 
expressed by endothelial cells, perivascular infiltrates and astrocytes and the expression 
was considerably reduced following recovery (Berman et al, 1996). Glabinski et al 
(1997) showed a dramatic increase in chemokine mRNA and protein expression of 
MCP1, IP-10, GROa, RANTES and M IPla during relapse in chronic EAE in mice. 
MCP1, IP-10 and GROa were expressed by astrocytes surrounding inflammatory lesions
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and RANTES and M IPla expression by leukocytes was identified at sites of 
inflammation.
Figure 1.4. Chemokine receptor interactions.
Leukocyte
chemokine .... .receptor— ^  1 /CHO \  
ligands integrin
■selectin chemokinel CAM .[presentingImolecules
ENDOTHELIUM
The presentation of chemokine to a specific receptor on a selectin bound leukocyte 
induces a series of intracellular signals. Binding to the chemokine receptor, linked to a G 
protein is believed to activate integrin adhesiveness. These signals also induce the release 
of enzymes which may facilitate transmigration and chemotaxis through the BBB. 
(Presenting molecules = glycosaminoglycans, CHO = carbohydrate, G = G protein, CAM 
= cell adhesion molecule.)
Active EAE lesions induced in rats, showed a dramatic increase in expression of 
the chemokines, RANTES, M IPla and MIPip at the peak of clinical disease, 
predominantly being expressed by infiltrating T cells but macrophages/amoeboid 
microglia and astrocytes were also found to express MIPip and RANTES (Miyagishi et 
al, 1997).
Elevated levels of M IPla have also been detected in the CSF of MS patients 
correlating with relapse of the disease (Miyagishi et al, 1995) as well as an increase in 
RANTES, MIG and IP-10 in the CSF of MS patients when compared to normal controls
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(Sorensen et al, 1999). Studies by Hayashi et al, (1995) showed LPS induced M IPla 
production from microglial cells and that MCP1 and another chemokine, T cell activation 
gene-3 (TCA 3) induced chemotaxis of microglia in vitro. Their findings also suggest 
that microglia and astrocytes differentially produce chemokines in the CNS and that 
astrocytes and T cells may recruit and activate microglial cells by production of C-C 
chemokines. Simpson et al (1998) have shown RANTES expression on the blood vessel 
endothelium in active MS plaques and that MCP1 is expressed by astrocytes and 
macrophages in the chronic MS lesion. M IPla and MIPip were shown to be expressed 
by astrocytes and microglia respectively. Similarly, cells resembling reactive astrocytes 
distributed throughout the demyelinated lesion in active demyelinating MS lesions were 
strongly stained for MCP1, although no positive staining on infiltrating macrophages or 
lymphocytes was apparent (Van Der Voom et al, 1999).
In vitro studies have shown that myelin proteolipid protein (PLP) specific CD8+ 
cytotoxic T lymphocyte (CTL) lines express increased amounts of M IPla and MIPip in 
response to stimulation with the appropriate peptide/MHC complex (Biddison et al,
1997) and their production may promote the inflammatory response in MS by further 
recruitment of inflammatory cells and resident macrophages/microglia. Human foetal 
microglia have previously been shown to migrate in vitro to the chemokines MIPla, 
MIPip and MCP1 (Peterson et al, 1997) as well as the classical chemoattractant C5a 
(Yao et al, 1990), also produced during the inflammatory process.
1.4.7 Chemokine expression bv microglia in vitro
Chemokine expression by microglia has been examined on freshly isolated 
microglia and microglial cell lines. Sun et al (1997) examined the in vitro mRNA 
expression of MCP1, MIPla, RANTES and IP-10 by microglial cell lines, immortalised
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by culturing freshly isolated mouse glial cells in macrophage colony stimulating factor 
(M-CSF) and although only MCP1 was sometimes detected in resting cells, all the other 
chemokines were expressed after lipopolysaccharide (LPS) stimulation. M IPla mRNA 
expression by a microglial cell line (BV-2) was also found to be induced by phorbol 12 
myristate 13 acetate (PMA) as well as LPS, although the proinflammatory cytokines 
TNFa and IL-lp had no effect (Murphy et al, 1995). LPS induction of M IPla 
expression by mouse primary microglia has been confirmed, but the microglial cultures 
did not express MCP1 either before or after LPS stimulation in contrast with primary 
astrocyte cultures which expressed MCP1 following stimulation (Hayashi et al, 1995). 
Conversely, Calvo et al (1996) showed MCP1 mRNA expression in unstimulated rat 
microglia which was upregulated by LPS and also by IL-ip, TNFa and IL-6, however 
these differences may be accounted for by species differences. Human microglia in vitro 
expressed the (3 chemokines, MIPla, MIPip and MCP1 and expression was shown to 
be increased when cells were stimulated with LPS, TNFa and IL-ip with LPS having the 
most pronounced effect (Peterson et al, 1997) The a  chemokine, IL-8 has also been 
found to be expressed by human microglia following LPS and IL-ip stimulation and to a 
lesser extent with TNFa stimulation (Ehrlich et al, 1998).
1.4.8 Chemokine receptor expression in the normal and diseased CNS
The response of cells to chemokines is dependent on their expression of the 
appropriate receptor. Many chemokine receptors have been found to be expressed in the 
brain under physiological and pathological conditions including CXCR2, CXCR3, and 
CXCR4 expression on neurons and CCR-3 and CCR-5 on microglia (Xia and Hyman, 
1999). Microglia and astrocytes in culture have also been shown to constitutively express
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CXCR4 although only microglia responded in chemotaxis experiments to the ligand, 
SDF-1 (Tanabe et al, 1997). Microglia also express CX3CR1, the receptor for 
fractalkine which is thought to be involved in signalling from neurons to microglia, as 
neurons are the predominant cell type expressing fractalkine in the CNS and CX3CR1 
was upregulated on microglia following facial nerve axotomy in the rat (Harrison et al,
1998).
T helper (Th) cell subsets have been shown to differentially express chemokine 
receptors. Thl cells expressed mainly CXCR-3 and CCR-5, whereas Th2 cells expressed 
mainly CCR-4 (Bonecchi et al 1998, Sallusto et al, 1998). Other receptors identified in 
SIV infected macaque CNS tissue include, CXCR4 expression by glial cells and CXCR-3 
expression by infiltrating lymphocytes (Westmoreland et al, 1998).
Chemokine receptor expression has been examined in many CNS diseases and in 
particular in AIDS, due to the discovery that the HIV virus utilises chemokine receptors 
to infect microglia. Microglia are the targets in HIV infection of the brain and the 
response of the migroglia to viral infection is thought to stimulate the release of 
neurotoxic substances such as reactive nitrogen species leading to the symptoms of 
AIDS dementia (Balter, 1996). HTV viruses infecting macrophages are known as 
macrophage tropic viruses and mainly utilise CCR5 as a co receptor for entry into cells 
(He et al, 1997). CCR3, expressed by microglia, was also shown to be a co receptor for 
HTV infection in primary brain cultures as the CCR3 ligand, eotaxin and the CCR5 
ligand, MIPip as well as an antibody against CCR3 inhibited 70-80% of microglial 
infection (He et al, 1997). Sheih et al (1998) reported that CCR5 was the major co 
receptor for HTV in primary cultures of adult microglia with antibodies to CCR3 having 
no effect in reducing the levels of infection. The difference in results was explained by 
the fact that other cell types present in the brain cultures used by He et al, may have
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affected the results and also that the maturation state of the microglia may affect the 
levels of receptor expression.
Reports on chemokine receptor expression in the CNS has since led on to studies 
of other disorders such as Alzheimer’s disease, where CCR3 and CCR5 are upregulated 
on some of the reactive microglia surrounding amyloid deposits (Xia and Hyman, 1999). 
In MS, chemokines are thought to play an important role in the recruitment of 
inflammatory cells. Recently, MDPla and MCP1 receptors were discovered on the 
endothelium on the abluminal surface of microvessels and although their function is 
unclear, it is thought that they may prevent chemokines from being diluted, augmenting 
the intensity and duration of the response at the site of inflammation (Andjelkovic et al,
1999).
1.5 Matrix metalloproteinases
Degradation of the extracellular matrix (ECM) by proteinases is important in 
many physiological processes in the CNS including tissue remodelling in development 
and cell migration. There are four classes of proteinases divided into two subgroups: 
these are the aspartic and cysteine, acid proteinases and the serine and metallo 
proteinases which are optimally active at neutral pH.
The matrix metalloproteinases (MMPs) are a family of zinc dependant enzymes 
capable of degradation of ECM proteins. MMPs, of which there are at least 18 members 
to date, can be further divided depending on their size and substrate specificity, into 
collagenases, gelatinases, stromelysins and membrane type MMPs (Yong et al 1998). 
The MMPs and their substrates are listed in Table 1.2.
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Table 1.2 Matrix metalloproteinase groups and their substrate specificities. Adapted from 
Chandler et al, 1997.
MMP sub-group Member Main substrates
Collagenases Interstitial collagenase (MMP1) fibrillar collagens
Neutrophil collagenase (MMP8) fibrillar collagens
Collagenase 3 (MMP 13) fibrillar collagens
Collagenase 4 (?) unknown
Gelatinases Gelatinase A (MMP2) Gelatin, type IV, V collagens, 
fibronectin
Gelatinase B (MMP9) Gelatin, type IV, V collagens, 
fibronectin
Stromelysins Stromelysin 1 (MMP3) Laminin, non fibrillar collagen, 
fibronectin
Stromelysin 2 (MMP 10) Laminin, non fibrillar collagen, 
fibronectin
Matrilysin (MMP7) Laminin, non fibrillar collagen, 
fibronectin
Stromelysin 3 (MMP11) a l  proteinase inhibitor (serpin, 
serine proteinase inhibitor)
MT-MMPs MT1-MMP (MMP14) Pro MMP2, collagens, gelatin
MT2-MMP (MMP 15) Pro MMP2, collagens, gelatin
MT3-MMP (MMP16) Pro MMP2, collagens, gelatin
MT4-MMP (MMP17) Pro MMP2, collagens, gelatin
Others Metalloelastase (MMP 12) Elastin
Enamelysin (?) unknown
Xenopus MMP (?) unknown
? (MMP19) Aggrecan
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1.5.1 Structures of matrix metalloproteinases
The MMP family members share many similarities in structure and biochemistry. 
The cloning of several family members has shown that they share amino acid sequence 
homologies. The catalytic domains of MMPs contain two zinc atoms which are required 
to maintain their three dimensional conformation and activity (Figure 1.5). Most are 
secreted as inactive zymogens which require cleavage, proteolytically or by treatment 
with mercurial compounds such as P-aminophenylmercuric acetate (APMA) The active 
enzymes are tightly controlled by naturally occurring inhibitors called Tissue Inhibitors of 
Metalloproteinases (TIMPs). The potential activities of MMPs are tightly controlled in 
several ways (Yong et al, 1998):
a) at the level of gene expression;
b) activation of the zymogen;
c) production of specific protease inhibitors.
Figure 1.5 The domain structure of the matrix metalloproteinases Adapted from Massova 
et al (1998)
N
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The schematic diagram shows the basic domain structure. The catalytic domain has an 
insertion of fibronectin like repeat in MMPs 2 and 9 and MT-MMPs have a 
transmembrane region.
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The N terminus pro peptide region contains approximately 80 amino acids and is 
found in all MMPs. The C terminus domain is shared by all MMPs, except MMP7 
(matrilysin), and is similar in sequence to the hemopexin family of glycoproteins 
(Massova et al, 1998). In the case of the collagenases and stromelysin 1, the hemopexin 
like domain is essential for binding to native collagens and in all of the MMPs it is 
involved in initial interactions with their specific inhibitors, the TIMPs (Murphy and 
Knauper, 1997). The C terminus is linked by a hinge region which is shorter in 
collagenases than in other MMPs (Yong et al, 1998).
The MT-MMPs are the only members of the MMP family that are localised on 
the cell surface by the presence of a membrane spanning domain and are involved in the 
cleavage and activation of pro MMP2 (Sato et al, 1994). MMP14 was first cloned from 
human placenta and has also been detected in a mouse fibroblast cell line and human lung 
tumours (Sato et al, 1994) as well as in white matter microglia in human brain tissue 
(Yamada et al, 1995a).
The gelatinases contain a gelatin binding domain which is an insert of three 
tandem repeats of fibronectin type II like modules in the catalytic domain. This allows 
high affinity binding to collagen type I (Goetzl et al, 1996) and to denatured type IV and 
V collagens (Murphy and Knauper, 1997).
1.5.2 Control of matrix metalloproteinase expression
Most MMPs are not constitutively expressed and their production is regulated by 
cytokines in a complex network which also regulates the production of their inhibitors 
(Opdenakker and Van Damme, 1994). Johnatty et al (1997) demonstrated the regulation 
of pro-MMP9 production by the chemokines MIPla, MIPip and RANTES in human 
peripheral blood lymphocytes. In most cases the stimuli induce the expression of
35
activator protein 1 (API) transcription factors which bind to promoters controlling 
transcription. The promoter regions of the collagenases, stromelysins and MMP9 contain 
the API binding site whereas MMP2 (and MMP 11) does not, and it is suggested that it 
may be constitutively expressed for this reason (Yong et al 1998). The API binding site 
is located between -65 and -79 base pairs upstream from the transcriptional start site and 
transcriptional activity in response to cytokines is thought to also involve interactions 
with other cis acting sequences located in the promoter sequences (Benbow and 
Brinkerhoff, 1997).
1.5.3 Activation of matrix metalloproteinases
The inactive pro enzymes contain a pro peptide region which is bound by a 
cysteine residue to the zinc atom in the active site. Disruption of this so called ‘cysteine 
switch’ is essential for activation, forming a partially active intermediate form, from 
which the pro peptide may then be cleaved (Birkedal-Hansen, 1995). Cleavage of the pro 
peptide may be by autocatalysis or by the actions of other MMPs or proteases. 
Activation of MMP2 occurs at the plasma membrane where it is cleaved by MT-MMP. 
Other MMPs may be cleaved by the serine protease, plasmin, itself secreted as a pro 
enzyme requiring activation (Vassali and Pepper, 1994). MMPs may also be activated by 
bacterial proteases and also by reactive nitrogen species which interact with the cysteine 
switch (Maeda et al, 1998). MT-MMPs require removal of a pro peptide for activation 
and this is catalysed by the serine protease, fiirin (Sato et al, 1996).
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1.5.4 Inhibition of matrix metalloproteinase activity bv tissue inhibitors of
metalloproteinases
Tissue inhibitors of metalloproteinases (TIMPs) are a family of four, so far 
identified, naturally occurring inhibitors ranging from 21-28 kDa in size. TIMPs 1, 2 and 
4 are secreted and TIMP3 is predominantly associated with the extracellular matrix. 
TIMPs contain 12 highly conserved cysteine residues forming six disulphide bonds which 
are essential in maintaining the correct 3D structure of the molecule (Willenbrock and 
Murphy, 1994). The six loops formed by the disulphide bonds are divided into two 
distinct domains termed the C terminal domain and the N terminal domain. The 3D 
structure of stromelysin 1 bound to TIMP1 has been elucidated by X ray crystallography 
and showed that the wedge shaped TIMP slots with its edge into the active site cleft of 
the enzyme, occupying the entire length of the active site (Gomis-Ruth et al, 1997). 
MMPs may be regulated by binding to TIMPs in 1:1 non covalent complexes. Active 
MMPs bind to TIMPs to regulate proteinase activity and TIMPs also bind the pro forms 
of the gelatinases (MMP2 and 9), controlling the rate at which physiological factors 
activate MMPs. The complex formed by TIMP2 and pro MMP2 has been shown to be 
important in allowing pro MMP2 to associate with MT-MMPs (Birkedal-Hansen, 1995). 
All active MMPs can also be inhibited by 0C2 macroglobulin (Cawson, 1998).
1.5.5 The Extracellular matrix of the CNS
The extracellular matrix (ECM) of the CNS is a complex meshwork of proteins 
and proteoglycans that provide structural support and influence many biological activities 
such as cell adhesion and migration (Carbonetto, 1984). It comprises of up to one fifth of 
the volume of the CNS and consists mainly of proteoglycans (Sobel, 1998). Versican, a 
product of glial cells in the adult CNS, is one of the largest members of a chondroitin
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sulphate proteoglycans family, abundant in the CNS white matter, which can be broken 
down to glial hyaluronic acid binding protein (GHAP) by MMPs. GHAP is lost in 
chronic MS plaques (Sobel, 1998). A critical role is played by activated macrophages, 
including microglia in the brain, in their ability to regulate ECM turnover, especially in 
inflammation (Gottschall et al, 1995). MMPs expressed by microglia, endothelial cells 
and infiltrating cells are involved in remodelling of the ECM following CNS injury. 
Breakdown of the BBB in MS with leukocyte infiltration, causes plasma components, 
not normally associated with the CNS, to become part of the CNS ECM therefore the 
ECM is altered during the course of the disease. This alteration in ECM deposition in the 
CNS may form a ‘scaffold’ for leukocyte and microglial migration within the parenchyma 
and is likely to depend upon protease secretion (Sobel, 1998). The ECM components 
themselves are thought to influence MMP secretion by macrophages, influencing their 
own breakdown, e.g. exposure of human alveolar macrophages exposed to denatured 
collagens in culture, stimulated the expression of interstitial collagenase (Shapiro et al, 
1993).
1.5.6 Matrix metalloproteinases produced bv microglia
Production of MMPs by microglia has been studied in vitro and has shown that 
rat brain microglia constitutively produce the highly controlled MMP9 which can be 
upregulated by treatment of the cells with bacterial LPS (Gottschall et al, 1995). Colton 
et al (1993) also found that microglia produced MMP9 as well as MMP2 by analysis of 
culture supernatants. Microglia have been shown to constitutively express MT-MMP 1 
with only a slight increase in expression in Alzheimer’s disease brain (Yamada et al, 
1995a).
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1.5.7 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in CNS
disease
There is growing evidence that MMPs are involved in many CNS pathologies, in 
particular, the gelatinases. Studies on human CNS tissue from stroke patients, dying at 
time intervals from 2 hours to several years after the ischaemic event, were carried out by 
analysing the gelatinase levels in protein extracts. This revealed that MMP9 was 
increased maximally in the cases dying after 2-4 days whilst MMP2 activity was 
maximally increased in cases dying at longer post stroke intervals (Clark et al, 1997). 
Both gelatinases persisted for many months after the event and since microglia are also 
locally abundant, it is postulated that microglia are the major cell type contributing to the 
gelatinase expression. Anthony et al (1997) also demonstrated the presence of MMP9 
positive macrophages in infarcted tissue although the predominant cell type expressing 
MMPs 2 and 9 were infiltrating neutrophils. Microglial activation was noted but little 
MMP2 or matrilysin staining in these cells was observed in the cases examined. A study 
on MMPs in cerebral aneurysms also demonstrated their importance in the pathological 
process in haemorrhage and showed MMP9 localisation in focal areas within aneurysms 
(Bruno et al 1998).
The gelatinases and other MMPs have long been implicated in tumour invasion 
and metastasis and they are overexpressed in tumours of the CNS, although it is difficult 
to define whether the MMPs are expressed by the tumour cells or other tumour 
associated cells e.g. macrophages (Rooprai and McCormick, 1997). CSF analysis of 
patients with malignant astrocytomas or brain metastases showed that it contained pro 
MMP9 which was not detected in control patients and it was suggested that this could be 
used for early diagnosis of brain tumours (Friedberg et al, 1998).
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MMPs are also associated with Alzheimer’s disease, as microglia expressing 
MMP2 are closely associated with amyloid p deposits. It is not clear whether microglia 
contribute to its deposition or prevent deposition by degrading amyloid precursor protein 
derived from damaged neurons (Yamada et al, 1995b). Other groups have recently 
shown that metalloproteinases expressed by microglia can degrade amyloid P in cultures, 
but the enzymes may not be members of the matrix metalloproteinase family (Qiu et al, 
1997, Mentlein et al, 1998)
1.5.8 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in MS and 
EAE
There is much evidence for the involvement of MMPs and TIMPs in MS. MS 
pathology is characterised by BBB breakdown, myelin loss and recruitment of 
inflammatory cells, all of which are thought to involve the actions of proteases. The 
importance of MMP production in MS is that it has a possible role in microglial 
migration to the inflamed site and MMPs have also been shown to cleave myelin basic 
protein (MBP) in vitro, which is the major constituent of the myelin sheath (Proost et al, 
1993). MMP9 is capable of digestion of MBP, a major component of the myelin sheath 
(Gijbels et al 1993) creating MBP fragments and at least one major encephalitogen was 
found to be released (Proost et al, 1993). MMP9 is thought to contribute to breakdown 
of the BBB and has been detected at elevated levels in serum from MS patients, 
compared to normal healthy controls (Lee et al, 1999). Serum levels were found to be 
higher during clinical relapse. MMP9 is also elevated in CSF samples from MS patients 
compared to healthy controls that had undetectable MMP9 levels in their CSF, although 
within the MS group, levels were found to be comparable between relapses and clinically 
stable periods of the disease (Leppert et al, 1998).
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Immunohistochemical studies on MS and EAE brain have detected 
immunoreactivity for MMPs 2, 3, 7, and 9, although only MMPs 2 and 7 were observed 
in normal human brain by Anthony et al (1997), whereas Cuzner et al (1996) observed 
MMP2 and 9 in normal brain with increased expression by macrophages and microglia in 
active MS plaques. Furthermore, injection of MMP2 into rat brain has been shown to 
cause leakage and destruction of the BBB (Chandler et al, 1997). MMP7 was found to 
be strongly upregulated in animals with EAE, coincident with the peak of clinical disease 
(Clements et al, 1997, Kieseier, 1998). MMP 9 has been shown to exhibit strong positive 
staining around CNS blood vessels in active demyelinating MS lesions (Cossins et al,
1997) and in inflammatory lesions in EAE induced by adoptive transfer (Kieseier et al,
1998).
The levels of both MMPs and TIMPs are important in the balance between lytic 
and anti-lytic activities and their distribution in CNS pathology must be considered. 
Studies on an SWR mouse model of EAE showed an increase in the expression of both 
MMP genes and TIMP1 by RNase protection assays on total RNA extracted from brain 
and spinal cord (Pagenstecher et al, 1998). Inflammatory lesions containing the MMP 
expressing mononuclear cells were surrounded by astrocytes that expressed the TIMP 1 
gene and it is suggested that this may confine the extent of tissue destruction and retard 
the migration of the inflammatory cells throughout the brain parenchyma (Pagenstecher 
et al, 1998). The beneficial effects of TIMP expression in MS, apart from MMP 
inhibition, may also be due to their growth promoting activities demonstrated in vitro 
(Hayakawa et al, 1992, Hayakawa et al, 1994) which could be important in 
remyelination. Despite the links between MMP9 and demyelination, it has also been 
discovered that oligodendrocytes stimulated with phorbol esters synthesise MMP9, 
which is utilised for process elongation. This is important in the developing CNS and this
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may also have implications for attempts at remyelination in remission phases of MS 
(Uhm et al, 1998). The levels of TIMP 1 and 2 have been assessed in patients with 
relapsing remitting MS and compared to healthy controls and patients with other CNS 
pathologies, with an inflammatory response. Mean TIMP 1 levels were lower in MS 
patients than in patients with other CNS inflammatory conditions but higher than healthy 
controls, whereas TIMP 2 levels were higher in MS patients than both control groups 
(Lee et al, 1999). With the knowledge that TIMP 1 preferentially binds to MMP9 and 
that MMP9 levels are increased, this may suggest that the ineffective inhibition of MMP9 
activity contributes to an overall lytic activity in MS.
1.5.9 Matrix metalloproteinase inhibition as a treatment for MS
The correlation between MMP activities and the pathology of the MS lesion has 
led to a growing amount of research on inhibitors of MMP activity as potential therapies. 
Suppression of actively induced EAE in Lewis rats was observed in 9 out of 10 animals 
after treatment with the MMP inhibitor, Ro31-9790, whereas 9 out of 10 of the group of 
animals receiving vehicle alone showed clinical signs of EAE (Hewson et al, 1995). An 
anti-rheumatic drug, D penicillamine, was found to effectively inhibit MMP2 and 9 
activity in the CSF of MS patients and also decreased the severity of relapse in a chronic 
relapsing EAE induced in Biozzi mice, when treated after the first episode (Norga et al,
1995). MS patients suffering acute relapse, when treated with the steroid, 
methylprednisolone, show reduced leakage of the BBB and analysis of MMPs and 
TIMPs in the CSF showed a decrease in MMP9 levels after steroid treatment and an 
increase in TIMP levels, suggesting that this may be the mechanism of steroid action 
(Rosenberg et al, 1996). Another drug used in the treatment of MS, Interferon P-lb, was 
shown to decrease the in vitro migration of activated T lymphocytes through fibronectin
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coated membranes and reduce their ability to degrade fibronectin. Treatment of the T 
cells with IFN P-lb also reduced their MMP9 activity and it is proposed that the 
decrease in cell migration was due to the effects on MMP9 activity (Stuve et al, 1996). 
The mechanism of action for IFN P-lb is thought to be by the reduced expression of IL- 
2 receptor on the cell surface. IL-2 increases MMP expression by T cells and enhances 
migration in vitro which can be reduced by pre-treatment with IFN P-lb (Leppert et al,
1996).
1.5.10 The plasmin/ plasminogen activator system in matrix metalloproteinase activation 
The control of MMP activity in part, is by proteolytic cleavage of the proenzyme 
of which the serine protease plasmin, plays a major role. Plasmin itself is secreted as the 
proenzyme, plasminogen, which is cleaved to its active form by the plasminogen 
activators, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen 
activator (uPA). tPA is the major circulating activator whereas uPA operates as a major 
cell surface activator when bound to its receptor, uPAR (Chapman, 1997). Plasminogen 
activators themselves are also regulated, similarly to MMPs by natural inhibitors, PAIs. 
tPA and PAI-1 have been found to be expressed by infiltrating mononuclear cells in MS 
white matter and primary lesions with a lack of tPA expression in control brain (Cuzner 
et al 1996). The expression of both enzyme and inhibitor emphasises the tight control of 
enzyme activity and the complexity of the activation pathways. Rat microglia in culture 
are a source of both uPA and plasminogen itself and stimulation with LPS was found to 
increase plasminogen secretion and decrease uPA secretion into conditioned medium 
(Nakajima et al 1992a,b). uPAR is also expressed on the surface of microglia and is 
upregulated in the MS lesion (Washington et al, 1996). The expression of plasminogen, 
uPA and uPAR by microglia are thought to have several implications in the development
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of MS lesions. As well as their role in proteolysis and activation of MMPs, they also play 
a complex role in cell migration and/or adhesion (Blasi, 1997, Chapman, 1997). uPAR 
also functions as a receptor for vitronectin (Wei et al 1994) and the receptor is 
distributed at sites of focal adhesions in fibroblasts and at the leading edge of migrating 
monocytes (Gyetko et al, 1994). uPA itself is a chemotactic factor for leukocytes, 
endothelial cells and macrophages, requiring binding to uPAR (Blasi, 1997) An epithelial 
cell line was found to exhibit a three fold enhancement of migration by binding of 
exogenous uPA to uPAR expressed by the cells (Busso et al, 1994).
1.6 Nitric oxide in CNS physiology/pathology
Nitric oxide (NO) is formed from a reaction between molecular oxygen and L- 
arginine catalysed by nitric oxide synthase (NOS). It is highly reactive and is rapidly 
oxidised to nitrite and then to nitrate.
L-arginine + O2 -> L-citrulline + NO’
There are three isoforms of NOS, all of which can be found in the CNS, these are 
endothelial (eNOS), constitutive (cNOS) and inducible iNOS (Rang et al, 1995). cNOS 
is found in neurons and is important in nerve transmission. It is calcium dependant and 
produces relatively small amounts of NO compared to iNOS which operates via a 
calcium independent mechanism (Smith et al, 1999).
iNOS is not constitutively expressed, as its name suggests and the induction of 
this isoform by cytokines in vitro has been reported in human astrocytes (Chao et al, 
1995) and microglia (Ding et al, 1997). Additionally, iNOS mRNA was detected by 
Northern blot experiments in mRNA extracts of total human brain from MS patients and
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was absent in control brain extracts from patients who had no neurological disease 
(Bagasra et al, 1995). The authors also reported that cells of the monocyte/macrophage 
lineage in MS brain sections expressed iNOS implicating NO, possibly macrophage 
derived, in MS pathology. There appears to be conflicting evidence as to whether nitrate 
measurement in CSF samples from MS patients is a good marker for diagnosis. Johnson 
et al (1995) reported an increase in nitrate levels in the CSF of MS patients whereas 
others (Ikeda et al, 1995, de Bustos et al, 1999) found no correlation between CSF 
nitrate in MS patients compared to normal controls or patients with non inflammatory 
neurological disorders.
Evidence suggests that the role of NO in CNS pathologies may be damaging. 
Minghetti et al, (1996) demonstrated that LPS induced PGE2 release by cultured rat 
microglia could be increased by addition of an inhibitor of NOS or decreased by the 
addition of a compound that spontaneously releases NO. This may suggest a 
neuroprotective role for NO, although PGE2 also has proinflammatory activities such as 
increasing vascular permeability. NO can have a wide variety of effects on cellular 
systems by altering protein structure and hence function. Several groups have reported 
on the ability of microglia derived NO to cause neuronal and oligodendroglial damage in 
vitro. Co-incubation of activated rat microglia with neurons resulted in neurotoxicity 
which was inhibited by the addition of an NO inhibitor (Boje and Arora, 1992). Similar 
results were also reported by Chao et al (1992), who showed that a ratio of 1 microglial 
cell to 200 neuronal cells was required to impair neuronal cell function. Merrill et al 
(1993) demonstrated the ability of IFNy stimulated rat microglia to mediate cytotoxicity 
of oligodendrocytes, and this was significantly reduced by inhibitors of NOS. This 
suggests an important role for NO in demyelination in MS. Furthermore, MBP mRNA 
expression by an oligodendrocyte cell line was shown to be significantly inhibited by the
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addition of S- nitroso, N- acetly- DL- penicillamine (SNAP), a chemical that 
spontaneously releases NO into cell cultures (Mackenzie-Graham et al, 1994).
Further evidence to suggest an involvement of NO in MS is the detection of 
iNOS in MS sections, with higher accumulations in areas containing plaques than areas 
without pathology (Hooper et al, 1997). The same group also showed that PLP induced 
acute EAE in mice was prevented by daily immunisation with an inhibitor of iNOS 
induction (D609) and that 24 hours after the last treatment, EAE developed. MMPs can 
also be activated by reactive nitrogen species which interact with the cysteine switch 
mechanism exposing the active site of the enzymes (Maeda et al, 1998). The expression 
of iNOS has been shown to be increased six fold in patients with AIDS dementia 
compared to seronegative controls (Adamson et al, 1996).
1.7 Superoxide in CNS pathology
Superoxide (O2') is produced by macrophages in respiratory burst and 
itsproduction from molecular oxygen is catalysed by the membrane bound NADPH 
oxidase (Smith et al, 1999). This highly reactive species is commonly used as a 
microbicidal agent by macrophages but is also heavily implicated in CNS demyelination. 
Microglia are known to produce superoxide in vitro in response to PMA stimulation 
(Colton and Gilbert, 1987) which is increased by first priming the cells with cytokines 
such as TNFa (Hu et al, 1995) or IFNy (Woodroofe et al, 1989, Hu et al, 1995). The 
priming effects of these cytokines on microglial superoxide production was found to be 
downregulated by addition of the anti inflammatory cytokine, TGFP to cell cultures. (Hu 
et al, 1995). It has also been shown that phagocytosis of myelin by macrophages triggers 
the production of reactive oxygen species whereas phagocytosis of latex beads did not 
produce the same effect (van der Goes et a,11998).
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Superoxide can combine with the highly reactive NO to form peroxynitrite with a 
half life of milliseconds (Beckman and Koppenol, 1996) and it is believed that many of 
the effects attributed to NO may be caused by formation of peroxynitrite and other 
agents derived from it such as peroxynitrous acid (Smith et al 1999). High intracellular 
levels of SOD provide some protection from superoxide and NO which competes with 
superoxide for SOD (Smith et al, 1999). Hartung et al (1988), however showed 
suppression of an EAE model in rats when treated with the hydrogen peroxide 
scavenger, catalase or superoxide dismutase. A peroxynitrite scavenger, uric acid, 
completely protected mice from PLP induced EAE when given a daily dose of 20mg, 
whereas all controls that did not receive uric acid became severely paralysed (Hooper et 
al, 1997). The study of superoxide and nitric oxide production by activated microglia, is 
important as their highly reactive nature is likely to cause tissue damage in the 
inflammatory response in the CNS.
Aims of this thesis
The overall aims of this thesis were to investigate the possible roles of the chemokines, 
present in multiple sclerosis plaques, on microglia in vitro. Previous research on 
chemokine function has mainly focused on their chemotactic effects on lymphocytes 
therefore we aimed to determine other effects on microglia as well as chemotaxis. The 
postulated functions of microglia include proteinase secretion, free radical production 
and phagocytosis, thus the roles of chemokines in modulation of microglial functions 
were of interest and will provide further knowledge on specific areas to target in the 
treatment of MS.
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Chapter 2
ISOLATION OF MICROGLIA AND IMMUNOCYTOCHEMISTRY
2.1 Introduction
2.1.1 Isolation of microglia from rat CNS tissue
The most widely used method of microglia isolation is dependant on the survival 
and different adherence under culture conditions of the various CNS cell types and was 
first described by McCarthy and de Vellis (1980). This method is lengthy and it can take 
7-10 days in culture before microglia cultures can be obtained. A different method was 
devised by Hayes et al, (1988) which exploits the expression of Fc receptors by 
microglia. In this method, tissue is dissociated mechanically with or without enzyme 
digestion to generate a mixed cell population containing the microglia. Opsonised 
erythrocytes are then used to ‘rosette’ the microglia which can be pelleted by density 
gradient centrifugation, removing contaminating astrocytes, oligodendrocytes and 
neurons. The erythrocytes are then removed by hypotonic lysis to achieve very pure 
cultures of microglia. Adult microglia isolated by Hayes et al (1988) lacked the non 
specific esterase activity, present in neonatal microglial cultures. As microglia isolated 
from 30 day old rats are more comparable to adult microglia than the neonatal microglia 
which may better represent amoeboid microglia, the 30 day old microglia have been used 
for the majority of experiments in this thesis. A more recent method has been developed 
by Sedgwick et al, (1991) which employs enzyme digestion, density gradient 
centrifugation followed by flow cytometry to select CD45low cell populations that were 
shown to be microglia. CD45 is a leukocyte common antigen and cells expressing high
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levels of this in the populations of cells isolated were found to be inflammatory 
leukocytes and represented only a small population of the total percentage of cells.
Due to the relatively small number of microglia that are isolated from rat CNS 
and the lack of proliferation in culture, it was necessary to use a human microglial cell 
line as a possible comparison to results obtained from the primary rat microglia.
2.1.2 CHME3. microglial cell line
CHME3 cells (a kind gift from Prof. M.Tardieu, Universite Paris Sud, Paris, 
France), are a human foetal microglial cell line derived from CNS tissue acquired from 8 
week old embryos after elective abortion, from which microglia were isolated using a 
shaking and adherence method and transformed with a plasmid containing cDNA 
encoding the SV40 large T antigen to confer immortality. The CHME3 clone were found 
to express the markers, CD68/EBM-11, CD68/Ki-M7 and displayed non specific 
esterase activity. The cells did not constitutively express MHC II but the expression 
could be induced by treatment with IFNy (lOOIU/ml) for 18 hours (Janabi et al, 1995). 
Transformed cells were also found to express IL-6 and display the macrophage 
characteristics of adherence and phagocytosis (Janabi et al, 1995).
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2.1.3 Aims
1. To isolate pure cultures of neonatal and adult rat microglia and astrocytes to study in 
vitro.
2. To assess the purity of these cultures by immunocytochemistry using cell type specific 
antibodies.
3. To culture a microglial cell line for use as a comparison to rat microglia in future 
experiments.
4. To identify whether chemokines have any effect on proliferation of the cell line.
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2.2 Materials and Methods
2.2.1 Culture media
Microglia, astrocytes, peritoneal macrophages and the cell line CHME3 were 
cultured in Dulbecco's Modified Eagles Medium (DMEM, Life Technologies, Paisley, 
U.K) supplemented with 10% heat inactivated foetal calf serum (Life Technologies), 100 
IU/ml penicillin and 100 pg/ml streptomycin (Life Technologies). This complete media 
was then termed cDMEM. Cells were maintained at 37°C, 5%C02/95% air in a 
humidified environment.
2.2.2 CHME3 cell culture
CHME3 cells were grown in 75cm2 flasks in cDMEM and passaged every 2-3 
days. Briefly, after rinsing with phosphate buffered saline (PBS) (Life Technologies), 
cells were removed by the addition of 2ml of trypsin/EDTA (Life Technologies) for 
approximately 5 minutes followed by tapping the flask to remove any remaining adherent 
cells. Cells were then transferred to 50ml centrifuge tubes in cDMEM and centrifuged at 
lOOg for 10 minutes. Cell pellets were resuspended in cDMEM and replated into new 
flasks. Cells were used between passages 3 and 12.
2.2.3 CNS Tissue
CNS tissue was obtained following cervical dislocation of 30, 30 day old Wistar 
rats of both sexes (purchased from Sheffield University, Field Laboratories). Cerebrae 
were dissected out and the meninges and large visible blood vessels removed by rolling 
on methanol sterilised filter paper (Whatman, U.K) in a lamina flow hood. CNS tissue
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was also obtained from 20-50, 2-3 day old Wistar rats following decapitation, and the 
meninges removed as above. Tissue was used for isolation of microglia and astrocytes.
2.2.4 Enzymes
Stock solutions of 10X concentrated collagenase, DNase I and trypsin (Sigma, U.K) 
were prepared in Earles Balanced Salt Solution with calcium and magnesium (EBSS+, 
Sigma) as shown below and filter sterilised by passing through a 0.22 pm filter (INC 
Flow Labs, U.K). Enzymes were stored in 10ml aliquots at -20°C.
Enzyme Concentration
Collagenase type XI lOOOU/ml
Deoxyribonucleate 5-
oligonucleotidohydrolase (DNase I), type II 200 pg/ml 
Trypsin type III 1.25% w/v
2.2.5 Haemagglutination titration
A haemagglutination assay was performed to identify the concentration of rabbit 
anti human erythrocyte membrane antibody (Dako, U.K) required to cause agglutination 
of erythrocytes. The sub-agglutinating concentration was then chosen to opsonise 
erythrocytes used to isolate microglia. Approximately 10 ml of human peripheral blood 
was obtained by venipuncture into EDTA tubes and centrifuged at 180g (Sorvall RT 
6000D centrifuge, DuPont, UK.) for 10 minutes at 4°C. A dilution series of rabbit anti 
human erythrocyte membrane antibody was prepared in duplicate in EBSS+ to give final 
volumes of250pl in a 96 well round bottomed microtitre plate.
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Ab concentration
1/ 1/ 1/ 1/ 1/ 1/ 1/ 1/ 1/ 1/ 0
50 100 200 300 400 500 600 700 800 1600
To each well, 5 pi of erythrocytes, packed by centrifugation, was added to give a 
2% v/v erythrocyte concentration. The plate was then incubated at room temperature for 
30 minutes before being examined over a light box to select the sub-agglutinating dose. 
The dose of antibody required was determined as 1/600.
2.2.6 Opsonisation of erythrocytes (EA)
Approximately 10 ml of human peripheral blood was obtained by venipuncture 
into EDTA tubes. Blood was centrifuged at 180g (Sorvall RT 6000D centrifuge, 
DuPont, U.K, used throughout the procedures) for 10 minutes at 4°C. The plasma and 
buffy coat layers were removed and the erythrocytes resuspended in EBSS without 
calcium and magnesium (EBSS-) to 50ml. The cells were then centrifuged at 180g for 10 
minutes at 4°C, resuspended in EBSS- the and the washing process repeated.
A 2% v/v suspension of erythrocytes in EBSS+, was then incubated with rabbit 
anti-human erythrocyte antibody (Dako, UK) at a 1/600 dilution which was the optimal 
concentration of antibody determined by agglutination titration. After 30 minutes at 
room temperature with constant mixing on a rotator, the cells were washed twice and 
resuspended in EBSS+ at 2% v/v and stored at 4°C for up to 24 hours.
2.2.7 30 day old rat microglia preparation
All manipulations were carried out under sterile conditions in a lamina flow hood. 
CNS tissue from 30 day old rats was chopped in two 90° planes on a Mcllwain chopper
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(The Mickle Lab. Engineering Co., Surrey, U.K) set at 0.4mm thickness, placed in a 
sterile pre-weighed 500ml bottle and the weight of tissue determined, lml/g of CNS 
tissue, of the stock enzymes trypsin, collagenase and DNase and 7ml EBSS+ per gram of 
tissue were added and incubated at 37°C with continuous stirring on a magnetic stirrer 
for 15 minutes. 1ml newborn calf serum (NCS) per gram of tissue was then added to 
stop the reaction followed by dilution to twice the original volume with ice cold EBSS-. 
The cell suspension was then centrifuged at 4°C, 180g for ten minutes. The pellet was 
resuspended and the enzyme digestion step repeated as above. The digestion was 
stopped again as before and the digested tissue pelleted again, by centrifugation. The 
pellet was resuspended and filtered through fine methanol sterilised nylon meshes of 132 
and 80pm pore sizes (J. Stanniar and Co., Manchester, U.K) by forcing through the 
suspension with a sterile 10ml syringe plunger (Figure 2.1).
2.2.8 Neonatal rat microglia preparation
CNS tissue from 2-3 day old rats was filtered immediately through the methanol 
sterilised mesh as above, without enzyme digestion as it is not required, and the amount 
of tissue was estimated. Both 30 day old and neonatal cell suspensions were then 
processed as below.
2.2.9 Isolation of microglia from mixed glia suspensions
Mixed glial suspension was made up to 5ml/g starting tissue in EBSS^ and mixed 
with an equal volume of 2% EA. This was incubated at 37°C for 30 minutes. Cells were 
then pelleted by centrifugation (180g for 10 minutes at 4°C) and resuspended in EBSS- 
to lOml/g starting tissue. 25 ml of cell suspension was carefully layered onto equal 
volumes of Percoll (62ml Percoll (Sigma), 10ml 10X Basal medium eagle (BME) (Life
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Technologies) 28ml sterile distilled water, giving a final density of.l.086g/ml) in 50ml 
tubes.
Figure 2.1 A schematic diagram of a sieve made from a 50ml tube 
mixed cell
suspension
cut off base
50ml centrifuge tube
r  132um 
T 80um nylon meshsc rew  lid with 
centre cut out
__i
The sieve was made out of a 50ml centrifuge tube with a piece of 132 and 80 pm pore 
nylon mesh over the end. Tissue is forced through to give the mixed glial suspension 
(diagram adapted from Woodroofe and Cuzner, 1995).
These cell suspensions layered on density gradients, were centrifuged at 500g for 
20 minutes at 18°C, with the brake off. Figure 2.2 shows the distribution of cells after 
density gradient centrifugation.
Cell pellets were pooled and resuspended to lml/g starting tissue in EBSS- and 
divided into 5ml quantities in 50ml tubes. Erythrocytes were lysed by addition of 40ml 
ice cold sterile distilled water for 45 seconds followed by the addition of 4.5ml 10X 
BME (Life Technologies) to restore tonicity. Cells were then pelleted at 180g for 10 
minutes at 4°C and the lysis step repeated. Cells were then resuspended to 2ml in
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DMEM for counting in a haemocytometer. Cells were diluted to the required density in 
cDMEM and placed into culture or in DMEM without foetal calf serum and used 
directly in chemotaxis assays.
2.3 Isolation of astrocytes
Astrocytes were isolated from 30 day old Wistar rats following the same method 
as for microglial cell isolation up to and including separation on density gradients. The 
layer of myelin containing the astrocytes (Figure 2.2) was removed and layered onto 
Percoll prepared as above and then diluted 1:1 with EBSS and centrifuged again at 500g 
for 20 minutes at 18°C with the brake off. Pellets were then resuspended in cDMEM and 
placed into 75cm2 culture flasks. Non adherent cells were washed away after 24 hours in 
culture.
Figure 2.2. Distribution of cells after density gradient centrifugation.
^  supernatant
  myelin layer containing
astrocy tes
< —..........  Percoll density gradient
  pellet of rosetted microglia
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2.4 Isolation of peritoneal macrophages.
Rat peritoneal macrophages were isolated from adult Wistar rats by peritoneal 
lavage with 50ml of ice cold EBSS-. These were pelleted by centrifugation at 180g for 
10 minutes at 4°C, washed in EBSS-, and resuspended in 2ml cDMEM. Cells were then 
counted using a haemocytometer and plated into 96 well plates at a concentration of 
5xl0s/ml in cDMEM (200nl/well).
2.5 Immunocvtochemistrv (TCC1 on isolated cells
Cells were plated into 8 well chamber slides (Gibco BRL, U,K) at densities of 
2.5xl05/ml, lx l05/ml and 0.5xl05/ml for microglia, astrocytes and CHME3 cells 
respectively. 400pl of cell suspensions were added per well. Microglia and astrocytes 
were maintained in culture for 3-7 days and CHME3 cells were cultured overnight, prior 
to fixing.
Immunocytochemistry was used in order to identify microglia and other cell types 
in cultures using cell type specific antibodies. Visualisation of the resulting 
antigen/antibody complex involves labelling the antibody with an enzyme such as 
peroxidase. The enzyme then produces a colour change on addition of a specific 
substrate. The technique may also employ the use of a biotinylated secondary antibody 
against the Fc portion of the primary antibody which binds avidin-peroxidase conjugate 
as in the Vectastain Elite ABC Kit (Vector laboratories, U.K) used in the following 
experiments. Figure 2.3 shows how antigens are visualised by this method.
57
Figure 2.3. Avidin biotin peroxidase complex method for Immunocytochemical detection 
of an antigen expressed by a cell.
Substrate Coloured precipitate 
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Antigen
Avidinjiperoxidase conjugate
Secondary bictinylated antibody
/ V
Primary antibody
CELL
Cells grown in 8 well chamber slides were fixed at 4°C in the appropriate fixative 
for the antigen under study for 2 minutes(see Table 2.2). The 30 day old rat microglial 
cells were all fixed in 4% paraformaldehyde prior to the experiment for convenience.
Table 2.1 Antibodies used for cell characterisation:
Antibody Concentration Purchased from Specificity
OX 42 1:100 Serotec rat macrophages
aGFAP 1:100 Sigma astrocytes
EDI 1:100 Serotec rat macrophages
*cxGC neat supernatant
-
oligodendrocytes
CD68/EBM-11 1:100 Dako human macrophages
* Anti GC (galactocerebroside) antibodies were obtained from the cell supernatant of a 
hybridoma cell line (a kind gift to Dr N Woodroofe from Dr B Rantsch
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Table 2.2 Fixatives used for specific antigens under study in immunocytochemistry 
experiments.
Antibody Fixative
Anti-GFAP Acetone
EDI Acetone
0X42 Ethanol
Anti-GC Acetone
CD68/EBM-11 5%acetic acid/95%ethanol
All fixatives were used at 4°C.
After fixing, slides were then washed in phosphate buffered saline (PBS) (Sigma). 
The plastic walls of the chamber slides were removed and wells were covered in 1.5% 
blocking serum (Normal horse serum, from the kit) in PBS for 30 minutes, to prevent 
non specific binding of antibodies. Cells, except for the control well, were then incubated 
with 50pl of primary antibody (Table 2.1) diluted in buffer (0.1% BSA in PBS) for 30 
minutes and then washed for 10 minutes with three changes of PBS. Control wells were 
incubated in 0.1% BSA in PBS alone. Slides were then incubated with biotinylated horse 
anti mouse secondary antibody at 1:200 dilution, (from the kit) in buffer with 100pl of 
blocking serum per 5ml of diluted antibody, for 30 mins.
Slides were washed in buffer again for 10 mins and then incubated for 30 mins 
with Vectastain Elite ABC reagent, prepared 30 minutes prior to use. Cells were then 
washed in PBS for 10 mins and incubated in 0.2% 3,3’diaminobenzidine 
tetrahydrochloride (DAB) substrate (Sigma Ltd, UK) containing H2O2 (40 pi/100ml 
DAB) for 2-7 mins until the desired staining intensity developed. Slides were finally 
washed in tap water and mounted in Immumount (Shandon,UK). For ICC on astrocytes,
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FITC labelled avidin (1/150) (Vector Laboratories, U.K) was used instead of the ABC 
reagent for 30 minutes. Following this incubation, cell were washed and mounted in 
Immumount (Shandon,UK).
Cell staining using DAB substrate was observed by light microscopy on the 
Olympus BX60 microscope and colour photographs taken at various magnifications on 
Kodak colour film (200 ASA). FITC staining of astrocytes was observed by fluorescence 
microscopy and images captured by CCD colour video camera (JVC).
2.6 MTT (3-f4.5-Dimethvlthiazol-2-vD -2.5-diphenvl tetrazolium bromide! assay.
The MTT assay is used to quantify cell numbers. MTT is a water soluble 
tetrazolium salt and is converted from a yellow solution to a purple insoluble formazan 
by cleavage of a tetrazolium ring by dehydrogenase enzymes present in the mitochondria 
of living cells. When solubilised in isopropanol, the amount of formazan produced can be 
measured spectrophomometrically and can be used to show the differences in cell 
numbers in cultures. MTT assays were performed on CHME3 cells following cytokine 
stimulation for 24 hours to see if this had an effect on cell proliferation.
2.6.1 MTT assay method
CHME3 cells were plated into 96 well plates at a concentration of lx l05/ml 
(200pl/well) and cultured for 24 hours. Cells were then stimulated in triplicate with 
human recombinant tumour necrosis factor a  (TNFa) (Peprotech, U.K) (0.1, 1 and 
lOng/ml), interleukin-lp (IL-ip) (Peprotech, U.K) (0.1, 1 and lOng/ml) and IFNy (Life 
technologies, U.K) (1, 10 and 100 IU/ml). The chemokine, MCP1, was also included at 
1, 10 and lOOng/ml. After stimulation for 24 hours, the supernatant was removed and 
50pl of MTT (Sigma) (1 mg/ml in Hanks Balanced salt solution (Life technologies)) was
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added to each well and the plate was incubated for two hours at room temperature. 
lOOpl of acidified isopropanol (20ml isopropanol + 25pi concentrated HC1) was then 
added and left for a further 20 minutes before the absorbance was read at 570nm on a 
Titertek plate reader.
2.7 Bicinchoninic acid (BCA) assay
This is a simple assay to determine total protein content which can be related to 
cell numbers in a 96 well plate. Protein reduces alkaline Cu (II) to Cu (I) in a 
concentration dependant manner to form a purple complex which can be read 
spectrophotometrically. The BCA assay was used to assess whether the chemokines 
exert an effect on cell proliferation.
2.7.1 BCA assay method
CHME3 cells were plated in to 96 well plates as above and stimulated with the 
human chemokines MCP1, MIPla, MIPlp, RANTES, IL-8, and IP-10 (a kind gift from 
Professor D Taub, NIH, Maryland USA) at 10, 20 and 50ng/ml for 24 hours. The 
supernatant was removed and the plate stored at -20°C to break open the cell 
membranes. After approximately 24 hours, plates were thawed and 50pl of lysis buffer 
was added (50mM Tris HC1, 0.1% Triton-X-100, pH 7.5) per well for 30 minutes at 
room temperature. Lysed cell supernatants were then removed, replicates pooled and 
then centrifuged (10,000g for 10 minutes in a micro centaur benchtop centrifuge) to 
remove cell debris. 20pl of pooled supernatants were then plated in duplicate into clean 
96 well plates followed by 200pl of BCA reagent (20ml BCA + 400pl 0.4% CuSCU) for 
30 minutes at room temperature, followed by measuring the absorbance at 570nm on a 
Titertek plate reader.
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2.8 Results
2.8.1 Microglial cell isolation from Wistar rat CNS tissue
Microglia isolated from 30 day old Wistar rats and 2-3 day old Wistar rats were 
counted and the yield was calculated following each isolation. Typical cell yields have 
been included in the following tables. Higher yields were obtained from neonatal rat 
brains than from adult rats.
Table 2.3 Examples of typical yields obtained from microglia isolations from 30 day old 
Wistar rats.
No. of animals used weight of tissue 
obtained (g)
Total no. of 
microglia isolated 
(xlO5)
Yield (xlO5) /g 
starting tissue
30 31 47 1.5
15 14 44 3.1
15 16 26 1.6
30 30 15.5 0.5
15 14 42 3
10 9 19 2.2
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Table 2.4 Examples of typical yields obtained from 2-3 day old Wistar rats
No. of animals used No. Microglia obtained
(xlO5)
Microglia yield /brain 
(xlO5)
40 44 1.1
50 33 0.6
25 58.5 2.3
25 46.5 1.9
32 26 0.8
2.8.2 Immunocvtochemistrv on cells in culture to identify cell specific markers
Microglial cells stained positively with antibodies against OX-42, which is an 
antibody against the complement receptor for C3b, and EDI a macrophage marker but 
were negative for GFAP, which was used to identify contaminating astrocytes and anti 
GC which was used to identify contaminating oligodendrocytes. (Figure 2.4a-d and 
Figure 2.5a-d)
CHME3 cells stained positively for CD68/EBM-11 which is an antibody specific 
for human macrophages and negative for GFAP which demonstrates that these cells are 
not of astrocyte origin. (Figure 2.6a-c).
Astrocyte preparations isolated from 30 day old Wistar rats all stained positively 
for GFAP indicating a highly pure population of cells, demonstrated by 
immunofluorescence (Figure 2.7a and b)
2.8.3 Proliferation assays on CHME3 cells
CHME3 cells when stimulated for 24 hours with the cytokines TNFa, IL-lp 
(0.1-10ng/ml) and IFNy (1-100 IU/ml) or the chemokines MCP1, M fPla, MLPip,
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Figure 2.4 Immunocytochemistry on 30 day old Wistar rat microglia
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using phase contrast microscopy so that cells could be more easily observed.
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b) OX-42 antibody (X400) Cells are stained positively for OX-42.
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Figure 2.4 continued. Immunocytochemistry on 30 day old Wistar rat microglia
c) ED-1 positive microglia (X400)
d) GFAP antibody to show the absence of contaminating astrocytes (X400)
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Figure 2.5 Immunocytochemistry on 2-3 day old rat microglia
a) Control (X200). Cells show negative staining. Photographs of control cells were 
taken using phase contrast microscopy so that cells could be more easily observed.
b) OX-42 antibody(X400). Cells are positive for OX-42.
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Figure 2.5 continued. Immunocytochemistry on 2-3 day old rat microglia
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c) ED l positive staining of 2-3 day old Wistar rat microglia (X400)
d) aGFAP (X400). Cells were negative for GFAP.
67
Figure 2.6 Immunocytochemistry on CHME3 cells
*
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%
a) control (X400) Cells show negative staining.
%
b) CD68/EBM-11 positive staining of CHME3 cells (X400)
Figure 2.6 continued. Immunocytochemistry on CHME3
c) GFAP negative CHME3 cells.
Figure 2.7 Immunofluorescence on astrocytes isolated from 30 day old Wistar rats.
a) Control (no primary antibody) (X400)
b) Rat astrocytes were stained positively using aGFAP (X400)
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RANTES, IL-ip and IP-10 at 10-50ng/ml, did not significantly increase cell proliferation 
when compared to control unstimulated cells (using a paired Student’s t test, P<0.05 was 
considered significant) thus demonstrating that at the concentrations used in the 
experiments in this thesis, these cytokines and chemokines had no significant effect on 
cell proliferation. This was shown using MTT and BGA assays (Figures 2.8 and 2.9).
71
Fig
ure
 2
.8 
MT
T 
ass
av 
on 
CH
ME
3 
ce
lls
   -
___________________ m m m m m
-----------------------------------
_______________________
-------------------------------
____________________
    • .
_ _
i-
      ; ; ____
(iuuozs) aoucq josqv
72
cell
 pr
olif
era
tion
 w
as 
obs
erv
ed 
(P<
0.0
5) 
usin
g 
a S
tud
ent
s' t 
tes
t.
Fig
ure
 2
.9 
BCA
 
ass
ay 
on 
CH
ME
3 
ce
lls
inCNJd CNJd
hBhSBB MiHlMHBI HHhhI I
-  '   ________________
___________________________________
_________
h
t ___________________ ________ _
o4->
(75
07
><u
. so
i n ’a3
oU.
C L
o (75
CNJ (75
o
■CL
07175(75
cd
o — O4-»
T D
O
Xo 4-*
m 0 )
e
c
20 CJ
00
PQ
a>
o
1— J X4-*
GO
. s
3
o 07l-H
c2a>
i n
o w X )
CNJ LU <17
1-
Z
Vh
3
o
<
DC | 3oT— CT)
C . G
(75a>
o c
i n 'Sco
ox
o
E
a> CN
CNJ ccl
CL
X
O
S-H
c2
o 3 )
c
o
m
o ■
i n or-H
3
o 07CNJ
a .
a
x
o
o 3<17
X
C7
X
o
m 'I
T O07
o 3
CNJ
Ko
G
. §Xo (7507<5
£
O cn
CJ
md inod
(uiuozs) aoueqjosqv
73
det
erm
ine
 th
e 
effe
ct 
of 
che
mo
kin
es 
on 
cell
 p
rol
ife
rat
ion
. N
o 
sig
nif
ica
nt 
inc
rea
se 
was
 o
bse
rve
d 
(P<
0.0
5) 
usin
g 
a S
tud
ent
s' t 
tes
t.
2.9 Discussion
2.9.1 Cell yields of microglia isolated from Wistar rat CNS tissue
The numbers of microglia obtained from 30 day old rats were generally lower 
than the yields reported by Hayes et al (1988) who reported yields of 8.2xl05 cells/gram 
of original starting tissue, using the same isolation procedure. Typical yields obtained 
here were between 0.5-3x105 cells/ gram of CNS tissue. One explanation for these lower 
yields may include the time between obtaining the CNS tissue and beginning the isolation 
process, which was up to an hour and involved storing the tissue on ice for 
transportation. Also, the large numbers of animals used each time may account for lower 
yields and this was also reported by Woodroofe et al (1989). It is estimated that there 
are around 3.5 million microglia in the rodent brain (Perry, 1994) which is far higher than 
the observed yields reported here. However, many cells are lost during the large number 
of steps in the isolation procedure, due to the adherent properties of microglia. Sedgwick 
et al, (1991) isolated cells by fluorescent activated cell sorting (FACS) and obtained 
yields of CD45low cells (reported as microglia) of 4.4x105 cells per brain using 3-4 week 
old Lewis rats. Although this is higher than the mean yields obtained here it is similar to 
maximal yields of 3x105 cells per animal using the rosetting method
The yields obtained from 2-3 day old rats were generally higher than those 
obtained from 30 day old rats which was also found by Hayes et al (1988). This could be 
accounted for by the remodelling process in the CNS in the pre-natal and early postnatal 
period, where microglia and macrophages are involved in phagocytosis of degenerating 
cells (Perry, 1994).
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2.9.2 Cell purity
Microglia cells showed a typical bipolar morphology in culture. Both 30 day old 
and 2-3 day old rat microglia showed positive staining by immunocytochemistry with 
OX-42 and ED-1 and were negative for aGFAP and aGC demonstrating the high purity 
of the cell preparations and lack of contamination with astrocytes or oligodendrocytes. 
Cells sometimes contained small numbers of erythrocytes which have been phagocytosed 
during the isolation procedure.
CHME3 cells stained positively for the macrophage marker, CD68/EBM- 
11 and were negative for GFAP demonstrating the cells were of macrophage and not 
astroglial origin. This was also found by Janabi et al (1995) who originally immortalised 
the cell line by EBV transformation of human foetal microglia.
Astrocytes isolated from Wistar rats were shown to be pure cultures by strong 
positive staining for glial fibrillary acidic protein and absence of staining for other cell 
types.
2.9.3 Proliferation assays
Since cytokines and chemokines were used to stimulate cells in culture it was 
necessary to examine the effects of these stimulations on CHME3 proliferation. Using 
MTT and BCA assays it was observed that the cytokines, TNFa, IL-ip and IFNy and 
the chemokines, MCP1, MIPla, MIPip, RANTES, IL-1 and IP-10 did not cause 
proliferation above control unstimulated cells. This indicates that any differences in 
results obtained in stimulation experiments with cytokines and chemokines, reported in 
the following chapters are not due to any effect on cell proliferation. Ganter et al (1992) 
reported that EL-1 and TNFa had no effect on proliferation of isolated microglia from 
Wistar rats although these cytokines did increase proliferation in mixed astrocyte/
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microglia cultures suggesting a role for other astrocyte derived factors. Ganter et al 
(1992) did however demonstrate microglia proliferation stimulated by EL-13 and GM- 
CSF.
76
Chapter 3
EFFECTS OF CHEMOKINES ON MICROGLIAL MIGRATION
3.1 Introduction
3.1.1 Microglia accumulation at sites of inflammation/tissue damage.
An important function of macrophages is their ability to migrate to sites of tissue 
infection and injury. Microglia and macrophages are found closely associated with areas 
of inflammation and tissue damage in many CNS pathologies and are involved in tissue 
destruction, by release of free radicals and secretion of proteases, proinflammatory 
cytokines and complement components (Sriram and Rodriguez, 1997). In the CNS in 
MS, EBM-11+ macrophage type cells with microglial morphology are associated at 
increased densities in active plaques and at their borders (Esiri and Reading, 1987). 
Activated microglia are also associated with mature senile plaques in Alzheimer’s disease 
and have been shown to accumulate at higher densities on cryostat sections of CNS 
senile plaques compared to the non-senile plaque area of the same tissue (Joshi and 
Crutcher, 1998). A model of experimentally induced glioma in the rat also demonstrated 
a massive infiltration of the tumour by activated microglial cells (Streit, 1996). The 
evidence from histopathological studies therefore suggest that microglia are able to 
migrate in vivo and a number of in vitro studies have been performed to reinforce this 
theory.
In vitro chemotaxis experiments, using microglia isolated from 2 day old rats, 
demonstrated their ability to migrate through polycarbonate filters in response to the 
chemotactic complement component, C5a (Yao et al, 1990) and this is thought to
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account, in part, for the accumulation of microglia at tissue injury sites. Other in vitro 
chemotaxis experiments, using a method of chemotaxis in agarose gels containing a 
chemoattractant, have shown that microglia are able to migrate towards nerve growth 
factor (NGF) whereas astrocytes in the same experiment did not migrate (Giliad and 
Giliad, 1995). Time lapse video recording of microglia in culture have further proved 
that microglia are highly motile cells (Booth and Thomas, 1991, Haapaniemi et al, 1995). 
Foetal rat microglia in culture changed the size and shape of their cell body continuously 
and this was accompanied by constant extension and retraction of long processes. These 
cells showed random migration about a small local area measured in micrometers (Booth 
and Thomas, 1991). Haapaniemi et al, (1995) demonstrated the use of lamellipodia for 
microglial locomotion of up to 1.01 jam per second with the lamellipodia frequently 
observed as two horns, said to behave like ‘blades of a pair of scissors’ possibly to engulf 
opsonised particles.
3.1.2 Effect of chemokines on chemotaxis of leukocytes in vitro
The chemotactic family of cytokines known as chemokines have been studied 
intensively for their ability to chemoattract leukocyte sub populations. The a  and (3 sub 
families of chemokines induce migration with distinct, and some overlapping, leukocyte 
specificities. Many of the ELR motif containing a  chemokines attract neutrophils and T 
cells with little effect on monocytes, whereas the (3 chemokines attract monocytes, 
macrophages and T cells with little effect on neutrophils. Interestingly, the non ELR 
motif containing a  chemokines, including IP-10 and PF4, fail to chemoattract neutrophils 
(Taub and Oppenheim, 1994). The (3 chemokines also show specificity for T cell subsets, 
such that M IPla is more chemoattractive for CD8+ T cells whereas MIP1J3 preferentially 
attracts CD4+ T cells (Taub et al, 1993). The most extensively studied
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monocyte/macrophage chemoattractant is MCP1 (Leonard and Yoshimura, 1990, 
Uguccioni et al, 1995, Rollins, 1996). MCP1 expression in the CNS has been detected 
following cerebral ischaemia and mechanical stab wound injury, consistent with 
macrophage chemoattraction (RansohofF and Tani, 1998). Furthermore, intracerebral 
injection of recombinant MCP1 into mice leads to accumulation of large numbers of 
monocytes in a concentration dependant manner (Bell et al, 1996).
3.1.3 Chemokines expressed in diseases of the central nervous system
A number of chemokines have been detected in the CNS in MS. These include, 
MCP1, MCP2, MCP3, MIPla/p, RANTES and IP-10 (Simpson et al, 1998, McManus 
et al, 1998). Chemokines present in the CNS of animals with EAE include MEPlot/p and 
RANTES (Eng et al, 1996, Miyagishi et al, 1997) as well as MCP1, IP-10 and GRO 
(Ransohoff and Tani, 1998). Although it appears that the P chemokines are the main sub 
group expressed in the CNS, fractalkine is also present and is produced predominantly by 
neurons in response to nerve damage (Harrison, 1998). EL-8 is produced by microglia in 
response to co-incubation with a cryptococcal fungus which infects the CNS (Lipovsky 
et al, 1998) or following stimulation with TNFa or EL-lp (Erlich et al, 1998). IL-8 was 
also found to be produced by a neuroblastoma cell line in response to EL-la stimulation 
(Chuluyan et al, 1998).The a  chemokine, MIG, has been found to be upregulated in 
acute MS lesions associated with perivascular leukocytes (Simpson et al, 1998b).
3.1.4 Migration of microglia to chemoattractants and chemokines in vitro
Human microglia have been previously shown to migrate in vitro to the 
chemokines MEPla, MEPip and MCP1 in a concentration dependant manner (Peterson 
et al, 1997) and recently, rat microglial migration has been demonstrated in response to
79
MCP1 and RANTES (Johnstone et al, 1999). Human microglia migrate in response to 
C5a and the classical chemoattractant peptide, f-met-leu-phe (fMLP) in higher numbers 
than to chemokines. In contrast, astrocytes did not respond to the chemokines tested 
(Peterson et al, 1997). Rat microglia were also shown to migrate to the complement 
component C5a but not fMLP (Yao et al, 1990).
3.1.5 Effect of chemokines on reorganisation of actin through G protein/GTP binding 
proteins
Chemokine-induced migration involves binding of a chemokine to its receptor on 
the responding cell. The interaction of the chemokine with its receptor causes an increase 
in intracellular calcium and activation of second messenger enzymatic pathways such as 
adenylate cyclase, via the seven transmembrane domain, G protein coupled receptors 
(Petrek et al, 1995) and polarisation of the receptors to the leading edge of the cell 
(Nieto et al, 1997). This leads to polymerisation and breakdown of actin causing 
formation and retraction of lamellipodia enabling the responding cell to become motile 
(Baggiolini, 1998). Lymphocyte activation by chemokines including IL-8, RANTES and 
MCP1, induce cellular polarisation and development of a projection known as a uropod 
(del Pozo et al, 1996).
Chemokine signalling involves activation of GTP binding proteins including Rac 
and Rho which are involved in cell motility through regulation of actin dependant 
processes (Takai et al, 1995, Premack and Schall, 1996). Microinjection studies on 
Swiss 3T3 fibroblasts revealed that Rho controls the formation of stress fibres and focal 
adhesions, whereas Rac causes membrane ruffling. Both Rac and Rho cause clustering of 
integrins (Machesky and Hall, 1996) which is likely to be involved in cell locomotion. IL- 
8 has been shown to increase the amount of radiolabelled GDP bound to RhoA ( the
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predominant isoform in lymphocytes) in lymphoid cells in culture, with up to 12 times 
more bound than in control cells (Laudanna et al, 1996). The complex series of signalling 
events from chemokine receptor to cell migration is not fully elucidated, although these 
experiments indicate some of the pathways involved and are illustrated in Figure 3.1 
which is modified from Premack and Schall (1996).
Figure 3.1 Illustration of pathways from chemokine receptor to chemotactic response.
Chemokine
receptor
G protein 
complex PLC
Adenylyl
cyclase
IP3 DAG
Rho Rac
PKC
increase membrane
ruffling
stress fibre 
formationN /actin polymerisation
CHEMOTAXIS
Dashed lines indicate connections where intermediates are not yet known (Premack and 
Schall, 1996). Abbreviations: PLC = phospholipase C, IP3 = Inositol trisphosphate, 
DAG = diacyl glygerol, Ca = intracellular free calcium, PKC = protein kinase C. ? = not 
known.
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3.1.6 Aims
Due to the reported observations on microglial migration to sites of tissue 
damage and inflammation and the localisation of chemokines within the CNS in 
pathological conditions, it is proposed that chemokines mediate the migration and 
recruitment of microglia through their actions on receptors on the cell surface and 
rearrangement of the cytoskeleton. The aims were to:
1. Examine microglial migration in response to a panel of chemokines.
2. Observe changes in the distribution of filamentous actin in response to chemokine 
stimulation.
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3.2 Materials and methods
3.2.1 Chemotaxis assay.
Cell migration in response to chemokines was assessed using a 48 well 
microchemotaxis chamber method (Neuroprobe MD, USA) as previously described 
(Cross et a l, 1997). Nucleopore membranes (Costar, U.K) with 8pm pores were coated 
with fibronectin (6.5 pg/ml) (Sigma, U.K) in PBS for 20 minutes at 37°C. These were 
then air dried, rinsed in PBS and dried again. Stock chemokines (lOOng/ml in PBS/0.1% 
BSA) were diluted in serum free DMEM and 28pl of each dilution pipetted in triplicate 
into the lower wells of the chemotaxis chamber. This was the volume required to fill the 
wells, with a slight positive meniscus. The human chemokines used included: MCP1, 
M IPla, MIPip, RANTES, IL-8 and IP-10 and were a kind gift from Prof. D Taub 
(NIH, Maryland, USA). 0.1% or 0.05% BSA in PBS was used as a negative control, as 
this was used in storage of the stock chemokines and present at these concentrations, in 
the highest chemokine concentration used, in experiments with rat microglia and 
CHME3 respectively. The response of rat microglia to rat MCP1 (Peprotech, UK) was 
also compared to the response with human MCP1, to examine the effects of species 
difference.
The filled lower chamber was then overlayed with the coated membrane and the 
top chamber assembled to form wells (Figure 3.2). 50pl of cell suspension (5xl05/ml) in 
serum free DMEM was added to each of the wells and the chamber was incubated at 
37°C, 95% air, 5% CO2 in a humid environment for a fixed time period. The incubation 
period was determined by preliminary time course experiments assessing the response of 
microglia to MCP1 (20ng/ml) with incubation times of 2, 4 and 6 hours for CHME3 cells 
and 5, 10 and 17 hours for rat microglia. The time was extended for primary microglia to
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allow recovery of the cell membranes, following the enzymatic isolation procedure. After 
incubation the chamber was dismantled and the cells on the membrane fixed in methanol 
for 5 minutes and stained. After fixing, the membrane was washed in distilled water and 
then placed in Harris' Haematoxylin (BDH) for 5 minutes. The membrane was rinsed in 
running tap water and then in Scots tap water (lOg magnesium sulphate, 1.75g sodium 
bicarbonate, 500ml distilled water) for a further 2 minutes to define the nuclei. Following 
this, the membrane was inverted onto a microscope slide and a cover slip mounted with 
Immumount (Shandon, Life Sciences, UK). Migration was assessed by counting 
migrated cells in 5 microscopic fields per triplicate well (i.e. 15 fields per chemokine 
concentration) at x400 magnification.
Figure 3.2 Assembly of the 48 well chemotaxis chamber.
upper wells containing cells, separated 
from lower wells by the membrane
<-------  Lower chamber of wells containing
chemoattractant
—  silicone gasket
polycarbonate membrane containing 
8um pores
The assembled chamber is held together tightly by 6 screws.
3.2.2 Statistical Analysis
Significant results were calculated using a one way ANOVA followed by a 
multiple range analysis, to compare migration of cells to the control (0.05 or 0.1% BSA)
84
with chemokine induced migration and P<0.025 was considered significant. Results were 
expressed as the mean number of cells migrating per 3 wells in 5 microscopic fields +/- 
SEM.
3.2.3 Actin staining of the cvtoskeleton using TRITC labelled phalloidin
Tetramethylrhodamine B Isothiocyanate (TRITC) labelled phalloidin (Sigma, 
UK) was used to visualise changes in actin fibre organisation in microglia, following 
incubation with chemokines. Phalloidin is highly toxic so the appropriate care must be 
employed when used i.e. wear protective clothing and use in a fume hood. Cells were 
seeded onto sterile fibronectin (6.5pg/ml) (Sigma, UK) coated coverslips (BDH, UK) in 
6 well plates (Costar, Northumbria Biosciences, U.K) at a concentration of 5xl04/ml 
(300pl on each coverslip) for about one hour to allow cells to adhere. A further 2ml of 
cDMEM was added and cells cultured overnight. Cells were washed in serum free 
medium (SFM) and incubated with the appropriate chemokine diluted in SFM at 37°C 
for 15, 60 or 180 minutes. Shorter incubation times were chosen for the actin studies 
than for the migration studies as the chemokines should elicit an effect on cell shape 
immediately. Serum free medium (or SFM + 0.1%BSA) was used as the control. Cells 
were then washed in PBS and fixed for 20 minutes in freshly prepared 4% 
paraformaldehyde in PBS at room temperature. The paraformaldehyde was then 
removed, the cells were washed in PBS and then fixed in ice cold acetone for a further 5 
minutes. Cells were then washed in PBS, and 200pl of TRITC labelled phalloidin 
(200ng/ml) in SFM, was added per well and incubated at room temperature for 45 
minutes. The coverslips were washed twice in PBS and once in distilled water and then 
inverted onto microscope slides mounted in PBS/glycerol (1:1). Cells were visualised
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under fluorescence microscopy (Olympus BX60) and photographed using Ilford HP5 
film.
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3.3 Results
3.3.1 Time course migration experiments
Time course experiments were carried out on CHME3 cells and rat microglia, to 
determine the optimal incubation time required to give a significant number of migrating 
cells. CHME3 cells were incubated in the chemotaxis chamber for 2, 4 or 6 hours and the 
number of cells migrating to MCP1 (20ng/ml) were counted in triplicate wells. Only 
small numbers of cells (mean of 10 per high power field), had migrated through the 
membrane after 2 hours and this was increased (mean of 30 cells per high power field) 
after a 4 hour incubation period. The number of cells migrating after 6 hours was 
substantially more than at 4 hours, therefore this was chosen as the appropriate 
incubation time for further experiments (Figure 3.3). Time course experiments for 
chemotaxis by rat microglia used incubation periods of 5, 10 or 17 hours, longer 
incubation times were used as cells were placed in the chemotaxis chamber directly after 
isolation. The number of primary rat microglia migrating after a 5 hour incubation time 
was comparable to the number of CHME3 cells that had migrated after the 4 hour 
incubation period (mean of 30 cells per high power field). When rat microglia were 
incubated for 10 hours in the chemotaxis chamber, the number of migrating cells more 
than doubled and after an overnight incubation of 17 hours the number of migrating cells 
increased further (Figure 3.4). The proportion of cells migrating after 17 hours was still 
relatively small compared to the number of cells added (approximately 0.6% in 5 
microscopic fields). This could be due to the small surface area of the membrane in 
contact with the cells and although longer incubation times would probably produce 
higher numbers of migrating cells, the nutrients in the media would be consumed due to a 
high cell density in a small volume and also the number of cells in the top and bottom
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Figure 3.3 Time course of CHME3 migration to MCP1
(20nq/ml)
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Figure 3.4 Time course of rat microglial migration to MCP1
(20ng/ml)
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A time course migration experiment was performed using CHME3 cells (Figure 3.3) and 
rat microglia (Figure 3.4). Triplicate wells were used and expressed as the mean number 
of migrated cells per 5 microscope fields +/- SEM.
chambers would reach equilibrium as the chemokine gradient would equalise by diffusion 
across the membrane.
3.3.2 Migration of primary rat microglia in response to chemokines
Migration responses of 30 day old rat microglia were examined in response to the 
chemokines MCP1, M IPla, MIPip, RANTES, IL-8 and IP-10. Migration experiments 
using rat microglia showed typical bell shaped curves to all of the chemokines tested, 
where optimal migration reached a peak and then declined at higher chemokine 
concentrations. The migration of primary isolated rat microglia to MCP1, MEPla and 
MIPip, RANTES, IL-8 and IP-10 and data from all experiments is summarised in Tables
3.1 and 3.2. Figures 3.5 a and b show representative data from one of three individual 
experiments. A significant response was observed, P<0.025, for MCP1, MIPla, MIPip, 
RANTES, IL-8, and IP-10 in all three repeat experiments, although the actual numbers 
of migrating cells was quite variable between experiments. The concentration of 
chemokine required to give the highest migration response of rat microglia to MCP1, 
M IPla and MIPip was between 20 and 50ng/ml. For RANTES, IL-8 and IP-10, the 
concentration required to give the optimal migration response was variable between 20 
and lOOng/ml. IL-8 and IP-10 gave the most variable responses in the actual numbers of 
cells responding between each experiment with counts between 164 and 617 migrating 
cells per 5 microscope fields, for IP-10 at 50ng/ml in one experiment. Rat microglia were 
also shown to migrate equally to rat and human MCP1 with similar numbers of cells 
responding (Figure 3.5c)
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Table 3.1 Summary of migration responses of rat microglia to human MCP1. M IPla and
MIPip in 3 individual experiments.
Chemokine
(ng/ml)
mean number of 
migrated cells*.
SEM Range No. exp. showing 
significant 
migration above 
control*
0 (control) 118 71 40-225 -
MCP 10 214 105 69-372 1
20 244 113 95-415 3
50 249 137 42-445 2
100 139 80 57-260 0
M IPla 10 145 84 19-211 1
20 188 166 31-437 1
50 217 148 38-439 2
100 185 126 43-375 1
M IPip 10 126 48 74-198 0
20 199 141 97-411 2
50 170 129 52-364 1
100 187 104 57-345 1
* represents mean of three individual experiments, each carried out in triplicate wells (i.e. 
9 wells were counted for each chemokine concentration).
# represents number of experiments showing significant migration above control 
migration (P<0.025) out of three individual experiments using a one way ANOVA 
followed by multiple range analysis.
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Table 3.2 Summary of migration responses of rat microglia to human RANTES. IL-8
and IP-10 in 3 individual experiments.
Chemokine
(ng/ml)
mean number of 
migrated cells*.
SEM Range No. exp. showing 
significant 
migration above 
control#
0 (control) 100 27 75-142 -
RANTES 10 92 21 69-125 0
20 163 38 105-193 2
50 122 27 81-154 1
100 160 71 99-267 1
IL-8 10 123 27 97-165 0
20 153 4 147-158 2
50 204 69 119-309 2
100 251 206 68-561 1
IP-10 10 142 76 27-245 2
20 164 42 100-208 2
50 323 196 164-617 3
100 239 143 91-454 2
* represents mean of three individual experiments, each carried out in triplicate wells (i.e. 
9 wells were counted for each chemokine concentration).
# represents number of experiments showing significant migration above control 
migration (P<0.025) out of three individual experiments using a one way ANOVA 
followed by multiple range analysis.
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3.3.3 Migration of CHME3 cells in response to chemokines
Results in migration experiments using the human foetal cell line, CHME3 show 
that a significant response was observed (P<0.025) for all chemokines tested at, at least 
one concentration. Figures 3.6a and b show representative data from one of three 
individual migration experiments for MCP1, M IPla, MIPip and RANTES, IL-8 and IP- 
10 and results from all experiments are summarised in Tables 3.3 and 3.4. The 
concentration of chemokine required to produce optimal migration of CHME3 using 
MCP1 was between 10 and 20ng/ml, for M IPla and MIPip this was lOng/ml, and using 
IP-10, a concentration range of 20 to 50ng/ml gave the highest response. The 
concentration of the chemokines RANTES and IL-8, required to produce the highest 
migration response was more variable. Numbers of migrated cells in experiments with 
CHME3 cells were generally lower than those seen using primary rat microglia with the 
highest response producing a count of just 113 migrated cells per 5 microscope fields in 
response to M IPla compared to the 617 cells counted at the highest response for rat 
microglia in response to IP-10, although incubation times used for the two cell types 
were very different (5 hours and 17 hours respectively). The numbers of cells migrating 
to controls (BSA) was also much lower using CHME3 cells possibly suggesting they are 
less motile than primary microglial cells.
3.3.4 Chemokine induced changes in actin polymerisation
Chemokine induced changes in actin polymerisation and distribution in microglia 
were visualised by incubating cell cultures with chemokines for 15 to 180 minutes and 
staining with TRITC labelled phalloidin, a stain specific for f-actin. All of the chemokines 
tested demonstrated the ability to cause redistribution and polymerisation of f-actin in 
both rat microglia and CHME3 cells.
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Table 3.3 Summary of migration responses of CHME3 cells to human MCP1. M IPla
and MIP1B in 3 individual experiments.
Chemokine
(ng/ml)
mean number of 
migrated cells*.
SEM Range No. exp. showing 
significant 
migration above 
control#
0 (control) 12 3 7-17 -
MCP1 5 68 19 44-97 3
10 69 11 51-70 3
20 63 12 45-74 2
50 24 7 14-33 1
M IPla 5 71 27 47-113 3
10 78 18 50-106 3
20 57 15 34-72 2
50 28 4 22-34 1
MIP1(3 5 62 26 34-102 2
10 62 3 57-66 3
20 52 8 39-65 3
50 39 10 27-54 2
* represents mean of three individual experiments, each carried out in triplicate wells (i.e. 
9 wells were counted for each chemokine concentration).
# represents number of experiments showing significant migration above control 
migration (P<0.025) out of three individual experiments using a one way ANOVA 
followed by multiple range analysis.
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Figure 3.6b Migration of CHME3 cells to chemokines
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________
spiay si s||93 pajBjBim ou uea|/\|
98
Bars represent the mean number of migrated cells per 5 microscope fields +/- SEM. * represents significant migration above control 
levels.
Table 3.4 Summary of migration responses of CHME3 cells to human RANTES. IL-8
and IP-10 in 3 individual experiments.
Chemokine
(ng/ml)
mean number of 
migrated cells*.
SEM Range No. exp. showing 
significant 
migration above 
control#
0 (control) 20 5 13-27 -
RANTES 5 45 4 40-51 2
10 53 21 22-78 2
20 56 19 30-86 3
50 47 12 29-61 3
IL-8 5 48 20 25-79 2
10 47 14 33-69 3
20 55 19 31-84 3
50 47 15 26-71 2
IP-10 5 38 8 27-51 1
10 53 16 40-78 3
20 53 6 46-62 2
50 51 5 46-59 2
* represents mean of three individual experiments, each carried out in triplicate wells (i.e. 
9 wells were counted for each chemokine concentration).
* represents number of experiments showing significant migration above control 
migration (P<0.025) out of three individual experiments using a one way ANOVA 
followed by multiple range analysis.
3.3.5 Chemokine induced changes in the actin cvtoskeleton in CHME3 cells
Although morphological changes were evident following incubation with 
chemokines for only 15 minutes, the difference between treated and control cells was 
more pronounced after 60 minutes and after 180 minutes there was little further change 
in appearance of the cells. Figure 3.7 shows CHME3 cells treated with MCP1 (20ng/ml) 
for 15, 60 and 180 minutes compared to the control, untreated cells. Control cells show 
diffuse staining of actin with poorly defined edges (Figure 3.7a). After 15 minutes 
treatment with MCP1, the cells showed formation of stress fibres across and around the 
edges of cells (Figure 3.7b). After treatment for 60 minutes the stress fibre formation 
was much more pronounced with more f  actin around the edges of cells (Figure 3.7c) 
and this was similar in the cells treated for 180 minutes (Figure 3.7d). Figure 3.8a and b 
show untreated and MCP1 treated CHME3 cells for 60 minutes at higher magnification 
to better illustrate the stress fibre formation after chemokine treatment. A comparison of 
untreated CHME3 cells compared with cells treated for 60 minutes with the chemokines 
MCP1, M IPla, MIPip, RANTES, IL-8, IP-10 and MIG is shown in Figure 3.8a-h. All 
the chemokines tested caused an increase in the amount of f  actin and increased the 
stress fibre formation.
3.3.6 Chemokine induced changes in the actin cvtoskeleton of primary rat microglia
Untreated rat microglia (Figure 3.9a) have the most intense stain of f-actin using 
TRITC phalloidin, around the nuclei and little staining was observed in the cytoplasmic 
regions as seen in similar experiments using CHME3 cells. Untreated cells had a bipolar 
branched morphology although only faint f  actin staining appeared in these ramifications. 
The human chemokines MCP1, MIPla, MIPip, RANTES, IL-8 and MIG, when added 
to rat microglia for 60 minutes caused a change in morphology. Treated cells have a
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Figure 3.7 Visualisation of F actin staining in CHME after treatment with MCP1 at 
20ng/ml (X200 magnification).
b) MCP1 stimulated (15minutes)a) Unstimulated cells
c) MCP1 stimulated (60 minutes) d) MCP1 stimulated (180 minutes)
Figure 3.8 Visualisation of F actin staining in CHME3 cells using TRITC Phalloidin, 
after chemokine treatment or control media for 60 minutes. (XI000). Chemokine treated 
cells show more actin fibres and are stained more intensely.
a) Control unstimulated cells
b) MCP1 treated (20ng/ml)
Figure 3.8 continued. Visualisation of F actin staining in CHME3 cells stained after
chemokine treatment for 60 minutes. (XI000).
c) M IPla (20ng/ml)
d) M IPip (20ng/ml)
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Figure 3.8 continued. Visualisation of F actin staining in CHME3 cells stained after
chemokine treatment for 60 minutes. (X I000).
e) RANTES (20ng/ml)
f) IL-8 (20ng/ml)
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Figure 3.8 continued. Visualisation of F actin staining in CHME3 cells stained after
chemokine treatment for 60 minutes. (X I000).
g) Mig (20ng/ml)
h) IP-10 (20ng/ml)
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Figure 3.9 Visualisation of F actin in 30 day old primary rat microglia using TRITC 
phalloidin following incubation for 60 minutes with chemokine (all used at 20ng/ml) or 
control media (XI000). Chemokine treated cells show a more highly branched 
morphology with intense f  actin staining in the pseudopodia.
a) Control unstimulated cells
b) rat MCP1 treated
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much more highly branched structure with intense f-actin staining within the pseudopodia 
(Figure 3.9b-g and i). The a  chemokine, IP-10 showed similar effects on the actin 
cytoskeleton however to a lesser extent than seen with the other chemokines in all 
experiments (Figure 3.9h). The effects of rat and human MCP1 on rat microglia were 
compared to assess if there was any species specific effect of the chemokine used, 
however the changes to the actin cytoskeleton using either chemokine were identical. 
Some of the chemokine treated rat microglia appeared to have a polarised morphology 
with ‘horns’ at one edge (shown in figure 3.9c) as described by Haapianiemi et al (1995). 
Rat microglia were treated with MCP1 that had been boiled for 5 minutes, prior to 
addition to cells, to determine if the chemokine effects were specifically due to functional 
activity of chemokine- chemokine receptor interactions. Cells treated with heat 
denatured chemokine appeared the same as control cells with only difiiise actin staining 
(Figure 3.9j).
The effects of chemokines on f  actin formation were observed to be different in 
rat microglia compared to CHME3 cells, with the most obvious change being the stress 
fibre formation in CHME3 cells, which was not seen to the same extent in the primary rat 
microglia. The change in staining intensity in the rat microglia was mainly confined to the 
pseudopodia and although the staining intensity was increased around the edges of 
CHME3 cells, they showed a much less branched morphology (compare Figures 3.8b 
and 3.9b/c)
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Figure 3.9 continued. Visualisation of F actin in 30 day old primary rat microglia after
incubation for 60 minutes with chemokine (all used at 20ng/ml) (XI000)
c) human MCP1
d) human M IPla
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Figure 3.9 continued. Visualisation of F actin in 30 day old primary rat microglia after
incubation for 60 minutes with chemokine (all used at 20ng/ml) (XI000)
e) human MIP1J3
f) human RANTES
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Figure 3.9 continued. Visualisation of F actin in 30 day old primary rat microglia after
incubation for 60 minutes with chemokine (all used at 20ng/ml) (XI000)
g) human IL-8
h) human IP-10
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Figure 3.9 continued. Visualisation of F actin in 30 day old primary rat microglia after
incubation for 60 minutes with chemokine (all used at 20ng/ml) (XI000)
i) human Mig
j) Denatured rat MCP1 The chemokine was boiled before adding to cells, to denature the 
protein.
I l l
3.4 Discussion
The results of this study clearly demonstrate that rat microglia and CHME3, the 
human foetal microglial cell line, migrate in response to chemokines. 30 day old rat 
microglia and not neonatal microglia were used in this study as they are more 
representative of neuroimmunological processes in vivo during inflammation. These 
primary microglia were compared to CHME3 in their migratory response to chemokines. 
Although CHME3 cells are of foetal origin, similar responses were observed to those of 
adult rat microglia. Both cell types migrated to a concentration range of chemokines 
giving a typical bell shaped curve, where the cells respond only weakly or not at all to 
low concentrations of chemokine and migration is attenuated at high concentrations. This 
presumably causes cells to migrate up a concentration gradient until they reach a critical 
point of receptor saturation.
To test whether the typically observed decrease in migration response at higher 
chemokine concentrations were significantly different from the peak response, further 
statistics were performed. The migration response at the highest chemokine 
concentration used with an apparent decrease in migration, was compared to the peak 
migration response, at a lower chemokine concentration. Paired T tests were used for all 
of the chemokines for both CHME3 cells and rat microglia, P<0.05 was considered 
significant.
The migration response of rat microglia to MCP1 was significantly less at the 
highest concentration used in two out of three experiments and only one out of three 
experiments using MIPla, RANTES, IL-8 and IP-10. Experiments with MIPip was not 
significantly reduced at the highest concentration used in any experiments suggesting that 
a higher concentration than lOOng/ml may be required to reach maximal migration.
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The numbers of migrated cells were generally higher in experiments using rat 
microglia with numbers of migrated cells as high as 617 per 5 microscopic fields. 
However longer incubation times were used for the primary rat microglia since the 
harshness of the isolation procedure of the cells required time for the cell membranes to 
recover. The actual numbers of migrated cells cannot be directly compared between the 
two cell types studied, although their responses to the different chemokines does allow 
comparison. The rat microglia generally migrated optimally to higher chemokine 
concentrations than those required for optimal CHME3 migration. This could be 
attributed to the fact that the chemokines used were recombinant human proteins, 
although experiments using rat MCP1 with rat microglia demonstrated no differences in 
the numbers of cells migrating, or the concentration required to produce optimal 
migration to those for human chemokines. Also the rat and human MCP1 both induced 
changes in the actin cytoskeleton of rat microglia. Therefore species difference does not 
appear to contribute to this differing response in this particular chemokine. Studies on 
human and mouse microglial cell migration to MCP1 by Peterson et al (1997) and 
Hayashi et al (1995) respectively, reported optimal migration at a chemokine 
concentration of lOng/ml which is comparable to the CHME3 migration to MCP1 
reported here although a higher concentration of MCP1 (50ng/ml) was required to 
produce optimal migration using rat microglia. CHME3 cells responded equally well to 
all a  and P chemokines tested whereas the migration response of rat microglia was 
greatest to the P chemokines tested.
It is now well documented that in areas of brain inflammation in MS lesions, 
there is perivascular cuffing consisting of inflammatory cell types including B cells, T 
cells and macrophages. (Woodroofe et al, 1986, Adams et al, 1989, Benveniste, 1997)
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Both infiltrating monocytes and resident brain macrophages or microglia, contribute to 
the macrophage population in lesions. A recent study by Simpson et al (1998) has 
reported that (3 chemokines are expressed in MS brain sections, by astrocytes, microglia 
and endothelial cells in active lesions with inflammation and demyelination. This would 
provide the stimulus required to chemoattract other inflammatory cells such as T and B 
lymphocytes and monocytes from the circulation, as well as astrocytes and microglia 
from adjacent areas of the brain, where they are normally evenly distributed (Perry and 
Gordon, 1991), to areas of inflammation and demyelination or to sites of tissue injury. 
Macrophages recruited to these sites may then contribute to the inflammatory response 
by production of inflammatory mediators such as IL-1, IL-6, TNFa and reactive oxygen 
species which promote and intensify the immune response. Macrophages are also 
involved in the breakdown and destruction of the myelin sheath and phagocytosis of the 
breakdown products of myelin (Benveniste, 1997).
Accumulation of activated microglia at sites of tissue injury have been reported in 
a number of CNS pathologies including Alzheimer’s disease (Dickson et a l, 1993, 
McGeer and McGeer, 1995) Creutzfelt-Jacob disease (Muhleisen et a l, 1995) and 
experimental glioma induced in rats (Streit, 1996). This present study would suggest that 
centrally produced chemokines may be involved in microglia recruitment in these CNS 
pathologies and is not restricted to the pathogenesis of MS.
The results of this study, both on isolated rat microglia and the human microglial 
cell line, demonstrate that the pro-inflammatory chemokines can induce microglial cell 
migration in vitro and this may be the mechanism of chemoattraction for microglia to 
areas of CNS inflammation or tissue damage in vivo. Chemokines are produced by 
activated cells already present in the lesion in MS (Simpson et a l, 1998) which may then 
chemoattract microglia, expressing chemokine receptors, to respond to these signals.
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The chemokine gradient established, with the highest concentration being at the lesion 
centre, may elicit their response by initially altering actin polymerisation and therefore 
motility of the cells. Our results display a dramatic change, following chemokine 
stimulation of microglia, in their morphology and distribution of f-actin within one hour. 
Although cell migration cannot be attributed to f- actin changes alone, redistribution of 
actin fibres and extension of pseudopodia is an important event in cell locomotion.
Experiments by Hayashi et al (1995) also demonstrate that microglia migrate to 
MCP1 in vitro and propose that production of MCP1 by astrocytes, modulates 
recruitment and activation of microglial cells in the CNS. In comparison to the results 
reported by Hayashi et al (1995), the wider range of chemokines tested in this present 
study, demonstrate that microglia migrate in response to many other chemokines in vitro 
which are likely to be the products of both inflammatory cells invading the CNS as well 
as the resident astrocytes and microglia. Chemokine receptors 3 and 5 (CCR3, 5) have 
been shown to be expressed by microglia (He et a l, 1997) and CXCR4 has been shown 
to be expressed by the murine microglial cell line, N9 (Tanabe et a l, 1997) for which 
SDF-1 (stromal cell derived factor) is the only known ligand. M IPla, MTPlp and 
RANTES are the ligands for chemokine receptor 5 (CCR5) and Eotaxin, RANTES, 
MCP3 and MCP4 are the ligands for CCR3. In the present study, microglia also 
responded to MCP1, IL-8 and IP-10 suggesting the presence of other chemokine 
receptors, possibly CCR2, CXCR1 and CXCR3, the receptors for MCP1, IL-8 and IP- 
10 respectively (Premack and Schall, 1996).
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Table 3.5 Summary of migration experiments.
CHME3 | Rat 
1 Microglia
Chemokine (ng/ml) Migration score #
MCP1 5 ***** NT
10 ***** +++++
20 He He He He He +++++
50 * +++++
100 NT +
M iPla 5 ***** NT
10 He He He He He He +
20 He He He He ++
50 H e * * ++++
100 NT -HI­
MLPlfl 5 He *  *  *  * NT
10 * * * * * +
20 He He *  * + + +
50 *** + +
100 NT - t - t -
RANTES 5 He He NT
10 He He +
20 He He + + +
50 He He +
100 NT ++
IL-8 5 He He NT
10 He He +
20 He He ++
50 He He + + + + +
100 NT + + + + +
IP-10 5 He NT
10 He He + +
20 He He + + +
50 He He + + + + + +
100 NT - t - l - l - l  -!■
# Migration score is the percentage increase in the mean number of cells migrating to 
chemokine compared to the mean number of cells migrating to the control.
* 0-100%, ** 101-200%, ***201-300%, ****301-400%, ***** 401-500%, ****** 
greater than 500%
+ 0-40%, ++ 40-60%, +++ 61-80%, ++++ 81-100%, +++++ greater than 100%, 
++++++ greater than 200%.
NT not tested.
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This table summarises the means of three repeat migration experiments for both 
CHME3 and rat microglia. As mentioned previously (section 3.2.2), the rat microglia 
migrated in higher numbers than CHME3 cells, although the actual percentage increase 
in migration to chemokines above migration to control media is much greater by 
CHME3 cells giving a much higher migration score. From this table it can be seen that 
CHME3 cells migrate less well to a  chemokines than rat microglia but also that the 
migration of both cell types to RANTES is less than to other p chemokines. It may be 
that RANTES is bound with a lower affinity to the shared receptor (CCR1) for MIPla/p 
and RANTES or the downstream signalling may differ between chemokines. It may also 
be that microglia are signalling through other receptors, that bind MIPla/p but not 
RANTES. A receptor has recently been discovered called CCR9 that could fit these 
criteria (Asensio and Campbell, 1999) although it is not yet known whether microglia 
express it. MCP1 was the best chemoattractant for both CHME3 and rat microglia 
although rat microglia showed a greater response to the a  chemokines than CHME3 
cells. This may be due to a species difference in the cell types or a difference between a 
cell line and primary cells which should be further investigated using primary human 
microglia.
The relevance of these results to the in vivo situation is that the chemokines, especially of 
the P sub-class, are the likely chemoattractant in CNS inflammation that recruit 
microglia. Chemokines are released by T cells, macrophages and microglia in the MS 
lesion probably under the control of cytokines. Cytokine release may be initiated by viral 
infection in the CNS or, by virally activated T cell populations in the periphery which 
may cross the BBB and react with CNS autoantigens. T cells infiltrating the CNS, may 
then be presented with self antigen with MHC class II and co-stimulatory molecules by
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microglia, further activating them to release proinflammatory cytokines and chemokines. 
Chemokines may then form a concentration gradient, and microglia possessing the 
correct receptors undergo polymerisation of actin, ultimately allowing the cell to become 
motile. Once the microglia are attracted to the site of inflammation within the 
perivascular cuff, they may be activated themselves to release further cytokines and 
chemokines and also release enzymes and free radicals, potentiating the damage to the 
myelin sheath. The chemokines and their receptors are therefore possible targets for 
downregulating the immune response in MS.
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Chapter 4
EFFECTS OF CHEMOKINES ON MATRIX METALLOPROTEINASE. 
UROKINASE TYPE PLASMINOGEN ACTIVATOR AND TISSUE 
INHIBITORS OF METALLOPROTEINASE PRODUCTION BY MICROGLIA.
4.1 Introduction
4.1.1 Effects of matrix metalloproteinases on mvelin components
Demyelination is one of the central pathological features of MS and myelin 
proteins have been shown to be degraded by MMPs. MMP9 was found to cleave myelin 
basic protein in vitro and two cleavage sites were identified that are within conserved 
amino acid sequences in different species. The degraded fragments of MBP retained 
encephalitogenic epitopes for EAE (Gijbels et al, 1993, Proost et al, 1993).
4.1.2 Beneficial effects of tissue inhibitor of metalloproteinase production
The most obvious role of TIMP production is to control the activity of MMPs so 
it is not surprising that TIMPs can be detected in most body fluids and tissues (Gomez et 
al, 1997). TIMP1 and TIMP2 also demonstrate growth promoting activities on a variety 
of cultured cell lines (Gomez et al 1997). Both MMP and TIMP immunoreactivity have 
been detected in MS CNS tissue with TIMP1 found to be associated with macrophages 
and blood vessel matrix in MS plaques. MMP9 and TIMP1 was also detected in normal 
control white matter associated with glial cells (Cuzner et al, 1996) with microglia and 
astrocytes being the principal cells expressing the enzyme and inhibitor in control tissue.
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4.1.3 Production of matrix metalloproteinases by microglia in vitro
MMP production by microglia has previously been studied in vitro and it has 
been found that rat brain microglia constitutively produce MMP9 which can be 
upregulated by treatment of the cells with bacterial lipopolysaccharide (Gottschall et al, 
1995). Colton et al (1993) also found that rat microglia constitutively produced MMP9, 
as well as MMP2 by analysis of culture supernatants and proteinase activity was 
increased by IL-ip treatment of the cells. In addition, microglia have been shown to 
constitutively express MT-MMP (Yamada et al, 1995a), a membrane bound 
metalloproteinase involved in the local activation of MMP2.
4.1.4 Effect of Cytokines and chemokines on the regulation of MMP and TIMP 
expression
Cytokines and chemokines have previously been shown to regulate the secretion 
of MMPs and TIMPs by human lymphocytes in vitro. In a study by Johnatty et al 
(1997), pro-MMP9 and TIMP1 secretion was analysed in cultures of human CD4+ and 
CD8+ T cells in response to cytokine and chemokine stimulation. Pro MMP9 secretion 
by CD4" T cells was increased by the P chemokines M IPla, MIPlp and RANTES and 
by the proinflammatory cytokines TNFa and IL-1. Secretion of pro MMP9 by CD8T T 
cells was also increased by the P chemokines whereas TNFa and IL-1 downregulated its 
secretion. The a  chemokines IL-8 and IP-10 showed no effects on either cell subtype. In 
contrast, only a small increase in TIM0P1 secretion was observed by the action of a  and p 
chemokines on CD4' T cells with no increase at all on CD8 cells (Johnatty et al, 1997). 
This study indicated that there is a shift in the balance between MMP and inhibitor in 
favour of protease activity by T cells in response to proinflammatory stimuli.
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Myelin proteolipid protein (PLP) specific T cell clones have also been shown to 
secrete pro MMP9 as well as M IPla and MTPlp in vitro and the levels of chemokine 
secreted were increased in the presence of specific antigen stimulation (Biddison et al, 
1997). The secretion of MMP9 by peripheral blood mononuclear cells (PBMCs) has 
been shown to be increased by MCP1 stimulation in vitro and this could be antagonised 
with IFNp-lb treatment which also decreased migration of PBMCs through fibronectin 
coated membranes, probably due to downregulation of protease activity (Stuve et al, 
1997). This illustrates the important role of metalloproteinases in enabling cells to 
migrate through extracellular matrices. Saren et al, (1996) found that MMP9 secretion 
by human macrophages was upregulated by the pro inflammatory cytokines, TNFa and 
IL-1 whereas IFNy suppressed TNFa and IL-1 induced production. TNFa and IL-1 also 
had no effect on TIMP1 secretion.
An increase in MMP activity by the effects of pro inflammatory cytokines and 
chemokines on cells in the inflammatory lesion in MS, is likely to lead to disruption of 
the blood brain barrier and demyelination as well as aiding the migration of further 
inflammatory cell types, including microglia, to the site of inflammation.
4.1.5 The plasminogen activator cascade
MMP activity is regulated at all levels, including activation of pro enzymes by the 
serine protease, plasmin (Cuzner and Opdenakker, 1999). Plasminogen, the inactive 
precursor of plasmin is cleaved by the plasminogen activators uPA and tPA. uPA 
localises the activation to the cell membrane as it binds to the cell surface receptor uPAR 
(Blasi, 1997). Increased levels of both uPA and tPA have been observed in the CSF of 
MS patients compared to healthy controls (Akenami et al, 1997) suggesting a role for 
these proteases in disease pathogenesis.
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Neonatal rat microglia in vitro secrete both plasminogen (Nakajima et al, 1992a, 
Inoue et al, 1998) and uPA (Nakajima et al, 1992b). IL-1 stimulation of microglia 
increased uPA secretion into the culture media whereas stimulation with LPS markedly 
decreased the amount of uPA in the culture medium (Nakajima et al, 1992b). uPA itself 
can degrade the extracellular matrix (Quax et al, 1992) and uPAR plays a role in the 
migration of human monocytes in vitro and localises to the leading edge of migration 
(Gyetko et al, 1994).
4.1.6 Aims
The MMPs clearly play an important role in demyelination in which microglia are 
heavily implicated. The secretion of MMPs, TIMPs and plasminogen activator was 
therefore analysed in cultures of 30 day old rat microglia and the human foetal cell line, 
CHME3. With the increasing evidence of the importance of chemokines in the 
pathogenesis of MS, the aim of this study was to determine the effects of chemokines on 
MMP, TIMP and uPA secretion in microglia.
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4.2 Materials and methods
4.2.1 Cell stimulation
CHME3 cells were seeded into 24 well plates at a concentration of lx l05 cells/ml 
(lml added per well) and cultured in serum containing medium (cDMEM) for 24 hours 
(see chapter 2.2.2). The cells were then washed with serum free DMEM and transferred 
to macrophage serum free medium (SFM) (Life Technologies) for 2 hours. Primary 
microglia were seeded at a density of 2x105 cells/well in lml of cDMEM and maintained 
in culture for 3-7 days prior to transfer to SFM. Cells were then stimulated in duplicate 
with 300jil of chemokine (MCP1, M IPla, MIPip, RANTES, IL-8 or Fractalkine) 
TNFa, or IL-1 P for 24 hours at a range of concentrations. Culture supernatants were 
harvested, centrifuged to remove cell debris at 10,000g on a bench top eppendorf 
centrifuge (Micro Centaur) at 4°C and either loaded immediately onto gelatin substrate 
SDS gels for electrophoresis or collected and stored at -20°C until required. In some 
experiments, cells were also used to isolate mRNA for RT-PCR experiments.
4.2.2 Substrate gel electrophoresis (Zvmographv)
Zymography is a sensitive qualitative technique that was developed to measure 
matrix metalloproteinases in cell culture supernatants and lysates (Kleiner and Stetler- 
Stevenson, 1994). Cell supernatants can be electrophoresed on SDS containing 
polyacrylamide gels to first separate the proteins by molecular weight. Following 
electrophoresis, the SDS is removed from the gel by exchange in a solution containing 
Triton X-100 to allow the proteolytic enzymes to renature. The gel can then be 
incubated in an appropriate buffer at 37°C to allow the enzyme to digest the substrate 
incorporated into the gel during polymerisation. The protein in the gel can then be
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stained and the enzyme activity is revealed by an absence in protein staining in the region 
where the substrate has been digested. The addition of molecular weight markers and 
positive controls allows identification of the bands.
4.2.3 Preparation of solutions for zvmographv
All zymography solutions with the exception of ammonium persulphate and 
gelatin were prepared and stored for up to 2 months prior to use.
Resolving gel buffer:
Trizmabase 18.16g
Sodium dodecyl sulphate 0.4g
The above chemicals were dissolved in 90ml of ultra pure water and the pH adjusted to
8.8 with concentrated HC1. The volume was then made up to 100ml with ultra pure 
water
Stacking gel buffer
Trizma base 6g
Sodium dodecyl sulphate 0.4g
The above chemicals were dissolved in 90ml of ultra pure water and the pH adjusted to
6.8 with concentrated HC1. The volume was then made up to 100ml with ultra pure 
water
Gelatin/
A 1% solution (w/v) of gelatin (Sigma) in ultra pure water dissolved at 54°C in a water 
bath. This was freshly prepared immediately prior to use
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Ammonium persulphate
A 10% solution (w/v) of ammonium persulphate in ultra pure water was prepared 
immediately prior to use.
Casein solution
Casein Hammarstein (Sigma) lg 
Resolving gel buffer 25ml
Ultra pure water 75ml
Tank buffer (XI0 concentrate)
Trizma base 30.27g
Glycine 150.14g
Sodium dodecyl sulphate lOg
The above chemicals were made up to 1L in ultra pure water and dissolved by 
continuous stirring. Tank buffer was made up as a 10X solution and diluted 1 in 10 in 
ultra pure water as required
Incubation Buffer for gelatin gels
Trizmabase 30.27g
Sodium chloride 58.44g
Cacium chloride 2.78g
Made up to 1L in ultra pure water with pH adjustment to 7.4 with concentrated HC1
Incubation buffer was made up as a 5X solution and diluted 1 in 5 in ultra pure water as
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required. For some experiments, a lOmM solution of EDTA was made up in IX 
incubation buffer to chelate divalent cations thus inhibiting metalloproteinase activity.
Incubation buffer for casein plasminogen gels (lOX concentrated 
Trizmabase 60.5g
This was dissolved in 500ml of ultra pure water. After dissolving, pH was adjusted to 8.1 
with concentrated HC1. The solution was made up as a lOx liquid and diluted 
accordingly prior to use.
Non reducing sample buffer 
Stacking gel buffer 10ml
Sodium dodecyl sulphate 2g
Glycerol 6.4ml
Sodium dodecyl sulphate was dissolved in stacking gel buffer and then mixed with the 
glycerol. A few grains of bromophenol blue were then added to allow easy visualisation 
of sample when loading onto gel.
2% Triton X-100
Triton X-100 20ml
Ultra pure water 980ml
Destaining solution 
Glacial acetic acid 100ml
Methanol 300ml
Ultra pure water 600ml
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Coomassie blue staining solution
Coomassie Blue (R-250) (Sigma) 0.5g dissolved in 150ml methanol 
Ultra pure water 300ml
Glacial acetic acid 50ml
Stain was prepared and filtered through Whatman (Kent) filter paper to remove any un­
dissolved particles.
Gel Recipes
Gelatin substrate gel (7.5%)
Component Volume (pD
Acrylamide/bis (29:1) 875
Resolving gel buffer 875
Ultra pure water 1400
Gelatin (warm) 350
Ammonium persulphate 30
TEMED 3
Approximately 3ml were loaded per gel.
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Casein and Plasminogen substrate gel (12%)
Component 
Acrylamide/bis (29:1)
Resolving gel buffer 
Ultra pure water 
Casein solution 
Plasminogen 
Ammonium persulphate 
TEMED
Approximately 3ml were loaded per gel
volume full 
1060 
780 
1270 
350
20 (of 1 mg/ml solution) 
30
Stacking gel f3.4%)
Component 
Ultra pure water 
Acrylamide/bis (29:1) 
Stacking gel buffer 
TEMED
Volume (p.D
1730
330
690
3
Approximately 2ml of stacking gel was loaded before inserting combs.
Gels were cast using a Biorad mini gel system with 0.5mm spacers between gel 
plates. Resolving gels were poured and then overlaid with n-butanol and allowed to 
polymerise for 30 minutes before the n-butanol was washed off with distilled water. The 
excess water was removed by blotting with filter paper and the stacking gels cast. Combs
were inserted to make 10 wells and the stacking gel allowed to polymerise for a further 
30 minutes before combs were carefully removed. Gels were placed onto the electrodes 
and inserted into the buffer tank which was then filled with IX tank buffer ensuring that 
the wells of the gel were filled and did not contain any air bubbles.
4.2.4 Sample preparation for zvmographv
Cell culture supernatants, including the positive control for MMP2 and 9 (DX3 
cell supernatant, a human melanoma cell line), or human uPA (1:100) (Sigma) as a 
positive control for casein/plasminogen zymography, were thawed at room temperature 
as required and mixed 2:1 in non reducing sample buffer. Some cell supernatants were 
activated by the addition of P- aminophenylmercuric acetate (lOmM APMA in 50mM 
sodium hydroxide) (Sigma). This was prepared freshly and added to the supernatants (1 
: 10) and incubated for 1 hour at 37°C, prior to loading onto the gel
After supernatants were removed from cell cultures, cell lysates were prepared. 
Cells were washed in PBS (Sigma) and lysed by the addition of cell lysis buffer (50mM 
Tris/HCl, pH 7.5, + 0.1% Triton X-100) for 5 minutes at room temperature. Lysates 
were removed by repeated pipetting into 1.5ml eppendorf tubes which were then 
centrifuged at 10,000g for 10 minutes at 4°C to remove cell debris.
4.2.5 Zvmographv
Cell supernatants or lysates were separated on 7.5% SDS- polyacrylamide gels 
containing gelatin substrate to analyse MMP2 and 9 activity. Plasminogen activator 
activity was determined on 12% gels containing casein and plasminogen. lOpl of marker 
or 20pl of sample was added per well. After electrophoresis for approximately 45 
minutes at 200V, gels were removed from the apparatus into weighing boats and washed
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with gentle shaking on an orbital shaker in 2% Triton X-100 for 1 hour. Gels were then 
incubated in incubation buffer for 18 hours at 37°C and stained with Coomassie blue for 
approximately 2 hours with gentle rotation. Gels were then destained until clear bands of 
protein degradation could be visualised against the blue background stain. Bands seen on 
gelatin gels were confirmed as metalloproteinases in replicate gels by addition of lOmM 
EDTA to the incubation buffer to inhibit enzyme activity. High molecular weight markers 
(Sigma) were also separated on the gels to determine the protein size by plotting logio 
molecular weight against the distance travelled by the protein in millimeters.
4.2.6 Enzyme linked Immunosorbent assay (ELISA) for matrix metalloproteinases and 
tissue inhibitors of metalloproteinases
Chemokine modulation of MMP2, MMP9, TIMP1 and TIMP2 secretion by 
CHME3 cells was quantified using Biotrak ELISAs (Amersham International pic, UK) 
according to the manufacturer’s instructions (see Table 4.1). All solutions were 
provided. Briefly, a range of standards were prepared in the same way as the samples, 
diluted in assay buffer provided in the kit. Samples and standards were added in duplicate 
to the antibody coated microtitre plate. Following incubation, plates were washed in PBS 
and peroxidase conjugate was added. Plates were washed again and 3,3’,5,5’- 
tetramethylbenzidine (TMB) substrate added. 1M sulphuric acid was then added giving 
the resulting yellow colour which was read spectrophotometrically.
Samples were assayed in duplicate, diluted 1:1 for both MMPs and TIMPs, and standard 
curves were set up in duplicate on each plate according to the manufacturers 
instructions. Results were multiplied according to the dilution factor. Standard curves
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Table 4.1 Specificities of Biotrak MMP/TIMP ELISAs
ELISA kit Specificity Detection range 
(ng/ml)
MMP2 pro-MMP2, pro-MMP2/TIMP complex 
but not active MMP2.
0.37-24
MMP9 pro-MMP9, pro-MMP9/TIMP complex 
but not active MMP9.
0.6-32
TEMPI TIMP1, TIMP1 complexed with MMPs 3.13-50
TIMP2 TIMP2, TIMP2/active MMP complex 
but not TIMP2/proMMP2 complex.
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were plotted on RIA calc (Wallac, USA) to calculate the MMP/TIMP concentration in 
samples from their absorbance readings at 450nm on a Titertek plate reader. The 
significant differences between controls and chemokine treated levels were calculated by 
a one way ANOVA followed by a multiple range analysis. Values of P<0.05 were 
considered significantly different from control.
4.2.7 ELISA for urokinase type plasminogen activator
Levels of uPA in cell supernatants from chemokine treated CHME3 cells were 
assayed using a uPA ELISA kit (Alpha laboratories, Eastleigh, Hants, UK.). The kit 
recognised: pro uPA, high molecular weight uPA and uPA bound to plasminogen 
activator inhibitors (PAI-1 and PAI-2). Samples were diluted 1:4 in the sample buffer 
provided and added to the microtitre plate in duplicate. Results were multiplied 
according to the dilution factor. A standard curve was provided in the kit between 0 and
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lng/ml. Briefly, standards and samples were pipetted in duplicate into the capture 
antibody coated wells and the plate was then incubated overnight at 4°C. Following this 
the plate was washed and a detection antibody was added and the plate incubated for one 
hour at room temperature. The plate was then washed again and an enzyme conjugate 
(horseradish peroxidase) added and incubated again for one hour at room temperature 
followed by a further wash step and the addition of the substrate solution. The substrate 
colour change was measured at 450nm on a Titertek plate reader and the concentrations 
of uPA in the samples calculated from the standard curve. The significance differences in 
uPA concentrations between controls and chemokine treated cell supernatants were 
calculated by a one way ANOVA followed by a multiple range analysis. Values of 
P<0.05 were considered significant.
4.3.1 RNA extraction from CHME3 cells for use in RT-PCR to detect MMP transcripts 
RNA was extracted from CHME3 cells in 24 well plates using an extraction kit, 
‘Totally RNA’ (Ambion, UK). All reagents were provided in the kit unless otherwise 
stated. After media was removed from the wells, 0.45ml denaturing solution per well was 
added and left for 2 minutes at room temperature. 45pi of 3M sodium acetate was then 
added and the solution mixed and transferred to 1.5ml autoclaved eppendorfs containing 
0.45ml of phenol:chloroform:isoamyl-alcohol (25:24:1) (pH 6.2). Tubes were then 
shaken vigorously for 1 minute, left on ice for 5 minutes, followed by centrifugation at 
10,000g for 10 minutes at 4°C in a Micro Centaur. The top phase was carefully removed 
into fresh eppendorf tubes containing 0.45ml of acid phenol:chloroform (1:1) (pH 4.5). 
This was shaken vigorously again for 1 minute, left to stand on ice for 5 minutes and the 
centrifugation step repeated (10,000g for 10 minutes at 4°C). The top phase was then 
removed and pipetted into fresh RNase free 0.5ml eppendorf tubes. An equal volume of
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isopropanol (Sigma) was then added to each tube and mixed gently. The tubes w ere then 
placed in a -20°C freezer overnight to precipitate the RNA. Tubes were centsfuged in a 
benchtop centrifuge (MSE microfuge) at 10,000g for 20 minutes at 4°C to pellet the 
precipitated RNA. The isopropanol was then carefully removed, without disldging the 
RNA pellet. 25pi of ultra pure water was added to each pellet, followed by voitexing to 
dissolve the pellets. The quality of the RNA was examined by electrophoresis on 1% 
agarose gels. Ribosomal RNA bands could be seen on agarose gels (Figure 4.13a)
4.3.2 Agarose gel electrophoresis
RT-PCR products and RNA were electrophoresed on 2 and 1% agarose gels 
respectively. Agarose gels were made up in IX Tris Borate EDTA (TBE) buffer which 
was made as a 1 OX solution for storage and diluted in water as required. A 1 litre stock 
of 10X TBE in ultra pure water contained 108g Tris Base, 55g Boric acid and 9.3g 
Na2EDTA (Sigma). 5pi of ethidium bromide (lOmg/ml) (Sigma) was added to each 50ml 
of liquid agarose gel, immediately prior to casting. This allowed visualisation of nucleic 
acids under UV transillumination as ethidium bromide binds to DNA and fluoresces 
under UV light. The gel was allowed to polymerise with a comb inserted to make 12 
sample wells, lpl of extracted RNA samples were mixed with 2ml of loading dye (50% 
glycerol, 0.2% bromophenol blue, 0.1M EDTA) provided in the extraction kit and 
loaded into the wells. The tank buffer used was 1XTBE and samples were 
electrophoresed at 100V for approximately 45 minutes. PCR products were mixed 3:1 
with loading dye (50% glycerol, 0.2% bromophenol blue, 0.1M EDTA) and 20pl loaded 
per well. A DNA marker was also electrophoresed on each gel (Phi X 174 DNA/ Hae 
III, 72-1353 base pairs (Promega, UK)) to allow calculation of the product size.
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4.3.3 RT-PCR
RT-PCR was performed using Thermus Thermophillus (Tth) enzyme (Bioline 
U.K) which has both reverse transcriptase and DNA polymerase activity to allow both 
the cDNA synthesis and amplification steps to occur in one reaction mixture. Human 
primers for MMP 2, MMP3, MMP7 and MMP9 were a kind gift of Dr John Clements, 
(British Biotech Pharmaceuticals Ltd, Oxford, U.K) and were used at a final 
recommended concentration of 0.5pM with a recommended annealing temperature of 
57°C.
Primer sequences
Human MMP2 product size: 202 base pairs
5’ CCGCCTTTAACTGGAGCAAA 3’
3’ GGACTTCGACCTCTTGGTTT 5’
Human MMP9 product size: 196 base pairs
5’ GAAGATGCTGCTGTTCAGCG 3’
3’ AACTTGGTCCACCTGGTTCA 5’
Human MMP7 product size: 219 base pairs
5’ TTTGATGGGCCAGGAAACAG 3’
3’ GATACCTTTACCTCTAGGGG 5’
Human MMP3 product size: 225 base pairs
5’ GAGGAAAATCGATGCAGCCA 3’
3’ GACCTAGAAGTGTCAACCTC 5’
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Table 4.2 RT-PCR Mastermix
RT-PCR mastermixes were made using the following protocol:
Component Volume
(hO
Water 22.5
5X reaction buffer (incl. 10
10mMMnCl2)
100 mM DTT 2
(Dithiothreitol)
Primers (40pM) 2.5
dNTP mixture 1
(12.5mM) (Bioline)
100U RNase inhibitor 1
RNAguard (Pharmacia
U.K)
5U Thermus 1
Thermophilus (Bioline)
RNA (or water for a 10
negative control)
Each mastermix prepared as above (Table 4.2) was divided into two Eppendorf 
tubes (25pi in each) for the RT reaction and no RT reaction which serves as a negative 
control to ensure the amplified products are not from genomic DNA contamination in the 
RNA sample. The ‘no RT’ tubes were added to the PCR block at step 4, missing out the 
reverse transcriptase conditions. All tubes were overlaid with 25pi of mineral oil to 
prevent evaporation of samples during the reaction. RT-PCRs were performed on a 
Biometra trio-thermoblock (Biometra, UK) using the conditions given in Table 4.3.
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Table 4.3 Thermal Cvcler conditions for RT-PCR amplification of MMP transcripts
Step Temperature (°C) Time (minutes)
1 65 5
2 57 5
3 70 30
4 94 1
5 57 1
6 72 1
7 72 6
8 4 End of programme
Steps 4 - 6  were cycled 35 times. Products were stored at 4°C before being visualised on 
agarose gels (as described in section 4.3.2)
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4,4 Results
4.4.1 ELISA experiments on CHME3 cells following chemokine stimulation
ELISA experiments were only carried out on CHME3 cells to detect MMPs 2 
and 9 and TIMPs 1 and 2. The human kits did not cross react with the rat proteins and 
only rat specific MMP and TIMP kits were unavailable. CHME3 cells were found to 
constitutively secrete MMP2 when assayed by ELISA (Figure 4.1). Using an ELISA kit 
which detected proMMP9 as well as MMP9 bound to TIMP1, gave negative results in 
two experiments (e.g. the zero control on the standard curve gave an absorbance reading 
of 0.045 and all samples were around this figure (+/-0.005) with none as high as the first 
standard of 4ng/ml) suggesting that only the active form of MMP9 was present 24 hours 
after stimulation, as shown by zymography experiments (Figure 4.7a). Time course 
experiments were carried out for MMP2 and TIMP 1 (Figures 4.1 and 4.2) TIMP1 and 
MMP2 levels were below the detection limit in supernatants after 2 hours in culture, 
however at 6 hours, slightly higher levels were detected although levels were much 
higher after 24 hours.
The production of MMP2 in response to the chemokines, MCP1, MIPip, 
RANTES, IL-8 and Fractalkine at 50ng/ml, was significantly increased above control 
unstimulated values in 3 out of 3 experiments When stimulated with the chemokines at 
20ng/ml, at least 2 out of 3 experiments for each chemokine produced a significant 
increase in MMP2 secretion (Table 4.4 and Figure 4.3). At the highest concentration of 
chemokine used (50ng/ml), there was an approximate 1.3-2 fold increase in MMP2 for 
all chemokines tested.
TIMP2 production was also significantly increased above control levels following 
treatment by all the chemokines tested with an approximate 2-5 fold increase at the
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Table 4.4 Chemokine stimulation of MMP2 production in CHME3 cells. Summary of 3
individual experiments.
Chemokine
(ng/ml)
Mean MMP2 
level (ng/ml)
SEM Range No. of 
experiments 
showing 
significant * 
increase 
above 
control
Control
(unstimulated)
15.9 8.8 8-29.2 -
M CP1 10 24.7 11.4 13.4-41.8 3/3
20 25.6 5.4 17.5-32.1 2/3
50 36.1 12.7 20.3-55.1 3/3
MIP1|3 10 24.6 7.1 18.0-35.3 2/3
20 29.0 5.7 20.6-37.6 3/3
50 32.4 12.4 22.3-51.0 3/3
RANTES 10 20.3 10.5 10.1-36.1 1/3
20 27.1 12.1 15.9-45.1 3/3
50 27.9 7.1 19.2-38.6 3/3
IL-8 10 31.0 10.5 18.2-46.8 3/3
20 37.7 17.1 12.1-51.8 2/3
50 39.6 12.2 21.3-52.2 3/3
Fractalkine 10 24.6 4.6 17.7-30.3 2/3
20 24.2 2.2 22.2-27.5 2/3
50 29.3 6.9 21.1-39.7 3/3
*The significant increase above control levels was calculated by a one way ANOVA
followed by multiple range analysis. P<0.05 was considered significant.
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highest concentration of chemokine (50ng/ml) in at least 2 out of 3 experiments. 
Constitutive expression of TIMP2 was between 9 and 25ng/ml (Table 4.5 and Figure 
4.4).
TIMP 1 production was significantly increased above unstimulated levels by the 
chemokines MCP1, M IPla, MIPlp, and Fractalkine, in at least two out of three 
experiments with a maximum of a 2 fold increase at the highest concentration of 
chemokine (50ng/ml) for each individual experiment (Table 4.6 and Figure 4.5). 
Stimulation of CHME3 cells with IL-8 at lOng/ml only gave a significant increase in 
TIMP1 secretion in 2 out of 3 experiments with a significant increase in only 1 out of 3 
experiments at the higher concentrations of 20 and 50ng/ml. Inter-experimental variation 
was marked and constitutive levels of TIMP1 secretion ranged between 24.7 and 73.1 
ng/ml (Table 4.6). The reasons for the variations are unknown but could be due to the 
passage number of the cells, although all experiments were performed between passages 
3 and 12.
4.4.2 Gelatin substrate zvmographv for detection of MMPs2 and 9
Gelatin zymography was used to detect changes in MMP2 and 9 production by 
CHME3 cells and primary rat microglia. Production of MMP2 and MMP9 by rat 
microgfia'could not be measured by ELISA, as commercial kits to measure rat MMPs 
are not available MMP9 production by CHME3 could not be quantified by ELISA as cell 
supernatants gave negative results in MMP9 ELISA experiments.
Preliminary experiments were carried out on supernatants from CHME3 cells at 6 
hours and 24 hours after stimulation with PMA, IFNy or chemokines. Although 
constitutive expression of MMPs were detectable after stimulation for 6 hours by 
zymography, there was! no obvious difference between control and stimulated
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Table 4.5 Chemokine stimulation of TIMP2 production in CHME3 cells. Summary of 3
individual experiments.
Chemokine
(ng/ml)
Mean TIMP2 
level (ng/ml)
SEM Range No. of 
experiments 
showing 
significant * 
increase 
above 
control
Control
(unstimulated)
15.7 6.4 9.1-25.3 -
M CP1 10 30.5 10.8 14.3-46.6 2/3
20 37.6 14.4 15.6-55.1 3/3
50 47.6 21.1 15.9-66.8 3/3
M IPla 10 33.4 14.2 12.0-51.6 3/3
20 35.2 13.5 15.3-46.3 3/3
50 39.8 15.2 17.4-56.5 3/3
MIPip 10 27.8 17.1 11.7-53.5 2/3
20 31.2 11.2 15.2-48.0 3/3
50 38.8 15.5 17.9-62.0 3/3
RANTES 10 23.2 6.9 12.9-32.6 1/3
20 28.4 9.7 15.1-43.1 2/3
50 30.2 7.0 19.7-40.6 2/3
IL-8 10 16.3 3.9 10.4-19.5 2/3
20 17.9 4.9 10.5-23.7 1/3
50 26.75 9.8 12.1-38.7 2/3
Fractalkine 10 16.5 3.9 12.9-22.3 2/3
20 22.0 7.4 16.5-33.2 2/3
50 32.4 7.7 20.9-42.1 3/3
*The significant increase above control levels was calculated by a one way ANOVA 
followed by multiple range analysis. P<0.05 was considered significant.
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Table 4.6 Chemokine stimulation of TIMP 1 production in CHME3 cells. Summary of 3
individual experiments.
Chemokine
(ng/ml)
Mean TIMP1 
level (ng/ml)
SEM Range No. of 
experiments 
showing 
significant * 
increase 
above control
Control
(unstimulated)
48.8 15.5 24.7-73.1 -
MCP 1 10 68.4 9.4 54.3-79.6 3/3
20 72.0 14.4 57.8-93.5 3/3
50 71.3 16.8 49.1-96.5 3/3
M tPla 10 79.7 20.0 59.7-99.6 3/3
20 78.5 22.0 56.5-100.5 3/3
50 100.7 38.4 62.3-139.1 3/3
MIPip 10 61.6 1.5 59.7-63.8 2/3
20 67.0 4.2 60.7-72.1 2/3
50 75.8 10.3 65.1-91.2 2/3
RANTES 10 47.8 18.3 20.4-63.1 1/3
20 46.9 18.7 18.8-62.3 1/3
50 56.7 19.3 27.7-73.7 1/3
IL-8 10 55.6 18.3 28.2-69.9 2/3
20 66.0 28.7 23.0-97.9 1/3
50 63.6 25.5 25.4-92.7 1/3
Fractalkine 10 64.7 18.2 37.3-87.5 2/3
20 65.8 22.5 32.1-96.4 2/3
50 66.3 18.4 42.2-93.9 2/3
*The significant increase above control levels was calculated by a one way ANOVA
followed by multiple range analysis. P<0.05 was considered significant.
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(See Figure 4.6) Cell culture supernatants from all experiments were subsequently 
harvested after 24 hours.
4.4.2.1 Detection of MMP2 and MMP9 secretion bv Rat Microglia
Primaiy rat microglia isolated from 30 day old Wistar rats, expressed both 
MMP2 and MMP9, constitutively and when stimulated with the cytokines TNFa 
(lOng/ml), IL-ip (lOng/ml) and IFNy (10 IU/ml) there was an increase in both MMP2 
and 9 production (Figure 4.7a). Following stimulation with PMA (lOOnM) there was a 
marked increase in MMP9 secretion (Figure 4.7b, lane 6). When stimulated with rat 
MCP1 (Figure 4.7c) or the human chemokines MEPlp (Figure 4.7d) or Fractalkine 
(Figure 4.7e) at concentrations of 10, 20, and 50ng/ml, MMP2 increased slightly or 
remained the same as control levels whereas MMP9 production was markedly increased. 
The increase in MMP9 secretion was most pronounced at chemokine concentrations of 
20 and 50ng/ml.
4.4.2.2 Detection of MMP2 and MMP9 secretion bv CHME3 cells
CHME3 cells constitutively expressed proMMP2 (72 Kda) (Figure 4.8a)and 
either lower or sometimes undetectable levels of proMMP9 (92 Kda) which can be easily 
observed when supernatants were electrophoresed along side DX3 supernatants (used as 
a positive control for MMP2 and 9) and/or a molecular weight marker. Treatment of 
supernatants with APMA confirmed these results. Activation of the pro enzymes 
occurred, resulting in both pro and active bands of MMP2 appearing on the gel (Figure 
4.8a).
The chemokines M IPla (Figure 4.8b), MIPip and RANTES were used in 
preliminary experiments at 0.1, 1.0 and lOng/ml to stimulate CHME3 cells, which
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Figure 4.6 CHME3, Gelatin zymogram of supernatant following a 6 hour and a 24 hour
stimulation period with PM A, IFNy and MCP1. Arrows indicate molecular weights in
kDa
5 6 7 8 9
1 DX3,
2 control 6h,
3 control 24h,
4 PMA lOOnM 6hu
5 PMA lOOnM 24h,
6 MCP lOng/inl 6h,
7 MCP lOng/ml 24h;
8 IFNy lOIU/ml 6h,
9 IFNy lOIU/ml 24h.
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Figure 4.7 Zymograms of rat microglia supernatants following chemokine and cytokine
stimulation to observe MMPs 2 and 9.
1 2  3  4  5  6  1 m a r k e r >
2 control,
3 TNFa 1 Ong/ml,
4 IL-ip 1 Ong/ml,
5 IFNy 1 Ong/ml,
6 rat MCP1 (20ng/ml)
72
a) Rat microglia, gelatin zymogram.
1 marker,
2 MMP2,
3 MMP9,
4 control,
5 IFNy lOIU/ml,
6 PMA lOOnM
b) Rat microglia, gelatin zymogram.
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Figure 4.7 continued. Zymograms of rat microglia supernatants following chemokine and
cytokine stimulation to observe MMPs 2 and 9.
1 DX3,
2 control, 
3MCP1 1 Ong/ml
4 MCP1 20ng/ml
5 MCP1 50ng/ml
c) Rat microglia, gelatin zymogram.
1 control,
2 M IPip 1 Ong/ml
3 M IPip 2 Ong/ml
4 M IPip 50ng/ml.
d) Rat microglia, gelatin zymogram.
* 2 3 4
92
72
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Figure 4.7 continued. Zymograms o f rat microglia supernatants following chemokine and
cytokine stimulation to observe MMPs 2 and 9.
1 2 3 4 5
2 control
3 Fractalkine 1 Ong/ml
4 Fractalkine 20ng/ml
5 Fractalkine 50ng/ml
L _  ■ . aI
e) Rat microglia, gelatin zymogram.
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Figure 4.8 Zymograms of CHME3 cell supernatants following chemokine stimulation for
24 hours to observe MMPs 2 and 9.
3 4  5 6 7
1 control+pAPMA,
2-4 MCP 1 Ong/ml,
5-7 MCP 1 Ong/ml+pAPMA.
66 ►
a) CHME3, gelatin zymogram.
66—
1 marker,
2M M P2,
3 MMP9,
4 control,
5 M IP la  0.1 ng/ml,
6 M IP la  1 ng/ml,
7 M IP la  1 Ong/ml.
b) CHME3 gelatin zymogram.
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showed only a very slight increase in MMP2 secretion at the highest concentration used 
(lOng/ml). The chemokines tested, MCP1, MIPla/p, RANTES, IL-8 and Fractalkine at 
10, 20 and 50ng/ml, were all shown to cause an increase in both MMP2 and 9 in 
CHME3 cells (Figure 4.8c-g). TNFa at 1 and lOng/ml also increased MMP2 and 9 
above control levels (Figure 4.8g).
To assess levels of MMP2 and MMP9 within the cytoplasm of CHME3 cells, 
lysates as well as supernatants were collected following MCP1 and Fractalkine 
stimulation to compare the cytoplasmic content of MMPs to the secreted MMPs. MMP 
2 and 9 could be detected in the cell supernatant as previously seen although only MMP2 
was detectable in the lysate which did not appear to be altered by chemokine stimulation 
(Figure 4.8h and i).
In zymography experiments, bands were shown to be metalloproteinases by the 
addition of EDTA, which chelates metal ions, to the incubation buffer of replicate gels 
and the bands of degradation did not appear in either the samples or the DX3 positive 
control supernatants indicating that the activity was inhibited (Figure 4.8j).
4.4.2.3 Rat Glioma cell line production of MMPs
The rat glioma cell line C6 was also used as a comparison for MMP secretion by 
microglia. Chemokines were used again at 20ng/ml and a panel of chemokines were 
chosen to compare the different effects of different chemokines (Figure 4.9). MMP 2 and 
9 were constitutively expressed and secreted by C6 cells after 24 hours in culture. The p 
chemokines RANTES and MIPlp, the 8 chemokine, Fractalkine and the a  chemokine 
IL-8, increased MMP9 secretion with no effect on MMP2 whereas the P chemokine 
MCP1, and another a  chemokine, MIG, increased MMP2 secretion with no effect on 
MMP9. This interesting observation implies that the chemokines do not always
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Figure 4.8 continued Zymograms of CHME3 cell supernatants following chemokine
stimulation for 24 hours to observe MMPs 2 and 9.
1 2  3 4
1 control,
92»-
72»-
2 MCP1 lOng/ml.
3 MCP1 20ng/ml,
4 MCP1 50ng/ml.
c) CHME3 gelatin zymogram.
1 marker,
2DX3,
3 control,
4 MDPip lOng/ml,
5 M IPip 20ng/ml,
6 M IPip 50ng/ml.
d) CHME3 gelatin zymogram.
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Figure 4.8 continued. Zymograms of CHME3 cell supernatants following chemokine
stimulation for 24 hours to observe MMPs 2 and 9.
92
72
1 control,
2 RANTES lOng/ml,
3 RANTES 20ng/ml,
4 RANTES 50ng/ml, 
5DX3.
e) CHME3 gelatin zymogram.
92*-
72 ►
1 control,
2 IL-8 lOng/ml,
3 IL-8 20ng/ml,
4 IL-8 50ng/ml, 
5DX3.
f) CHME3 gelatin zymogram.
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Figure 4.8 continued. Zymograms of CHME3 cell supernatants and cell lysates following
chemokine stimulation for 24 hours to observe MMPs 2 and 9.
1 2 3 4 5 6 7
92 ► I  
72 ► I
g) CHME3 gelatin zymogram.
1,2 control,
3,4 MCP1 lOng/ml,
5,6 MCP1 20ng/ml,
7,8 MCP1 50ng/ml,
1 2  3 4 5 6 7 8 9 90X3
92 ► *
72 ►
h) CHME3 gelatin zymogram. Lanes 1, 3, 5 and 7 are cell supernatants, lanes 2, 4, 6 and 
8 are cell lysates.
1 control,
2 TNFa lng/ml,
3 TNFa 1 Ong/ml,
4 control,
j 5 Fractalkine 1 Ong/ml, 
[ 6 Fractalkine 20ng/ml, 
|  7 Fractalkine 50ng/ml, 
! 8DX3
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Figure 4.8 continued. Zymograms of CHME3 cell supernatants and cell lysates following
chemokine stimulation for 24 hours to observe MMPs 2 and 9.
3 4 5 6 7
92 »-
1,2 control,
8  9  3,4 Fractalkine 1 Ong/ml,
5,6 Fractalkine 20ng/ml,
7,8 Fractalkine 50ng/ml, 
9DX3.
i)CHME3 gelatin zymogram. Lanes 1, 3, 5 and 7 are cell supernatants, lanes 2, 4, 6 and 
8 are cell lysates.
1 2
-pr-
5 6 7 1 marker,2 MMP2,
3 MMP9,
4 control,
5 M f f la  O.lng/ml,
6 MTPla lng/ml,
7 M IP la  1 Ong/ml
j) CHME3 gelatin zymogram. No bands of gelatinase activity were observed as 
incubation buffer containing EDTA was used to show bands were metalloproteinases.
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Figure 4.9. Gelatin zymogram of C6 rat glioma cell line supernatants following
chemokine stimulation for 24 hours.
1 2 3 4  5 6 7 8 9
1 marker,
2DX3,
3 Control,
4 MCP1 (20ng/ml),
5 M IPip (2Ong/ml),
6 MIG (20ng/ml),
7 RANTES 2Ong/ml),
8 IL-8 (20ng/ml),
9 Fractalkine (20ng/ml).
C6 gelatin zymogram.
Figure 4.10 Gelatin zymogram of rat astrocyte cell supernatants following chemokine 
stimulation for 24 hours.
1 DX3,
2 control.
92*-
72»-
3 rMCPl 2Ong/ml,
4 Fractalkine 20ng/ml,
5 M IPip 20ng/ml,
6 RANTES 2 Ong/ml.
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have the same effects on a particular cell type (as in microglia) and that these differences 
cannot be attributable to the different sub-classes of chemokine. As these results differ 
from those seen in primary rat astrocytes, the effects may be due to the heterogeneous 
and complex nature of tumour cell lines.
4.4.2.4 Primary rat astrocyte production of MMPs
Astrocytes isolated from 30 day old Wistar rats were found to constitutively 
secrete MMP2 and there was no detectable constitutive MMP9 present after 24 hours in 
culture. Stimulation of astrocytes with the chemokines rat MCP1, or human Fractalkine, 
MIPip and RANTES all used at a concentration of 20ng/ml (as this concentration was 
found to have a clear effect on microglia), showed an increase in the secretion of MMP2 
with no detectable induction of MMP9 expression (Figure 4.10). This is in contrast with 
findings for both CHME3 cells and primary rat microglia which both demonstrated an 
increase in MMP9 secretion after stimulation with these chemokines.
4.4.3 Detection of urokinase type plasminogen activator using Casein/ plasminogen gels 
Pure human urokinase type plasminogen activator (uPA) was electrophoresed on 
each gel as a positive control which had an observed molecular mass of approximately 43 
Kda. Primary rat microglia were found to produce 2 bands close together at around the 
same size as the human uPA positive control. Rat microglia when stimulated with MCP1 
appeared to show a slight decrease in both secreted plasminogen activator bands (Figure 
4.11a).
CHME3 supernatants constitutively secreted a plasminogen activator (Figure 
4.11a), of the same RMM as the positive control and was later confirmed to be uPA 
secretion by ELISA experiments (See section 4.4.4). Unstimulated CHME3 cells as well
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Figure 4.11 Casein/ plasminogen zymograms on rat microglia and CHME3 cell
supernatants or cell lysates following chemokine stimulation for 24 hours to observe
plasminogen activator activity.
43* -
] marker,
2 uPA,
3 CHME3 control supernatant,
4 CHME3 control cell lysate,
5 rat microglia control,
6 rat microglia MCP1 50ng/ml,
7 rat microglia MCP1 50ng/ml.
a) CHME3 and rat microglia cell supernatants and lysates.
1 2 3 4 5 6 7 8
43*- F | : ; f  m  i
b) CHME3 cell supernatants.
1 marker,
2 control,
3 IL-8 1 Ong/ml,
4 IL-8 2Ong/ml,
5 IL-8 5Ong/ml,
6 Fractalkine 1 Ong/ml,
7 Fractalkine 20ng/ml,
8 Fractalkine 50ng/ml.
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as MCP1, MIPla, MIPip, RANTES, IL-8 and Fractalkine (10-50ng/ml) stimulated cell 
supernatants and lysates were collected after 24 hours and separated on casein/ 
plasminogen gels. All appeared to have decreased uPA in the supernatants as the 
chemokine concentration increased to 50ng/ml (Figure 4.11). In the cell lysates the 
chemokines appeared to slightly increase the amount of uPA (Figure 4.1 lc and d). TNFa 
was found to increase uPA secretion (Figure 4.1 le).
4.4.4 Urokinase plasminogen activator ELISA
Urokinase secretion in unstimulated and chemokine stimulated CHME3 cell 
supernatants were assessed by ELISA (Figure 4.12). The mean unstimulated levels of the 
three individual experiments was l.lng/ml and this was significantly reduced using a one 
way ANOVA followed by multiple range analysis (P<0.05), by all of the chemokines 
tested, MCP1, MIPla, MIPip and RANTES, at 5Ong/ml in three out of three 
experiments. These levels were within the detection limit of the assay which was 
lOpg/ml. MCP1 also caused a significant decrease at 20ng/ml (Figure 4.12).
4.4.5 MMP RT-PCR
Expression of mRNA for MMPs 2, 3, 7 and 9 were assessed in CHME3 cells by 
RT-PCR. Although the experiments were repeated a number of times and care was taken 
with each of the steps, results were inconsistent, i.e. sometimes the mRNA was not 
detected in repeat experiments, probably due to experimental errors or lack of activity of 
reagents used in RT-PCR experiments. Bands corresponding to MMP 2, MMP9, MMP7 
and MMP3 (Stromelysinl) mRNA were all detected in CHME3 cells. MMP2 and MMP3 
were seen most consistently with MMP9 and faint MMP7 bands seen occasionally 
(Figure 4.13b).
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Figure 4.11 continued. Casein/ plasminogen zymograms on CHME3 cell supernatants
and cell lysates following chemokine stimulation for 24 hours to observe plasminogen
activator activity.
1 2  3 4 7 8 9 10
43»~
1 marker,
2 uPA,
3,4 control,
5,6 M IP la  1 Ong/ml, 
7,8 M IP la  20ng/ml, 
9,10 M IP la 5Ong/ml
c) CHME3. Lanes 3,5,7,9 cell supernatants, lanes 4,6,8,10 cell lysates.
1 2  3 4
4 3 » -
7 8  9  10 1 marker,
2 uPA,
3,4 control,
5,6 RANTES lOng/ml, 
7,8 RANTES 20ng/ml, 
9,10 RANTES 50ng/ml.
d) CHME3. Lanes 3,5,7,9 cell supernatants, lanes 4,6,8,10 cell lysates.
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Figure 4.11 continued. Casein/ plasminogen zymograms on CFDVEE3 cell supernatants
following chemokine or cytokine stimulation for 24 hours to observe plasminogen
activator activity.
4 3 * -
1 control,
2 TNFa lng/ml,
3 TNFa 1 Ong/ml,
4 RANTES 2Ong/ml,
5 RANTES 5Ong/ml.
e) CHME3 Casein/ plasminogen zymogram.
Figure 4.12 uPA secretion by CHME3 cells in response to chemokine
stimulation for 24 hours
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Significant decrease in uPA secretion below that of control cells.
Figure 4.13a RNA extracted from CHME3 cells, separated on agarose gels containing 
ethidium bromide and visualised by UV transillumination.
28s 
18s
Each lane shows RNA extracted from one well of a 24 well plate using the Totally RNA 
extraction kit (Ambion, U.K) The bands are. 18 and 28s ribosomal RNA.
Mtiiiill HHH
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Figure 4.13b RT-PCR on CHME RNA using primers for MMPs 2, 3, 7 and 9. Arrows 
indicate numbers of base pairs. Lane 1 in all gels contains the molecular weight marker. 
All other lanes indicated contain PCR products from RT-PCR experiments on CHME3 
cell RNA.
1 2 3 4 5 6 7 1 2 3 4
«t . . .
b) (i) MMP2 (ii) MMP3
1 2
(iii) MMP7 (iv) MMP9
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4.5 Discussion
The presence of MMPs has been under much investigation in a number of CNS 
disease states including stroke (Todor et al, 1998), MS (Anthony et al, 1997), 
Alzheimer’s disease (Yamada et al, 1995) and brain tumours (Freidberg et al, 1998). In 
the present study, the secretion of MMPs, TIMPs and urokinase type plasminogen 
activator by microglia in vitro was investigated and the influence of chemokines and 
other inflammatory cytokines on their secretion was assessed. The results demonstrated 
that all the chemokines tested were able to upregulate CHME3 cell secretion of MMP 2 
and TIMPs 1 and 2 assayed in ELISA experiments and upregulation of MMP2 and 9 in 
cultured rat microglia was observed assessed by zymography. Since MMPs have been 
implicated in causing BBB breakdown and myelin degradation and are involved in cell 
migration, these results further support a role for chemokines in (1) the regulation of 
breakdown of the blood brain barrier (2) demyelination in MS as well as (3) chemotaxis 
of inflammatory cells, including microglia, in vitro (Cross and Woodroofe, 1999). This 
evidence would support the postulated role of chemokines in the CNS in the recruitment 
of T cells and resident microglia to areas of inflammation and tissue damage. MMPs 
produced by microglia could contribute to the formation of the plaque in MS by 
proteolysis of myelin and also by aiding migration of microglia through the extracellular 
matrix in response to chemoattractants produced at the site of inflammation. Baseline 
levels of TIMP1 were higher than TIMP2 in CHME3 cells although both were 
constitutively expressed by resting cells in culture after 24 hours. Pagenstecher et al 
(1998) found MMP gene products and TIMP gene products coincided at sites of 
inflammation and tissue damage in EAE and suggested a ‘dynamic state’ in which the
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levels of each of these proteins and their interaction may determine the extent of the 
inflammatory lesion.
The levels of MMPs and TIMPs cannot be compared directly in these 
experiments due to the nature of the ELISA specificities, i.e. the ELISA for MMP2 
measures both free pro enzyme and that bound to the inhibitor but not active enzyme, 
however it may be that there is a time lag in the secretion of the inhibitor. This would 
allow initial MMP activity which is then regulated by TIMP secretion as well as other 
factors involved in the activation of pro enzymes. This time lag in TIMP secretion was 
found in human T lymphocyte cells by Johnatty et al (1997). The upregulation of 
microglial secretion of both gelatinases and TIMPs by chemokines may be a regulatory 
mechanism to limit and tightly control extracellular matrix breakdown. It has also been 
shown that TIMP 1 has cell growth promoting activity and therefore could be beneficial 
to remyelination of axons (Hayakawa et al 1992).
It is also likely that the plasminogen activator cascade will fit into this model, by 
exerting an effect on the extent of pro-MMP activation. Plasminogen activators are 
involved in the tightly regulated cascade as they cleave plasminogen to plasmin which 
activates proMMPs and also degrades several components of the extracellular matrix 
alone (Vassalli et al, 1994). CHME3 cells were shown to constitutively secrete a 
urokinase-type plasminogen activator and all the chemokines tested significantly reduced 
the amount of uPA in the supernatant, when cells were stimulated for 24 hours with 
chemokine at a concentration of 50ng/ml assessed by ELISA experiments. This may be 
due to an increase in the number of uPA receptors expressed on the cell surface or an 
increase in the binding affinity of uPA for its receptor. Microglial uPAR expression is 
shown to be increased in the MS lesion (Washington et al, 1996) and this increase in 
expression could be due to the increase in chemokines present in the lesion. If this is the
168
case, in the cell culture system, this would suggest more binding sites are then available 
to bind uPA, decreasing the amount detectable in the supernatant. The decrease in uPA 
in culture supernatants also appeared to be evident in zymography experiments, using 
primary rat microglia, when stimulated with chemokine. The decrease in uPA in 
stimulated microglia cultures has also been shown by Nakajima et al, (1992b) when cells 
were stimulated with LPS.
Several protease inhibitors have been shown to have a beneficial effect in EAE. 
An inhibitor, D-penicillamine, was found to decrease gelatinase A and B activity in CSF 
from patients with MS or optic neuritis and also reduced mortality and morbidity in mice 
developing acute demyelination in EAE (Norga et al 1995). The metalloproteinase 
inhibitor, Ro31-9790 was found to prevent disease onset when given to rats at the same 
time as induction of EAE (Hewson et al 1995). The inhibitors of MMPs are important 
considerations in the treatment of MS, but it is becoming clear that the molecules that 
upregulate the MMPs, such as the chemokines, are also important targets for potential 
therapies to restore the balance of MMP and TIMP activities. This study provides a base 
for further research which should include inhibition of chemokine stimulated gelatinase 
production by microglia, using chemokine and/or MMP inhibitors.
Chemokines indicated in figure 4.14 were used to stimulate the cells for 24 hours in 
culture. The summary of the effects produced and measured by ELISA and/or 
zymography are shown.
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Figure 4.14 Schematic representation of chemokine effects on MMP2 and 9, TIMPs and uPA secretion by rat microglia, CHME3 cells and rat astrocytes 
in vitro.
The results discussed here, have important implications in the study of MS, in that once 
chemokines, released by infiltrating T cells under the control of pro-inflammatory 
cytokines, have recruited microglia to the inflamed site, the microglia (and also 
astrocytes) are able to further act in response to (3 chemokines and Fractalkine, by 
release of gelatinases, uPA and their natural inhibitors, TIMPs. The fact that microglial 
secretion of both MMPs and TIMPs were increased by chemokines, may suggest that the 
overall lytic activity in MS is due to a time lag in inhibitor secretion or incomplete 
inhibition. MMP2 requires TIMP2 for its own activation from the pro-enzyme form, 
increasing the complexity of the fine balance. The release of uPA adds to this complexity 
as it can activate plasmin which cleaves pro-MMPs and is also involved in chemotaxis 
when bound to its receptor, uPAR. Chemokine upregulation of MMP secretion may 
therefore be of critical importance in damage to the blood brain barrier allowing 
increased leukocyte migration as well as in myelin damage, leading to demyelination 
making them potential targets for MS therapy.
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Chapter 5
PRODUCTION OF NITRIC OXIDE. SUPEROXIDE AND FC RECEPTOR
EXPRESSION
5.1 Introduction
5.1.1 Microglia are the effector cells of the CNS
Microglia are believed to play a central role in both inflammatory and 
degenerative processes in the CNS and are able to respond to a wide range of stimuli. 
They are often the first cell type to be activated in CNS injury and respond by secretion 
of cytokines, chemokines, proteases, nitric oxide and superoxide radicals (Peterson et al, 
1997, Minghetti and Levi, 1998).
5.1.2 Nitric oxide production and its effects in the CNS
Nitric oxide (NO) is an inorganic free radical generated through an enzymatic 
reaction involving the conversion of L-arginine to L-citrulline by the enzyme nitric oxide 
synthase (NOS) with consequent release of NO radicals (See section 1.6). The reaction 
requires molecular oxygen and reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as co-substrates (Minghetti and Levi, 1998). Inflammation in the CNS can 
increase the levels of nitric oxide produced by induction of NOS in microglia and 
astrocytes (Smith et al, 1999). iNOS activity is regulated mainly at the level of 
transcription and several upstream transcription factors have been identified including 
sites for NF-kB, IFNy response element, TNFa response element and AP-1 (Minghetti 
and Levi, 1998). iNOS mRNA is elevated in MS plaques and is located mainly in 
monocytes and microglia (Bagasra et al, 1995, Smith et al, 1999). Nitric oxide synthase
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activity can be induced by the cytokines IL-lp, TNFa and IFNy in rat macrophages, 
microglia and astrocytes, however expression by human monocytes/macrophages is 
controversial (Brosnan et al, 1995). iNOS activity could be induced after just 2 hours, 
following stimulation with these cytokines, in human foetal mixed glial cultures with 
translation of iNOS protein expressed after 24 hours (Ding et al, 1997). NO radicals can 
affect lipid peroxidation which in turn affects membrane fluidity and permeability and can 
change the functions of proteins embedded in the lipids (Smith et al, 1999). Nitric oxide 
also causes cell damage particularly by its effects on mitochondrial enzymes and in vitro 
experiments have shown that oligodendrocytes are more susceptible to damage by NO, 
with a 40% loss of succinate dehydrogenase activity, than are the producers of NO, the 
microglia (Mitrovic et al, 1994). Oligodendrocytes were also found to be more 
susceptible to single stranded DNA breaks caused by NO than either microglia or 
astrocytes (Mitrovic et al, 1994). IFNy activated microglia were shown to be cytotoxic 
to oligodendrocytes in vitro and this effect was shown to be reduced by inhibitors of 
nitric oxide synthase (Merrill et al, 1993). This provides further evidence to suggest that 
NO plays a direct role in demyelination in the CNS.
Although the effects of chemokines on NO production have not been studied 
until now, chemokines themselves have been shown to be regulated by NO. A 
competitive inhibitor of L-arginine dependant NO synthase, N°-methyl-L-arginine 
(NMA), was shown to increase IL-8 and ENA-78 production from peripheral blood 
monocytes, during a mixed lymphocyte reaction in vitro, whereas levels of M IPla and 
MCP1 were unaffected (Orens et al, 1994). This suggests that NO production may have 
downregulatory effects on some chemokines in certain cell types, which could be a 
feedback mechanism to prevent further chemokine release and could also infer selectivity
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on the cell types recruited by the downregulation of some chemokines in favour of 
others.
5.1.3 Superoxide production bv microglia and its effects on the CNS
Cultured microglia, activated by phorbol myristate acetate (PMA) can respond by 
production of superoxide radicals produced as part of a ‘respiratory burst’ mediated by 
NADPH oxidase (Colton and Gilbert, 1987, Smith et al, 1999). Superoxide radicals are 
implicated in the pathogenesis of MS (Smith et al, 1999), as they are involved in lipid 
peroxidation and can affect the lipid and protein content of myelin (Bongarzone et al, 
1995). PMA triggered production of superoxide by mouse or rat microglia can be 
increased by pre-treatment of cultures with TNFa or IFNy (Hu et al, 1995, Woodroofe 
etal, 1989). Stimulated blood monocytes, isolated from MS patients have been found to 
produce significantly more superoxide than monocytes from healthy controls, which may 
be due to the monocytes from MS patients being ‘primed’ to trigger superoxide 
production (Fisher et al, 1988). Reactive oxygen species may contribute to 
demyelination by killing oligodendrocytes. This has been demonstrated in vitro by culture 
of dog oligodendrocytes in the presence of a reaction to generate superoxide anions, 
which killed the oligodendrocytes at concentrations that did not appear to affect 
astrocytes or brain macrophages (Griot et al, 1990).
Further effects of superoxide can be attributed to the formation of peroxynitrite 
in the presence of nitric oxide free radicals. Peroxynitrite, although not a highly reactive 
free radical itself (Beckman and Koppenol, 1996), can lead to cell death by mechanisms 
including nitration of tyrosine residues affecting cell signalling or by direct interaction 
with DNA causing DNA strand breakages. Peroxynitrite also affects lipid peroxidation 
(Smith et al, 1999). Peroxynitrite has been shown to induce the release of active MMPs
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from their precursors by interaction with the cysteine switch mechanism in the pro­
peptide autoinhibitory domain (Maeda et al, 1998).
Peritoneal macrophages have been shown to produce superoxide in response to 
phagocytosis of myelin in in vitro experiments and treatment with NADPH oxidase 
inhibitors, which prevent reactive oxygen species generation, resulted in inhibition of 
myelin phagocytosis (Van der Goes et al, 1998). This evidence suggests that reactive 
oxygen species can activate macrophages to phagocytose myelin as well as its role in the 
direct damage of myelin.
5.1.4 Phagocytosis bv microglia and its relevance to the study of MS
Rat microglia and peritoneal macrophages have been demonstrated to 
phagocytose myelin in vitro and antibody opsonisation of myelin resulted in increased 
phagocytosis by peritoneal macrophages, which could be further increased by stimulation 
with IFNy (Mosley and Cuzner, 1996). There appears to be some controversy in the 
regulation of respiratory burst following phagocytosis. Myelin and opsonised myelin 
uptake were shown to increase nitrite production, although opsonised myelin uptake 
caused a decrease in superoxide release (Mosley and Cuzner, 1996) in contrast with 
findings by Van der Goes, (1998). Schwacha et al (1993), found that PMA-triggered 
release of hydrogen peroxide, by rat peritoneal macrophages, was decreased following 
phagocytosis of opsonised erythrocytes but only when PMA was used at maximum 
stimulating concentrations of 50ng/ml.
Myelin phagocytosis has been shown to be increased in vivo when anti-myelin 
antibody is present. This was demonstrated by injection of antibodies against myelin 
oligodendrocyte glycoprotein, after induction of EAE in Lewis rats which lead to 
enhanced demyelination (Smith, 1999). Furthermore, cytokines have been shown to
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modulate the expression of Fc receptors on microglia in vitro. Fc receptor expression 
can be increased on rat microglia by treatment with IFNy (Woodroofe et al, 1989), 
TNFa, LPS, IL-ip (Loughlin et al, 1992) and IL-4 (Loughlin et al, 1993), demonstrated 
by binding of antibody opsonised erythrocytes to microglia. TGF-P reduces Fc receptor 
expression by microglia and also antagonises the induction by IFNy (Loughlin et al, 
1993). Increased Fc receptor expression has also been observed on reactive microglia in 
MS tissue (Ulvestad et al, 1994).
5.1.5 Aims
The aim of the following investigations were to:
a) Examine the effects of chemokines on primary rat microglial nitrite and PMA 
triggered superoxide production in vitro.
b) Observe the effects of chemokines on Fc receptor expression and phagocytosis of 
opsonised erythrocytes by microglia
c) Compare the findings for (a) and (b) with the human neonatal microglial cell line, 
CHME3 and rat peritoneal macrophages
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5.2 Materials and methods
5.2.1 Cell culture
Rat microglia were isolated as in chapter 2 (Section 2.2.8) and plated into 96 well 
plates at a concentration of 2.5xl05/ml in cDMEM (200pl/well). Plates were incubated 
overnight in a humid atmosphere at 37°C, 5%CC>2/95% air and then washed in warm 
cDMEM to remove any non adherent cells or remaining erythrocytes.
Rat peritoneal macrophages were isolated from adult Wistar rats by peritoneal 
flushings with ice cold EBSS' (Chapter 2, section 2.3). Briefly, these cells were pelleted 
by centrifugation at 180g for 10 minutes at 4°C, washed in EBSS*, counted and plated 
into 96 well plates, at a concentration of 5xl05/ml in cDMEM (200pl/well).
CHME3 cells were trypsinised and plated into 96 well plates at a concentration of 
lx l05/ml (200pl/well) in cDMEM and cultured for 24 hours. Cells were then washed in 
cDMEM before use in the assays.
5.2.2 Cell stimulation
Cells were stimulated in triplicate wells (unless otherwise stated) with the human 
chemokines MCP1, MIPip, RANTES and IP-10 between 0 and 50ng/ml in cDMEM or 
the cytokine IFNy, at 1 and 10 IU ml for 24 hours. cDMEM alone was used in control 
wells.
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5.2.3 Nitrite assay
Nitric oxide release from cells was estimated by measuring nitrite levels in cell 
supernatants, as nitric oxide has a half life of only milliseconds before it is converted to 
nitrite. Following the 24 hour stimulation period, cell supernatants were harvested and 
used to determine the amount of nitrite released compared to control, unstimulated 
levels. Nitrite levels were measured colourimetrically using Greiss reagent (consisting of 
1% sulphanilamide (Sigma), 0.1% napthylethylene diamine dihydrochloride (Sigma) and 
2.5% phosphoric acid (Vincent et al, 1997). The sulpanilamide in H20  and 
napthylethylene diamine dihydrochloride in 5% phosphoric acid were made up separately 
and stored at 4°C. The two components were mixed 1:1 immediately prior to use. lOOpl 
of cell supernatants were mixed 1:1 with freshly mixed Greiss reagent in clean 96 well 
plates and incubated at room temperature for 10 minutes and the absorbance read at 
550nm on a Wallac spectrophotometer. Standard curves were prepared by dissolving 
sodium nitrite in cDMEM (0-25 pM) and pipetted in duplicate into the 96 well plates 
alongside the test samples. A standard curve was plotted of nitrite concentration against 
absorbance at 550nm. Nitrite levels in test supernatants were calculated from the curve 
using Microsoft Excel. Nitrite levels (pM) in the supernatants are expressed as a mean of 
three experiments, unless stated otherwise.
5.2.4 Fc receptor assay
Fc receptor expression was estimated on microglia and CHME3 cells using the 
method of Woodroofe et al (1989). Following stimulation of cells in 96 well plates with 
chemokines or cDMEM alone (as above), plates were washed in warm PBS, and 50pl of 
1% EA (see chapter 2, section 2.2.6) in EBSS+ /0.5%BSA was added to each well and 
the plates incubated at 37°C for 90 minutes. The plates were washed four times in warm
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PBS by immersion and flicking out. The cells were then solubilised by the addition of 
100|il of 0.3% SDS (Sigma) in distilled water for 10 minutes at room temperature 
followed by lOOpl of substrate solution made according to the manufacturers’ 
instructions (Sigma fast OPD (O-phenylene diamine) tablets, Sigma) using one tablet 
dissolved per 20ml of PBS, to measure peroxidase activity of bound and ingested 
erythrocytes. The plates were further incubated for 30 minutes at 37°C and the 
absorbance read at 450nm on a Wallac spectrophotometer. The mean absorbance values 
of control unstimulated cells was subtracted from the mean absorbance values of 
chemokine stimulated cells and then expressed as a mean of 3 separate experiments 
performed in triplicate wells.
5.2.5 Phagocytosis assay
To visualise the extent of phagocytosis by neonatal rat microglia, cells were 
plated into 8 well chamber slides (Nunc, Life Technologies, UK) following isolation, at a 
density of 2x105 cells/well in 400pl of cDMEM. After 24 hours in culture, cells were 
washed in cDMEM and 4 wells of the chamber slide stimulated with MIPlp (lOng/ml) as 
this chemokine gave a good response in the Fc receptor assay. After a further 24 hours, 
cells were washed in warm PBS and lOOpl of 0.5% EA in EBSS+ /0.5% BSA and the 
cells were incubated at 37°C for 90 minutes. The chamber slides were then washed 4 
times in PBS and the cells fixed in cold acetone for 5 minutes followed by washing again 
in PBS and addition of the peroxidase substrate, diaminobenzidine hydrochloride (DAB) 
(Sigma), 0.2mg/ml in PBS containing 0.4pl/ml hydrogen peroxide (30%w/v) for 5 
minutes at room temperature. Slides were then washed in tap water, mounted in 
Immumount (Shandon, UK) and observed by light microscopy (Olympus BX60) to
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compare the phagocytosis of unstimulated and MEPip stimulated microglia. Cells were 
photographed on Kodak colour film (200ASA).
5.2.6 Assay for superoxide production
Superoxide production by microglia, CHME3 cells and splenic macrophages was 
assessed colourimetrically using a modified method of Pick and Mizel (1981) utilising the 
reduction of ferricytochrome c by superoxide anions in the absence or presence of 
superoxide dismutase. Following stimulation, for 24 hours, cells were washed in DMEM 
without phenol red (Sigma) and incubated at 37°C with ferricytochrome c (from horse 
heart), 160pM (Sigma) and phorbol-12-myristate-13-acetate (PMA) (20nM) to trigger 
superoxide production, in phenol red free DMEM (Life Technologies, U.K) for 60 
minutes. To calculate the reduction of ferricytochrome c by superoxide only, superoxide 
dismutase (from bovine erythrocytes) (Sigma) at a final concentration of 375 IU/ml was 
included in replicate experiments. Triplicate wells were averaged and superoxide 
expression per 105 cells was calculated using the formula by Pick and Mizel (1981):
A^ nnm without SOD-A^nnm with SOD X 100.
6.3
This gives the amount of superoxide produced in nmoles per 105 cells per hour. CHME3 
results were calculated based on the number of cells plated out at the start of the 
experiment.
5.2.7 Statistical analysis
Significant differences between control and stimulated cells were calculated using one 
way ANOVAs followed by multiple range analyses for all experiments. P values of <0.05 
were considered significant.
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5.3 Results
5.3.1 Nitrite Results
A standard curve was produced for each experiment, to determine the amount of 
nitrite in cell culture supernatants. All standard curves were highly reproducible and a 
typical example is shown in Figure 5.1. The plot is linear and absorbance values obtained 
from test supernatants were converted into nitrite levels in pM, directly from the curve 
using Microsoft Excel spreadsheets.
5.3.2.1 Nitrite production bv rat microglia and peritoneal macrophages following IFNy 
stimulation
To assess the assay protocol, IFNy , which has previously been demonstrated to 
upregulate nitrite production in microglia (Chao et al, 1992), was used to stimulate rat 
microglia and rat peritoneal macrophages. Nitrite levels produced by 30 day old rat 
microglia (2 experiments) and peritoneal macrophages (3 experiments) were compared in 
response to stimulation with IFNy at 1 and lOIU/ml (concentrations reported by 
Woodroofe et al (1989) to stimulate microglia). Primary microglia showed a significant 
increase in nitrite levels above unstimulated levels (P<0.05) (Table 5.1) when stimulated 
for 24 hours with IFNy at HU/ml (1/2 experiments) and 10IU (2/2 experiments) using a 
one way ANOVA followed by multiple range analysis. Similarly, rat peritoneal 
macrophages also showed a significant increase in nitrite levels when stimulated with 
IFNy at 1 and lOIU/ml (3/3 experiments). Nitrite levels produced by peritoneal 
macrophages were generally higher in response to IFNy compared to microglia (Table 
5.1), although the levels produced in response to the chemokines tested were veiy 
similar.
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Figure 5.1 A typical sodium nitrite standard curve for determination of nitrite concentration in cell
supernatants
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Table 5.1 Nitrite production bv 30 day old rat microglia and peritoneal macrophages in
response to IFNy.
Mean nitrite production (pM) +/- SEM
IFNy microglia peritoneal macrophages
(IU/ml)
0 2.52+/-1.96 4.07+/-2.94
1 6.47+/-0.026 (1/2)* 37.0+/-11.8 (3/3)
10 7.26+/-0.52 (2/2) 42.7+/-15.9 (3/3)
Results are expressed as the mean +/- SEM.
*Brackets show number of experiments giving a significant (P<0.05) response above 
control levels. Experiments were performed twice using microglia and three times using 
peritoneal macrophages.
5.3.2.2 Nitrite production bv neonatal rat microglia following chemokine stimulation
Nitrite production by neonatal microglia was assessed in vitro following 
stimulation for 24 hours with the p chemokines MCP1, MIPlp and RANTES and the a  
chemokine IP-10, used at concentrations between 0.1 and 50ng/ml. Experiments were 
performed three times and the mean nitrite levels +/- SEM determined. Control levels 
were very low in 2/3 experiments (0.23 pM and 0.49pM) and were undetectable in the 
third experiment. Nitrite levels were significantly increased above control levels (P<0.05) 
by all of the chemokines tested at at least one concentration of chemokine (Figure 5.2a). 
The response to stimulation with MIPip was consistently the highest above control 
levels, when compared to the other chemokines with a peak increase in nitrite production
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at lOng/ml. IP-10 showed a comparable increase at 50ng/ml (Figure 5.2a) in 2/3 
experiments. Stimulation with MIPip also appeared to have an effect over a wider range 
of concentrations when compared to the other chemokines tested. Nitrite production was 
decreased by MIPip and RANTES at the higher concentration of 50ng/ml when 
compared to results at lOng/ml. RANTES only caused a significant increase in nitrite 
production by neonatal rat microglia above control levels at lOng/ml, and was not 
significantly different from control when used at 50ng/ml, whereas stimulation with 
MCP1 and IP-10 gave the highest response above control levels at 50ng/ml (Figure 
5.2a).
5.3.2.3 Nitrite production bv 30 day old rat microglia
Microglia isolated from 30 day old rat brains were stimulated with the P 
chemokines, MCP1 and MIPip, to compare their response with that of neonatal 
microglia. These experiments also showed a significant increase in nitrite production 
above control levels when stimulated for 24 hours, under the same conditions (Figure 
5.2b). Control unstimulated production of nitrite was generally higher than in the 
neonatal microglia with a range of between 0.4 and 4.6 pM in three experiments. Both 
chemokines showed the maximal increase above control levels at the higher end of the 
concentration range (50ng/ml). The increased nitrite production seen with increasing 
chemokine concentrations, was not as marked with the 30 day old rat microglia as seen 
with the neonatal microglia, although the levels obtained were higher e.g. with MIPip at 
lOng/ml the mean nitrite levels for neonatal microglia were 10pM and was 8pM using 30 
day old rat microglia.
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Figure 5.2b Nitrite production bv 30 day old rat microglia following chemokine stimulation for 24
hours
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The graph shows a mean of three individual experiments +/- SEM. * Represents a significant increase in nitrite p r o d u c t !  
levels using a one way ANOVA followed by multiple range analysis.
5.3.2.4 Nitrite production bv CHME3 cells
CHME3 cells were used in the same experiments, to compare their nitrite 
production to that of primary rat microglia. Unstimulated levels of nitrite produced were 
comparable to the neonatal microglia and lower than the 30 day old microglia. The 
response to the four chemokines, MCP1, MIPip, RANTES and IP-10, showed a very 
similar pattern to that of the primary microglia, although the actual amount of nitrite 
produced was lower (Figure 5.2c). The highest increase above control levels was after 
stimulation with MIPip which also gave a significant increase above controls over the 
full range of concentrations tested. MCP1 gave the highest response at the higher 
concentrations. When stimulated with RANTES, there was a peak response at lOng/ml, 
whereas IP-10 gave a significant increase in nitrite over the whole range of 
concentrations tested.
5.3.2.5 Nitrite production bv rat peritoneal macrophages
Nitrite levels in rat peritoneal macrophages were also tested following chemokine 
stimulation, for comparison. Nitrite levels in unstimulated peritoneal macrophages in 
these experiments were generally higher than with microglia, although the percentage 
increase above the control levels, when stimulated with a  chemokines was comparable to 
the microglia. The intra and inter experimental variation was greater and although there 
is an apparent increase in nitrite production, this was not a significant increase above 
control levels, at the 5% level when stimulated with MCP1, MIPip or RANTES at 
concentrations of between 0.1 and lOng/ml (Figure 5.2d). There appears to be a slight 
increase in nitrite production at lng/ml for all three chemokines but these were not 
significant at the P<0.05 level of significance due to the variability of the results. Nitrite 
levels in rat peritoneal macrophages were also tested in response to the a chemokines IP-
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Figure 5.2c Nitrite production by CHME3 cells following chemokine stimulation for 24 hours
(IAI11) 3»M1!N
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The graph shows the mean of three individual experiments +/- SEM. + Represents a significant increase in nitrite production above 
levels using a one way ANOVA followed by multiple range analysis.
Figure 5.2d Nitrite production bv rat peritoneal macrophages following chemokine stimulation for
24 hours
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as individual experiments or as the mean of three, using a one way ANOVA followed by multiple range analysis.
10, IL-8 and MIG in two experiments (Figure 5,2e). In contrast to the response using the 
p chemokines, these all gave a significant increase in nitrite produced above the control 
levels. The chemokines IL-8 and MIG had a similar effect on nitrite production at all 
three concentrations used and IP-10 had a significant effect at only the higher 
concentrations used (1 and lOng/ml).
5.4.1 Superoxide production bv rat peritoneal macrophages, microglia and CHME3 cells 
Superoxide anion production by rat microglia and peritoneal macrophages was 
assessed in vitro in response to stimulation with IFNy for 24 hours as a positive control. 
Peritoneal macrophages were stimulated with IFNy at 1, 10 and 100 IU/ml and 
compared to unstimulated controls in medium alone. The experiments were performed in 
quadruplicate wells and were repeated 3 times (Table 5.2) Unstimulated levels of 
superoxide release were 0.012 nmoles/105 cells/hour. The superoxide release was 
markedly and significantly (P<0.05) increased by IFNy at 1 IU/ml in all three 
experiments. At the higher concentrations of 10 and 100 IU/ml, the levels of superoxide 
release were not significantly different from control levels (P<0.05). With this prior 
knowledge, the response of neonatal and 30 day old rat microglia was assessed when 
stimulated with IFNy at 1 IU/ml and compared to unstimulated levels (Table 5.3). Cells 
were stimulated in quadruplicate and the experiments were performed twice. Both 
neonatal and 30 day old rat microglia did not release a measurable amount of superoxide 
anions under control, unstimulated conditions although there was a marked induction by 
IFNy stimulation. 30 day old rat microglia produced slightly higher levels of superoxide 
when stimulated with IFNy than the neonatal microglia, e.g.0.253 nmoles/105 cells/hour
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Figure 5.2e Nitrite production bv rat peritoneal macrophages following chemokine stimulation for
24 hours
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The graph shows the mean of two individual experiments +/- SEM. * Represents a significant increase in nitrite production above control 
levels using a one way ANOVA followed by multiple range analysis.
compared with 0.206 nmoles/105 cells/hour. Conversely, CHME3 cells did not release 
any detectable amount of superoxide when stimulated with IFNy at 1 or 10 IU/ml.
Table 5.2 Induction of superoxide production by IFNy stimulation of rat peritoneal 
macrophages for 24 hours.
IFNy
(IU/ml)
mean superoxide 
levels (+/- SEM) 
(nmoles/105cells/ 
hour)
0 0.063 (0.063)
1 0.243 (0.036) *
10 0.032 (0.042)
100 0.032 (0.042)
Mean superoxide production is shown from three individual experiments. Significance 
was calculated using a one way ANOVA followed by multiple range analysis. * indicates 
significant increase above control levels (P<0.05)
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Table 5.3 Induction of superoxide production by IFNy stimulation of neonatal and 30
day old rat microglia and peritoneal macrophages for 24 hours.
Superoxide production (nmoles/105 cells/hour)
IFNy (IU/ml) neonatal microglia adult microglia peritoneal macrophages
0 0 0 0.012+/-0.012
1 0.206+/- 0.016 * 0.253+/-0.001 * 0.243+/-0.036 *
Results are expressed as mean superoxide production +/- SEM for 2 experiments for 
neonatal and adult microglia, and 3 experiments for peritoneal macrophages. Each 
stimulation was performed in quadruplicate wells. Significance was calculated by a one 
way ANOVA followed by multiple range analysis. * indicates significant increase above 
control unstimulated cells (P<0.05).
Superoxide anion production by rat microglia, CHME3 cells and rat peritoneal 
macrophages was then assessed in vitro in response to stimulation with chemokines for 
24 hours. The effects of the chemokines, MCP1, MIPip, RANTES and IP-10 were 
examined on neonatal rat microglia. Stimulations were performed in triplicate wells and 
each experiment was repeated three times.
5.4.2.1 Superoxide production bv neonatal rat microglia in response to chemokines
Neonatal microglial cells did not produce any measurable amount of superoxide 
anions under resting, unstimulated conditions in any experiments (Figure 5.3a). There 
was a significant induction of superoxide anion production (P<0.05) in response to
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MCP1 and MIPip at lng/ml, and to IP-10 at lOng/ml, although actual levels were quite 
variable between experiments. MIPip at lng/ml consistently induced the greatest 
amount of superoxide release, when compared to the other chemokines tested. RANTES 
did not induce a significant release of superoxide anions in response at any of the 
concentrations tested and only one experiment out of three showed a small positive 
response above control, when cells were stimulated using RANTES at lng/ml.
5.4.2.2 Superoxide production bv CHME3 cells in response to chemokines
As a comparison, the superoxide anion released from CHME3 cells in response 
to the same chemokines was examined. Stimulations were carried out again in triplicate 
wells and experiments repeated 3 times. Control, unstimulated levels of superoxide 
release were undetectable in two out of three experiments and were very low 
(0.01nmoles/105cells/hour) in the third experiment. Superoxide release was significantly 
increased above control levels (P<0.05) by all of the chemokines tested, in at least one 
concentration used, although similarly with the neonatal microglia, the levels of 
superoxide produced were variable between experiments (Figure 5.3b). A significant 
increase in superoxide production was observed when CHME3 cells were stimulated 
with MCP1, MIPip and IP-10 at 0.lng/ml, with no detectable superoxide production 
following stimulation by RANTES at this concentration under the same conditions. 
MCP1 stimulation also produced a significant increase at lng/ml although 10 and 
50ng/ml MCP1, produced a much smaller and non significant, increase above control 
levels with superoxide levels being undetectable in two out of three stimulation 
experiments with MCP1 at 50ng/ml. Stimulations with MIPip at the highest 
concentration tested, 50ng/ml, did not produce detectable levels of superoxide by 
CHME3 cells in any of the three experiments. CHME3 cells showed a significant
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response to RANTES and IP-10 at 1 and 50ng/ml however an apparently lower and non 
significant increase above control was observed at lOng/ml probably due to the inter- 
experimental variability.
Levels of superoxide production by CHME3 cells were generally higher than 
from neonatal rat microglia with maximal levels of up to 0.9nmoles/105cells/hour, when 
stimulated with MCP1 whereas the highest level of superoxide production by neonatal 
microglia following chemokine stimulation with MIPip was just 0.44nmoles/105 
cells/hour. The major difference between the response of CHME3 and primary neonatal 
rat microglia was in their response to RANTES, whereas all the other chemokines 
appeared to significantly increase superoxide release in both types of cells, RANTES 
only produced this effect in CHME3 cells (Figures 5.3a and b.)
5.4.2.3 Superoxide production bv rat peritoneal macrophages in response to chemokines
Rat peritoneal macrophages were used as a comparison for microglia and 
CHME3 cells to assess the difference in the levels of superoxide produced when 
stimulated with chemokines (Figure 5.3c). Cells were stimulated with MCP1, MIPip, 
RANTES and IP-10 between 0.1 and lOng/ml for 24 hours. Unstimulated levels of 
superoxide production were between 0.1 and 0.25 nmoles/105cells/hour which was 
higher than that observed for CHME3 cells and neonatal rat microglia, which did not 
produce any superoxide under resting conditions. When stimulated with the chemokines 
MCP1 and MIPip at 0.lng/ml, there was an apparent increase in superoxide production 
by peritoneal macrophages although this was not statistically significant at the P<0.05 
level. RANTES appeared to increase superoxide production at lng/ml in all three 
experiments but similarly, this was not statistically significant. IP-10 stimulation had no
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effect on superoxide production by peritoneal macrophages in any experiments (Figure 
5.3c).
5.5.1 Fc receptor expression bv rat peritoneal macrophages, microglia and CHME3 cells, 
assayed bv measurement of phagocytosis of opsonised erythrocytes
Fc receptor expression was assessed by the ability of macrophages and microglia 
to bind and/or ingest antibody coated erythrocytes via the Fc portion of the opsonising 
antibody. Phagocytosis of antibody coated erythrocytes after 90 minutes was first 
observed using light microscopy, comparing chemokine stimulated and unstimulated 
neonatal and 30 day old rat microglia. (Figure 5.4). The mean number of phagocytosed 
erythrocytes per microglial cell was increased above that of unstimulated cells by 
stimulation with MIPip at lOng/ml for 24 hours. To quantitate the amount of 
erythrocytes bound to or ingested by cells, the pseudoperoxidase activity of the 
bound/ingested erythrocytes was examined colourimetrically in 96 well plates. Fc 
receptor expression was examined by neonatal and adult rat microglia, peritoneal 
macrophages and CHME3 cells to allow comparison between the cell types.
5.5.2.1 Fc receptor expression bv neonatal rat microglia in response to chemokines
Fc receptor expression by neonatal microglia was assessed, with or without 
stimulation by the chemokines, MCP1, MIPip, IP-10 and RANTES at 0.1, 1.0, 10, and 
50ng/ml. Experiments were carried out three times (twice with RANTES) and the mean 
absorbance +/- SEM calculated. No statistically significant increase (P<0.05) in Fc 
receptor expression above control was observed due to inter-experimental variation, 
therefore individual experiments were plotted and the significant increase above control 
levels calculated (Figure 5.5a and b). MCP1 appeared to increase Fc receptor expression
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Figure 5.4 Phagocytosis of antibody coated erythrocytes by neonatal microglia after 90
minutes.
a) Control, microglia incubated with opsonised erythrocytes without pre-treatment with 
chemokine (X400)
b) Microglia incubated with opsonised erythrocytes. Microglia were incubated with 
M IP 1(3 (lOng/ml) for 24 hours before addition of erythrocytes (X400).
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Figure 5.5a Fc receptor expression bv neonatal microglia after chemokine stimulation for 24
hours
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Figure 5.5b Fc receptor expression bv neonatal rat microglia in response to chemokine
stimulation for 24 hours
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+/- SEM. * Represents a significant increase in Fc receptor expression above centrol levels.
above control levels in all three experiments although this was only statistically 
significant (P<0.05) in one out of three experiments, at a concentration of lOng/ml. 
MIPip, however produced a much greater, statistically significant increase in Fc receptor 
expression, up to 1.75 fold, when compared to control levels, at all concentrations 
tested. MIPip at concentrations of 1, 10, and 50ng/ml, in all three experiments a 
significant increase above control was observed.
When neonatal rat microglia were stimulated with IP-10 at 0.1, 1, 10 and 
50ng/ml (Figure 5.5b) there was a significant increase in Fc receptor expression in 3/3 
experiments although the concentration giving the most significant response was variable 
between experiments. Neonatal rat microglia did not show any significant increase in Fc 
receptor expression above control levels in response to RANTES stimulation at any of 
the concentrations tested.
5.5.2.2 Fc receptor expression bv 30 day old rat microglia in response to chemokines
30 day old rat microglia were also used in this assay to assess the effect of 
chemokine stimulation on Fc receptor expression (Figure 5.5c). The chemokines used 
were MCP1 and MIPip, at concentrations between 0.1 and 50ng/ml. A similar effect 
was observed as with neonatal microglia in response to MCP1 where there appeared to 
be an increase in absorbance above control levels but this was only statistically significant 
(P<0.05) at one concentration (O.lng/ml). MIPip, however, again showed a more 
significant increase than MCP1 stimulated cells with a statistically significant increase 
(P<0.05) at concentrations between 0.1 and lOng/ml.
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Figure 5.5c Fc receptor expression by 30 day old rat microglia following chemokine stimulation
for 24 hours
_____________________
_________________
(luuosfr) sqv
ZOi.
expression above control levels using a one way ANOVA followed by multiple range analysis.
5.5.2.3 Fc receptor expression bv CHME3 cells in response to chemokines
CHME3 cells were compared to neonatal rat microglia in their Fc receptor 
expression in response to the same chemokines as above (Figure 5.5d). There was less 
inter-experimental variation, therefore a mean of results from three individual 
experiments could be taken. Stimulation with MCP1 gave a similar response to that of 
the rat microglia in that there appears to be an increase in Fc receptor expression above 
control levels, although the response was only significant (P<0.05) at a concentration of 
50ng/ml. MIPip induced a greater response above control, which was statistically 
significant at concentrations of 0.1, 1 and lOng/ml. RANTES and IP-10 caused a 
significant increase above control levels at all concentrations tested on CHME3 cells in 
contrast to rat microglia which did not show any response to RANTES stimulation. 
Absorbance values were generally lower in CHME3 cells compared to rat microglia 
suggesting a lower level of expression of Fc receptors.
5.5.2.4 Fc receptor expression bv rat peritoneal macrophages in response to chemokines 
Rat peritoneal macrophages were also used in the Fc assay and tested in their 
response to MCP1 and MIPip. Due to inter-experimental variation, all three repeat 
experiments (two for MCP1 and MIPip at 50ng/ml) were plotted together on one graph 
(Figure 5.5e). A significant increase in absorbance was observed when cells were 
stimulated with MCP1 at lOng/ml (2/3 experiments) and at 50ng/ml (1/2 experiments). 
MIPip, showed a significant increase above controls over a wider range of 
concentrations which was consistent with results seen with neonatal and 30 day old rat 
microglia, as well as with CHME3 cells. The mean level of Fc receptor expression by 
peritoneal macrophages was similar to those seen in experiments with CHME3 cells, but 
this was lower than found using primary rat microglia.
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5.5.2.5 Summary of results
Table 5.4 summarises the results of chemokine stimulation experiments on nitrite 
and superoxide production and Fc receptor expression by microglia, CHME3 cells and 
peritoneal macrophages.
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Table 5.4 Summary of the effects of chemokines on nitrite and superoxide production
and Fc receptor expression by microglia, CHME3 cells and peritoneal macrophages.
Chemokine
Cell type Assay MCP1 MEP1P RANTES IP-10
2-3 day old rat 
microglia
Nitrite + + + +
Superoxide + + +
Fc receptors +/- + +
30 day old rat 
microglia
Nitrite + + NT NT
Superoxide NT NT NT NT
Fc receptors +/- + NT NT
CHME3
Nitrite + + + +
Superoxide + + + +
Fc receptors +/- + + +
Rat peritoneal 
macrophages
Nitrite NT +
Superoxide
Fc receptors + + NT NT
+ represents significant increase above control levels (P<0.05)
- represents no significant increase above control levels (P<0.05) using a one way 
ANOVA. NT represents not tested
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5.6 Discussion
Microglia are thought to cause cellular damage in vitro by the production of 
reactive oxygen and nitrogen intermediates and are capable of phagocytosing products of 
demyelination. NO, measured as nitrite production, has been previously shown to be 
upregulated by IFNy in rat microglial cell cultures in vitro (Chao et al, 1992) and these 
effects were confirmed in the present study. Nitrite levels reported by Chao et al (1992) 
were much higher than those found in this study although this could be accounted for by 
both the longer stimulation period (72 hours) used, allowing greater accumulation of 
nitrite in the culture medium and a much higher concentration of IFNy (500IU/ml). In 
this present study, an increase in nitrite production by microglia was observed using only 
1 and 10 IU/ml IFNy.
IFNy was also found to increase superoxide production by rat microglia and 
peritoneal macrophages, in agreement with experiments by Woodroofe et al, (1989). 
Treatment with IFNy induced the greatest amount of superoxide production by 
peritoneal macrophages followed by 30 day old rat microglia and slightly less by neonatal 
microglia. This also mirrored findings by Woodroofe et al, (1989). The human foetal 
microglial cell line, CHME3 did not release any detectable amount of superoxide in 
response to IFNy, indicating a difference between the primary rat microglial cultures and 
the cell line, although this effect may be accounted for by species differences. The 
generation of reactive oxygen intermediates by microglia from different species has been 
noted by Colton et al, (1996).
Since the generation of superoxide and nitric oxide and the subsequent formation 
of peroxynitrite in the CNS has clearly important implications in the pathogenesis of MS, 
and since a plethora of cytokines as well as the more recently documented chemokines,
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are present in the MS lesion, it was hypothesised that chemokines may regulate the 
production of reactive oxygen and nitrogen intermediates by microglia. This study clearly 
indicates that the chemokines are able to increase their release by microglia at least in 
vitro and this may indicate a detrimental role for chemokines in causing damage to 
myelin in vivo, in MS.
MCP1, MIPip, RANTES and IP-10, all increased nitrite production in both 
microglia and CHME3 cells above control levels, although nitrite levels were generally 
found to be higher in rat microglia than in CHME3 cell supernatants. This may also be 
accounted for by the species difference. It has often been debated whether or not human 
microglia produce nitric oxide, although it may be that stimuli capable of inducing iNOS 
in human microglia may be different from those effective in rat microglia. Species 
differences have previously been described along the signal transduction cascade required 
for the induction of the iNOS gene which may be responsible for the hypo- 
responsiveness of human iNOS to IFNy stimulation (Zhang et al, 1996) and this could 
also be the case for the differences found here following chemokine stimulation.
The chemokines MCP1, MIPip and IP-10, all increased superoxide production 
by both rat microglia and CHME3 cells. A difference was observed in the responsiveness 
to RANTES whereby only CHME3 cells produced a significant increase in superoxide 
production above unstimulated levels. In contrast, rat peritoneal macrophages did not 
show a significant increase in superoxide production following stimulation with any of 
the chemokines. This is an interesting difference because as mentioned previously, the 
peritoneal macrophages produced the highest response to IFNy stimulation, yet seem 
unresponsive in generating superoxide after chemokine stimulation.
Important biological links between chemokines and reactive oxygen species/nitric 
oxide have been observed in previous studies. NO has been shown to inhibit the
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expression of IL-8 and MCP1 in endothelial cells and upregulates DL-8 transcription in 
leukocytes and melanoma cells (Merrill and Murphy, 1997). Reactive oxygen species 
including H2O2 and OH', have also been shown to upregulate IL-8 (DeForge et al, 
1993). This present study is the only one to datethat has examined the effects of 
chemokines on nitrite production and superoxide production by microglia.
The present study also indicates that chemokines play a role in the regulation of 
Fc receptor expression by microglia, which may in turn increase the cells’ phagocytic 
abilities. The effects of the chemokines tested on Fc receptor expression by microglia 
were quite variable between experiments and whereas MCP1, MIPip and IP-10 all 
increased Fc receptor expression in rat microglia, RANTES had no effects at all on these 
cells, which was similar to the response by these cells on the production of superoxide. 
This cannot be explained by a lack of receptor for RANTES as a positive response was 
seen in microglia in NO production, migration experiments and MMP production in 
response to RANTES stimulation. CHME3 cells however did respond to RANTES by an 
increase in Fc receptors as well as to all the other chemokines tested and peritoneal 
macrophages also showed an increase in Fc receptor expression following chemokine 
stimulation. Experiments on rat microglia in culture showed that MIPip stimulation did 
in fact increase phagocytosis of opsonised erythrocytes.
Many studies have focused on downregulating the effects of reactive oxygen 
intermediates in experimental models of MS. The use of peroxynitrite scavengers 
including uric acid, was shown to decrease the severity of disease symptoms in EAE, 
whether treatment was initiated before or after clinical symptoms of EAE had appeared 
(Hooper et al, 1997). This group found that the incidence of MS and gout, where
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patients are hyperuricaemic, are virtually mutually exclusive and suggest that 
hyperuricaemia may protect against MS due to its effects on peroxynitrite mediated CNS 
damage (Hooper et al, 1998). The present study has demonstated that chemokines play 
an important role in the production of reactive oxygen and nitrogen species and it may be 
that chemokines could be a potential therapeutic target in downregulating CNS damage.
Figure 5.6 Summary of chemokine effects on microglial nitric oxide and superoxide 
production and Fc receptor expression with possible pathological consequences in MS.
MCP1 +
MEPla +
Oxygen
NADPH
ox] das
NADPHMicroglianucleus NADP + O
iNOS
Increased Fc receptor 
expressionNO O
ONoa
p e r o x y n i t n t e Increased phagocytosis of opsonised myelin 
fragments.
I )amage to oligodendrocyte cell membrane by fatty acid oxidation, release of membrane 
components, lipid/protein crosslinking.
The chemokines MCP1, IP-10, MIPip and RANTES were all found to increase nitrite 
and superoxide production by CHME3 cells as well as increasing Fc receptor expression. 
MCP1, IP-10 and MIPlf3 had similar effects on rat microglia, although RANTES did not 
increase superoxide production and Fc receptor expression in these cells. This may be 
due to different signalling pathways in different cell types through the receptors 
CCR1/CCR5 or a lower affinity binding of RANTES to the receptor. Chemokines 
released by activated T cells within MS plaques could therefore be responsible for the 
recruitment and activation of microglia which then release free radicals causing damage
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to the myelin sheath. The increase in Fc receptor expression would increase antibody 
mediated phagocytosis of opsonised myelin fragments which could be processed and 
presented to T cells, exacerbating the inflammatory response. Targeting the chemokines 
responsible for microglia activation, or their receptors may be an important consideration 
in the development of MS treatments
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Chapter 6
DISCUSSION
Accumulation of microglia at sites of CNS injury is common to many 
neurological diseases, including MS (Esiri and Reading, 1987, Streit, 1987, Joshi and 
Crutcher, 1998). Immunohistochemical analysis of MS lesions has clearly shown that 
macrophages are a major cell type in perivascular cuffs and throughout the lesion and 
that they are present in an activated state. Activated microglia are capable of expressing 
MHC class II as well as a cascade of proinflammatory molecules from cytokines to 
proteases (Sriram and Rodriguez, 1997, Minghetti and Levi, 1998). Recent 
investigations have demonstrated the presence of chemokines in MS lesions (Simpson et 
al, 1998, McManus et al 1998a, Van der Voom et al, 1999) and the use of animal model 
systems has shown the importance of chemokine expression for disease progression and 
correlate with disease severity (Miyagishi et al, 1995).
The purpose of this series of experiments was firstly to assess the migration 
response of microglia to a panel of chemokines, as these are obvious candidates for the 
recruitment of microglia in vivo to the inflammatory lesion in MS. Chemokines have 
been shown to be expressed by infiltrating T cells, astrocytes, endothelial cells and 
macrophages/ microglia in the lesion which could be the signal required for the further 
recruitment of microglia (Simpson et al, 1998). Microglia have previously been shown to 
migrate in vitro towards C5a and fMLP, the classical chemoattractants. Also a number of 
P chemokines have been shown to chemoattract human foetal microglia in vitro in 
migration studies (Peterson eta l, 1997).
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The present study has shown that primary rat microglia from 30 day of rats, 
representative of an adult phenotype, migrate to the chemokines MCP1, MIPla, MPip, 
RANTES, IL-8 and IP-10. The rat microglia were able to respond to both rat and hman 
chemokines in chemotaxis experiments, probably due to the high degree of amino icid 
homology. The human foetal microglial cell line, CHME3 also showed a consistent 
migration response to the same panel of chemokines and the migration of both cell types 
was dose dependant, showing a typical bell shaped curve, where migration reached an 
optimal level and was then attenuated at higher concentrations of chemokine. This may 
cause the microglia to respond to a concentration gradient of a chemokine produced in 
vivo by cells present in the MS lesion by migrating up the concentration gradient until a 
point of receptor saturation where the microglia may become arrested and perform their 
functions within the lesion. Obviously in the in vivo situation, it is not as simple as in the 
migration studies reported here with one chemokine attracting the cells at one time, there 
seems to be an overwhelming presence of chemotactic signals produced in vivo. For the 
microglia to respond, there has to be the presence of the particular chemokine receptor 
on the responding cell as well as the chemokine gradient. It may be that there is a 
hierarchy of chemoattractants in vivo whereby some are preferential to others, or that 
binding of one particular chemokine to its receptor may downregulate the expression of 
another receptor. Chemoattractant receptor crosstalk in neutrophils has been 
demonstrated in vitro by Campbell et al (1997) and Foxman et al (1997), who showed 
‘multistep navigation’ of neutrophils in a more complex environment of two different 
chemoattractants. Cells were able to migrate up a concentration gradient to a 
chemoattractant and then down that concentration gradient, towards a more distant, 
different chemoattractant. This may explain how microglia can negotiate the complex 
array of chemotactic stimuli in vivo.
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Migration of cells involves changes in the actin cytoskeleton, allowing the 
formation and retraction of pseudopodia with focal adhesions for the cell to ‘puli’ itself 
along a substratum. Chemokine signalling through G protein coupled receptors involves 
the activation of small GTP binding proteins of the Ras superfamily. Rac and Rho lead to 
membrane ruffling, where cells form lamellipodia which extend outwards and then fold 
back over the cell as the cell moves forward. Rho induces the formation of stress fibres 
and focal adhesions (Machesky and Hall, 1996). The present study has demonstrated that 
the chemokines MCP1, MIPla, MIPip, RANTES, IL-8, IP-10 and MIG, cause 
morphological changes and actin reorganisation of the cytoskeleton in rat microglia and 
CHME3 cells. Stress fibre induction was the most obvious change in CHME3 cells, 
suggesting a typical Rho activated morphology, whereas an increase in F actin in 
pseudopodia was a more common feature in chemokine treated rat microglia, suggesting 
Rac activation. Some rat microglia also demonstrated a polarised morphology, indicating 
a response causing directed migration possibly due to formation of a local gradient in the 
microenvironment. The study clearly demonstrates that chemokines are likely candidates 
in the recruitment and accumulation of microglia to areas of inflammation or tissue 
damage in the CNS.
Migration of microglia through CNS tissue probably involves breakdown of the 
extracellular matrix. Microglia have been previously demonstrated to produce a whole 
range of proteases including MMPs in response to IL-1 and LPS (Colton et al 1993, 
Gottschall et al, 1995). The second part of this present study was undertaken to examine 
whether chemokines were able to regulate MMP and plasminogen activator production 
by microglia, as well as the inhibitors of MMPs, the TIMPs. The chemokines MCP1, 
MIPip, RANTES, EL-8 and Fractalkine were all found to increase the secretion of 
MMP2 (gelatinase A) as well as TIMP1 and TIMP2 above control unstimulated levels.
217
Gelatin substrate zymography also showed an increase or induction of MMP9 (gelatinase 
B) by CHME3 cells. The increase in MMP secretion occurred slightly earlier than the 
TIMP secretion in preliminary experiments suggesting an initial release of proteolytic 
activity, followed by a regulation of this activity by the inhibitors. The chemokines tested 
including MCP1, MIPip and Fractalkine were also shown to produce a similar effect on 
MMP expression by primary rat microglia. The effect of chemokines on MMP9 secretion 
by rat microglia was much more pronounced than the response seen in CHME3 cells. 
This may be explained by species differences or the use of a transfected immortalised cell 
line rather than primary cells. These results suggest that the chemokines exert an effect 
on the production of MMPs by microglia to allow them to break down the extracellular 
matrix, allowing them to migrate through the tissues’ ECM along a chemokine gradient. 
This again may depend on the receptors expressed at any particular time. MMPs also 
play an important role in the breakdown of the blood brain barrier which in turn allows 
leakage of substances into the CNS which are normally excluded as well as further 
recruitment of circulating cells into the CNS. Myelin degradation in MS is also thought 
to be due partly to the actions of proteases and MMPs are known to cleave myelin basic 
protein in vitro (Gijbels et al, 1993, Proost et al, 1993). Chemokines may therefore, not 
only recruit microglia, but contribute to the progression of MS by increasing protease 
secretion by microglia. Even though the chemokines also increased TIMP secretion, 
there may be a time lag or a local imbalance to favour lytic rather than anti-lytic activity.
Plasminogen activators have also been previously detected in MS lesions (Cuzner 
et al, 1996) therefore the present study examined the effect of chemokine stimulation on 
the secretion of urokinase-type plasminogen activator. Interestingly the chemokines 
appeared to downregulate uPA secretion into culture supernatants in a dose dependant 
manner. uPA is active when bound to a cell surface receptor which localises the
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activation of plasmin to the cell surface. The effect of the chemokines apparently 
downregulating the secretion of uPA may in fact be an effect of upregulating the 
expression of the cell surface receptor with an increase in binding of uPA. The effect of 
this in vivo may be localised breakdown of the ECM at the microglia cell surface to aid 
migrationin response to chemokines at the lesion site.
Microglia produce many different responses following cytokine stimulation which 
are thought to promote a pro-inflammatory response resulting in tissue damage. These 
cells are also involved in late ‘cleaning up’ events following inflammation. The third aim 
of this study was to examine the effects of chemokine stimulation on microglia effector 
functions. Reactive oxygen and nitrogen species are heavily implicated in inflammatory 
CNS lesions and are associated with microglia/macrophages (Bagasra et al, 1995, 
Hooper et al, 1997, Smith et al, 1999). Microglia have also been shown to produce nitric 
oxide and superoxide in vitro (Chao et al, 1992, Woodroofe et al, 1989), which together 
produce highly reactive peroxynitrite which would damage the myelin sheath by lipid 
peroxidation. The present study demonstrated that chemokines could in fact increase 
nitrite and superoxide in rat primary microglia and CHME3 cells. The relevance of this 
may be that the chemokines not only recruit microglia but also activate them, with 
resultant oligodendrocyte cytotoxicity in vivo. Reactive nitrogen species have also been 
shown to activate pro-MMPs in vitro (Maeda et al, 1998) which may suggest an 
important biological link between chemokines, nitric oxide and MMPs. Nitric oxide has 
also been shown to regulate chemokine expression (Orens et al, 1994) thus the findings 
in the present study that chemokines regulate nitrite production by microglia suggests an 
important feedback mechanism.
This present study has further demonstrated that chemokines increase Fc receptor 
expression on rat microglia and CHME3 cells and were able to increase the phagocytic
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ability of rat microglia. The effects of this, if they also occur in vivo, may be the 
promotion of phagocytosis of myelin degradation products, following the proteolysis and 
lipid degradation by peroxynitrite. The chemokines may firstly attract the microglia at the 
onset of the inflammatory event and also promote the removal of debris by phagocytosis.
Activated T cells and monocytes/macrophages recruited from the circulation into 
inflamed CNS tissue, as well as astrocytes and microglia themselves, are sources of 
chemokine secretion. These chemokines exert multiple effects on microglia/ CHME3 
cells in vitro, as demonstrated in this study. Chemokines act on microglia causing an 
increase in filamentous actin, allowing the cells to become motile and may allow 
recruitment of microglia to areas of inflammation in vivo. Chemokines induce an increase 
in the amount of MMP2 and MMP9 secretion as well as the inhibitors of the MMPs, 
TIMPs 1 and 2. This suggests either an imbalance in the proteinase/inhibitor ratio to 
favour lytic activity or an initial time lag in the secretion of the inhibitor to allow some 
lytic activity followed by a tighter control. Chemokine upregulated MMP activity could 
aid in microglia motility by breakdown of the extracellular matrix but may also cause 
demyelination of axons and disruption of the blood brain barrier. This allows further 
recruitment of inflammatory cells into the CNS as well as proteins such as antibodies, 
that are normally excluded.
Chemokines were found to increase free radical production by microglia, which could 
cause oligodendrocyte damage in vivo by lipid peroxidation and release of membrane 
components. An increase in their Fc receptor expression was observed following 
chemokine stimulation which would allow increased phagocytosis of antibody opsonised 
myelin fragments.
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Figure 6.1 represents a tiny portion of the whole CNS inflammatory picture and shows 
only the chemokine effects observed in this thesis.
Many studies to date have observed the chemotactic effects of chemokines on 
various cells types but this study represents one of the few to examine other effects of 
chemokines on cell functions and probably the only study to date to show these effects 
on microglia. This study has clearly shown the importance of the chemokines present in 
MS lesions in the CNS and has underlined the importance of the actions of microglia. It 
may be that depletion of these chemokines using antibody therapy or the use of 
chemokine receptor agonists could limit the amount of damage to the CNS and improve 
the clinical outcome for patients.
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Figure 6.1 Summary diagram of the identified effects, of chemokines on microglia and astrocytes.
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7 FURTHER WORK
The present study has highlighted the importance of chemokines in the 
recruitment and activation of microglia in vitro. Further work should focus on the roles 
of chemokines in the recruitment of microglia by utilising different methods to assess 
chemotaxis in sequential migration experiments to more than one chemokine. Also, pre­
treating the cells with antibodies to the chemokines receptors may determine if the 
migration response could be blocked.
The chemokines clearly have an effect on the production of MMPs by microglia 
in vitro and it would be interesting to see if the chemokines together work in synergy or 
in opposition. This study has also shown a link between chemokines and uPA, which 
itself is involved in the activation of MMPs. Future work should include examining uPA 
receptor expression by microglia in response to chemokines as this may indicate why the 
uPA secretion by microglia was lower than control levels after chemokine stimulation. 
The chemokine control of uPA receptor expression by microglia may also regulate 
chemotaxis.
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Chemokines Induce Migration and Changes 
in Actin Polymerization in Adult Rat Brain 
Microglia and a Human Fetal Microglial 
Cell Line In Yitro
Alison K. Cross and M. Nicola Woodroofe*
Division of Biomedical Sciences, School o f Science, Sheffield Hallam University. Sheffield, England
Microglia, the resident macrophages of the central 
nervous system, are the primary cells to respond to 
injury in the brain, both in inflammation, e.g., in 
multiple sclerosis, and trauma. Chemokines are poten­
tial mediators of microglial cell recruitment to sites of 
injury; thus, the ability of microglia to migrate in 
response to a number of chemokines was assessed. The 
chemokines monocyte chemoattractant protein 1, mac­
rophage inflammatory protein la , macrophage inflam­
matory protein 1(1, RANTES (regulated upon activa­
tion normal T cell expressed and secreted), interleukin 
8, and IP-10 (interferon gamma inducible protein-10), 
induce migration and changes in the distribution of 
f-actin in adult rat microglia and a human microglial 
cell line, CHME3, in vitro. Both cell types show a 
significant migration response, above control levels, to 
all the chemokines tested in a typical dose-dependent 
manner. These chemokines also induced a reorganiza­
tion of the actin cytoskeleton of the cells. This study 
indicates that chemokines play an important role in 
the recruitment of microglia to areas of central 
nervous system inflammation. J. Neurosci. Res. 55: 
17—23,1999. © 1999 W iley-Liss, Inc.
Key words: chemokines; microglia; inflammation; in­
jury; cytoskeleton
INTRODUCTION
Microglia are the resident macrophages of the brain 
and are able to produce and respond to a wide range of 
inflammatory stimuli, including tumor necrosis factor a , 
interferon gamma, interleukin (IL) 1, and IL-6 (Ben- 
veniste, 1997; Gehrmann et al., 1995). Microglia have 
heen studied extensively for their role in the pathogenesis 
i»f the demyelinating disease multiple sclerosis (MS). It 
lias been shown by immunocytochemistry that post 
mortem central nervous system (CNS) white matter from 
patients with MS often shows perivascular cuffing with 
inflammatory T lymphocytes, macrophages, and plasma 
cells (Woodroofe et al., 1986; Adams et al., 1989;
Benveniste, 1997). It has been proposed that cytokines in 
the brain are localized to inflammatory cuffs (Woodroofe 
and Cuzner, 1993; Brosnan et al., 1995), and their 
production by activated immune cells may directly dam­
age myelin and make it a target for phagocytosis by 
activated microglia (Sriram and Rodriguez, 1997). Microg­
lia have been shown to be present in active MS lesions, 
expressing increased levels of major histocompatibility 
complex class II (Woodroofe et al., 1986). An important 
factor to consider in the functional role of microglia in 
CNS disease is their ability to respond to chemoat- 
tractants to reach areas o f CNS injury or inflammation. 
Although few studies have been performed, it has been 
shown that rat microglia are able to migrate towards the 
classical chemoattractant C5a (Yao et al., 1990) and that 
human fetal microglia migrate to the |3 chemokines, 
macrophage inflammatory proteins (MIPs) l a  and 1(3, 
and monocyte chemoattractant protein (MCP) 1 in vitro 
(Peterson et al., 1997). For any cell to migrate by 
chemotaxis or haptotaxis to areas of inflammation, there 
must be a soluble chemoattractant gradient in which cells 
move from a low concentration to a high concentration. 
The process o f cell migration also involves polymeriza­
tion and depolymerization of filamentous actin, which in 
turn leads to spatial asymmetry of the cytoskeleton and 
elongation of lamellipodia and filopodia (Lauffenburger 
and Horwitz, 1996). Binding of a chemokine ligand to its 
seven transmembrane domain receptor on a cell causes
Abbreviations: CNS, central nervous system: DMEM, Dulbecco's 
modified Eagle medium; IL, interleukin; IP, interferon gamma induc­
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expressed and secreted.
*Correspondence to: Dr. M. Nicola Woodroofe. Division o f Biomedi­
cal Sciences, School o f Science, Sheffield Hallam University, Sheffield 
SI 1W B, England. E-mail: n.woodroofe@shu.ac.uk
Received 22 May 1998: Revised 7 September 1998; Accepted 18 
Septem ber 1998
" 1999 Wiley-Liss, Inc.
18 Cross and Woodroofe
the release of intracellular second messengers via G- 
protein complexes. This in turn causes effects, such as the 
reorganization of the cytoskeleton, formation of focal 
adhesions, and pseudopod extension, that ultimately lead 
to movement of the cell. Chemokine signaling also 
involves activation of the guanosine triphosphate- 
binding proteins of the Ras, Rac, and Rho families. Rac 
and Rho are involved in actin reorganization events and 
motility, including membrane ruffling (Premack and 
Schall, 1996).
Chemokines are a rapidly expanding family of 
chemotactic cytokines of which there are more than 30 
recognized members to date. These are subdivided into 
four groups depending on the positions of conserved 
cysteine residues in their amino acid sequences. These are 
termed the CXC, CC. and C chemokines (Taub, 1996) 
and also a more recent CX3C chemokine motif of which 
fractalkine, also known as neurotactin (Pan et al., 1997), 
is the only member to date (Bazan et al., 1997; Schall, 
1997). The chemokine subfamilies were also originally 
distinguished on the basis of their ability to cause 
migration of the different leukocyte populations. The 
CXC or a  chemokines that contain the ELR peptide 
motif, including IL-8 and granulocyte chemotactic pep­
tide-2 (GCP-2), are potent mediators of neutrophil chemo- 
taxis, whereas the a  chemokines that lack the ELR 
peptide motif, including interferon gamma inducible 
protein (IP-10) and platelet factor-4 (PF-4) fail to chemoat- 
tract neutrophils. The CC or (3 chemokines were thought 
to act mainly on monocytes. This subdivision of the 
chemokines based on the cells they chemoattract in vitro 
is becoming increasingly invalid as more cell types, such 
as natural killer cells and B and T lymphocytes, were 
examined to find that there was an overlap of activities 
(Taub, 1996).
Several of these chemokines have been identified in 
CNS disease and detected in cultures of cells from the 
CNS. Miyagashi et al. (1995) detected elevated levels of 
the (3 chemokine M IP -la  in the cerebrospinal fluid of 
patients with MS during relapse. This increase was also 
observed in the cerebrospinal fluid of patients with other 
neurological disorders including human T-cell lymphotro- 
phic virus type 1-associated myelopathy and meningitis. 
In this laboratory, a study of (3 chemokine expression in 
MS tissue showed that MIP-1(3 and MCP-1 were the 
predominant chemokines expressed in CNS inflamma­
tory lesions in MS (Simpson et al., 1998). MCP-1 has 
been shown to be present in CNS sections of Lewis rats 
after stab wound injury, which was not found in the 
normal rat brain. This correlated with the earliest detec­
tion of inflammatory cells in the area (Berman et al., 
1996). After this study, it was found that two other (3 
chemokines, regulated upon activation normal T cell 
expressed and secreted (RANTES) and MIP-1(3, were 
also expressed in rat stab wound brain injury and that
MIP-1(3 was localized to reactive astrocytes and macro­
phage-like cells at the sites of injury (Ghimikar et al., 
1996).
This present study was undertaken to assess the 
potential of microglia to respond to a range o f a  and 3 
chemokines. The results indicate that a number of human 
chemokines, but especially the chemokines belonging to 
the (3 family, are able to induce migration of rat microglia 
and a human fetal microglial cell line (CHME3) (Janabi 
et al., 1995). The (3 chemokines MCP-1, M IP -la , MIP- 
13, and RANTES are also shown to elicit a change in the 
organization of the f-actin cytoskeleton within these cells.
MATERIALS AND M ETHODS 
Cell C ulture
Rat microglia and a human fetal Microglial cell line, 
CHME3 (a gift from Prof. M. Tardieu, Universite Paris 
Sud, France) were cultured in Dulbecco’s modified Eagle 
medium (DMEM; GIBCO BRL, Paisley, England) supple­
mented with 10% heat-inactivated fetal calf serum 
(GIBCO BRL), 100 IU/ml penicillin, and 100 pg/ml 
streptomycin (GIBCO BRL).
Isolation of M icroglia
Microglia were isolated using a rosetting method as 
described by Hayes et al. (1988). Briefly, a mixed glial 
suspension was prepared by enzyme digestion o f chopped 
CNS tissue obtained after cervical dislocation o f 30-day- 
old Wistar rats of both sexes. Cerebrae were dissected 
out, and the meninges were removed. The enzymes 
collagenase (1,000 U/ml), deoxyribonuclease I (200 
jig/ml), and trypsin (1.5%, w/v) (Sigma Ltd., Dorset, 
England) at 1 ml/g tissue along with 7 ml Earle’s 
balanced salt solution (EBSS)/g, were incubated at 37°C 
for 15 min with the chopped tissue. The enzyme digestion 
was repeated, and the resultant suspension was forced 
through 132- and 80-pm pore nylon mesh. M icroglia 
were then isolated from the single mixed cell population 
by incubation of 1:1 with a 2% suspension o f opsonized 
erythrocytes. Rosetted cells were then separated by 
density gradient centrifugation on Percoll (Sigma Ltd.), 
and erythrocytes were flash lysed. Cells were then 
counted and resuspended in DMEM alone or DMEM +  
10% fetal calf serum and used directly in the chemotaxis 
chamber or placed into culture.
Chemotaxis Assay
Cell migration in response to chemokines was 
assessed using a 48-well microchemotaxis chamber 
method (Neuroprobe, Cabin John, MD) as described 
previously (Cross et al., 1997). Nucleopore membranes 
(Costar, High Wycombe, England) with 8-pm pores were 
coated with fibronectin (6.5 pg/ml) (Sigma Ltd.) in
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phosphate-buffered saline (PBS) for 20 min at 37°C. 
These were then air dried, rinsed in PBS, and dried again. 
Stock chemokines (100 ng/ml in PBS containing 0.1% 
bovine serum albumin) were diluted in serum-free DMEM, 
and 28 pi of each dilution was pipetted in triplicate into 
the lower wells of the chemotaxis chamber. The human 
chemokines used included MCP-1, M IP -la , MIP-1(3, 
RANTES, IL-8, and IP -10 and were a kind gift from Prof. 
D. Taub (National Institutes of Health, Bethesda, MD). 
Bovine serum albumin (0.1% or 0.05%) in PBS was used 
as a negative control because this was used in storage of 
the stock chemokines and present at these concentrations 
in the highest chemokine concentration used in experi­
ments with rat microglia and CHME3, respectively.
The filled lower chamber was then overlaid with the 
coated membrane, and the top chamber was assembled to 
form wells. Fifty microliters of cell suspension (5 X  
105/ml) in serum-free medium was added to each of the 
wells, and the chamber was incubated at 37°C, 95% air, 
and 5% CCL in a humid environment for a period of 17 hr 
for microglia and 6 hr for CHME3 as previously deter­
mined by time course experiments (data not shown). 
After incubation, the chamber was dismantled, and the 
cells on the membrane were fixed in methanol and 
stained. Briefly, after fixing, the membrane was washed in 
distilled water and then placed in Harris’ hematoxylin 
(Sigma Ltd.) for 5 min. The membrane was rinsed in 
running tap water and then in scots tap water (10 g 
magnesium sulphate, 1.75 g sodium bicarbonate, and 500 
ml distilled water) for a further 2 min to define the nuclei. 
After this, the membrane was inverted onto a microscope 
slide, and a coverslip was mounted with Immumount 
(Shandon, Life Sciences, UK). Migration was assessed 
iiy counting migrated cells in five microscopic fields per 
triplicate well (i.e., 15 fields per chemokine concentra­
tion) at X400 magnification.
Statistical Analysis
Significant results were calculated using a one-way 
analysis of variance comparing migration of cells to the 
control (0.05% or 0.1% bovine serum albumin) with 
chemokine-induced migration. Results were expressed as 
mean number o f cells migrating per three wells in five 
microscopic fields ±  SD (P <  0.025; significant).
Actin Stain (Using Tetramethylrhodamine 
Isothiocyanate-Labeled Phalloidin)
Tetramethylrhodamine isothiocyanate-labeled phal­
loidin (Sigma Ltd.) was used to visualize changes in actin 
fiber organization in microglia after incubation with 
chemokines. Cells were seeded onto sterile fibronectin- 
coated (Sigma Ltd.) coverslips (6.5 mg/ml) in six-well 
plates at a concentration of 5 X  104/ml (300 pi on each 
coverslip) for about 1 hr to allow cells to adhere. A further
2 ml DMEM (10% fetal calf serum) was added, and cells 
were cultured overnight. Cells were washed and incu­
bated with the appropriate chemokine in serum-free 
media under study at 37°C for 15,60, or 180 min. Shorter 
times were chosen for the actin studies than for the 
migration because the chemokines should elicit an effect 
on cell shape immediately. To examine whether the effect 
o f chemokine on cells was specific, boiled MCP-1 was 
added to some cells. Serum-free medium (or serum-free 
media with 0.1% bovine serum albumin) was used as the 
control. Cells were then washed in PBS and fixed for 20 
min in 4% paraformaldehyde at room temperature. The 
paraformaldehyde was then removed, cells were washed 
in PBS, and acetone was added for a further 5 min at 
room temperature. Cells were then washed in PBS, and 
200 pi o f tetramethylrhodamine isodnocyanate-labeled 
phalloidin (200 ng/ml) (Sigma Ltd.) was added per well 
and incubated at room temperature for 45 min. The 
coverslips were washed twice in PBS and once in distilled 
water and then inverted onto microscope slides mounted 
in PBS/glycerol ratio of 1:1. Cells were visualized under 
fluorescence microscopy (Olympus, Tokyo, Japan; BX60) 
and photographed using Ilford (Mobberley, England) 
HP5 film.
RESULTS
Adult primary rat microglia isolated by the rosetting 
method were shown to be >95%  0X 42 positive by 
immunocytochemistrv and have been previously shown 
to express Fc receptors (Hayes et al, 1988), produce 
cytokines (Loughlin and Woodroofe, 1996), and release 
superoxide (Woodroofe et al., 1989) on stimulation with 
interferon gamma. Immunocytochemistry on cultures and 
cytospins of CHME3 cells showed them to be EBM/11 
positive, and they did not stain positively for glial 
fibrillary acidic protein (GFAP) (not shown).
Migration responses o f microglia in response to the 
chemokines MCP-1, M IP -la , MIP-1J3, RANTES, IL-8, 
and IP -10 were determined using an in vitro chemotaxis 
assay method (Fig. 1A and B). Preliminary time course 
experiments for rat microglia at 5, 10, and 17 hr showed 
an increase in cell migration with time. The 17-hr 
migration time was used in all further experiments. 
Similarly for CHME3. 2-, 4-, and 6-hr times were used in 
preliminary migration experiments, and the 6-hr time 
point was selected for further experiments. All migration 
experiments using rat microglia and CHME3 showed 
typical bell-shaped curves to all of the chemokines tested. 
Results using primary isolated rat microglia show repre­
sentative data from one o f three individual experiments 
for MCP-1, M IP -la  and MIP-1|3, RANTES, IL-8, and 
IP-10. A significant response was observed: P <  0.025 for 
MCP-1, M IP -la , MIP-10, RANTES, IL-8, and IP -10 in 
all three repeat experiments. The concentration o f chemo-
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kine required to give the highest migration response of rat 
microglia to MCP-1, M IP-la, MIP-1J3, and IP -10 was 
between 20 and 50 ng/ml. For RANTES and IL-8, the 
concentration required to give the optimal migration 
response was variable between 20 and 100 ng/ml.
BSA 10 20 50 100 10 20 50 100 10 20 50 100
0.1* MCP1 MIPIa MIP1(5
Chemokine (ng/ml)
iL-a
Chemokine (ng/ml)
BSA 5 10 20 50 5 10 20 50 5 10 20 50
0Q5*  MCP1 MIPIa MIPIp
Chemokine (ng/ml)
#o ----------------- .---- —------------------------------------------------------------------------------------------------
BSA 5 10 20 50 5 10 20 50 5 10 20 50
DOSS RANTES «-■« |p.10
Chemokine (ng/ml)
Results using the human fetal cell line CHME3 
show that, for all chemokines tested, a significant re­
sponse was observed (P <  0.025) at least at one 
concentration. Figure 1C and D show representative data 
from one of three individual experiments for MCP-1, 
M IP-la, M IP-1 p, RANTES, IL-8, and IP-10. The concen­
tration of chemokine required to produce optimal migra­
tion of CHME3 using MCP-1 was between 10 and 20 
ng/ml; for M IP -la  and M IP -ip , this was 10 ng/ml, and 
using IP-10, a concentration range of 20 to 50 ng/ml gave 
the highest response. The concentration of the chemo­
kines RANTES and IL-8 required to produce the highest 
migration response was variable. Numbers of migrated 
cells in experiments using rat microglia were higher than 
those using CHME3. Migration studies gave inter- 
experiment variation such that exact numbers of migrat­
ing cells were different, although iall showed similar 
pattern of migration to the different concentrations of 
chemokine used.
Chemokine-induced changes in actin polymeriza­
tion and distribution in microglia were visualized by 
incubating cell cultures with chemokines and staining 
with tetramethylrhodamine isothiocyanate-labeled phal­
loidin, a stain specific for f-actin. All of the chemokines 
tested showed the ability to cause redistribution and 
polymerization of f-actin in both rat microglia and 
CHME3. Although both cell types showed morphological 
changes after incubation with chemokines for only 15 
min (not shown), the difference between treated and 
control cells was more pronounced after 60 min. Rat 
microglia treated with boiled MCP-1 looked the same as 
control cells (not shown). Results from cells treated for 3 
hr were similar to those at 60 min. Figure 2A and C shows 
untreated CHME3 cells at low and high magnification, 
respectively, with f-actin concentrated around the nuclei, 
whereas CHME3 cells treated for 60 min with MCP-1 or 
RANTES (Fig. 2B and D) show more cytoplasmic f-actin 
staining. Untreated rat microglia (Fig. 2E) again have the 
most intense stain around the nuclei, and little staining
Fig. 1. Chemokine-induced migration was assessed using a 
48-well chemotaxis chamber. Human chemokines were diluted 
in serum-free DMEM and were added to the lower wells o f the 
chamber in triplicate. CHME3 cells and primary isolated rat 
microglia were placed into the upper chamber o f the chemo­
taxis chamber at a concentration of 5 X 105 cells/ml. A: 
Migration response o f rat microglia to 3  chemokines. B: 
Migration response o f rat microglia to the (3 chemokine 
RANTES and the a  chemokines IL-8 and IP-10. C: Migration 
response of CHME3 to (3 chemokines. D: Migration response 
of CHME3 to RANTES and the a  chemokines IL-8 and IP-10. 
Representative data from one experiment is expressed as the 
mean migration per three wells ±  SD. Significant migration 
above control (0.05%-0.1% bovine serum albumin [BSA]) was 
calculated using a one-way analysis of variance. ^Significant 
migration above control levels (P <  0.025).
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Fig. 2. CHME3 cells and rat microglia were incubated with 
chemokines (20 ng/ml) or control medium for 1 hr and were 
stained with tetramethylrhodamine isothiocyanate-labeled phal­
loidin to show the distribution of actin filaments and changes in 
cell morphology. A: CHME3 control untreated cells. B: 
CHME3, MCPl-treated cells. C: CHME3 control cells. D: 
CHME3, RANTES-treated cells. E: Rat microglia control 
untreated cells. F: Rat microglia, rat MCP1 (Peprotech, 
London, England)-treated cells. G: Rat microglia, RANTES- 
treated cells (magnification: A,B, X430; C-G, X 1070).
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was observed in the cytoplasmic regions. Rat M CP-1- 
and RANTES-treated rat microglia show a more highly 
branched morphology with intense f-actin staining within 
the pseudopodia (Fig. 2F and G). The effects of rat and 
human MCP-1 on rat microglia were compared to 
examine if there was any species specific effect; however, 
the changes to the actin cytoskeleton using either chemo­
kine were identical. All the chemokines used in the 
migration studies caused similar effects on the cytoskel­
eton of both cell types.
DISCUSSION
The results of this study clearly show that rat 
microglia and CHME3, the human fetal microglial cell 
line, migrate in response to chemokines. Thirty-day-old 
rat microglia, not neonatal rats, were used in this study 
because they are more representative of neuroimmuno- 
logic processes in vivo. These cells were compared with 
CHME3 in their response to chemokines. Although 
CHME3 are of fetal origin, similar responses were 
observed to those of adult rat microglia. Both cell types 
migrated to a concentration range of chemokines giving a 
typical bell-shaped curve where the cells respond only 
weakly or not at all to low concentrations of chemokine 
and where migration is attenuated at high concentrations. 
This presumably causes cells to migrate up a concentra­
tion gradient until they reach a critical point of receptor 
saturation. The numbers of migrated cells were generally 
higher in experiments using rat microglia with numbers 
of migrated cells as high as 900 per five microscopic 
fields. However, longer incubation times were used for 
the primary rat microglia because the harshness of the 
isolation procedure of the cells required time for the cell 
membranes to recover. The actual numbers of migrated 
cells cannot be directly compared between the two cell 
types studied, although their responses to the different 
chemokines does allow comparison. The rat microglia 
migrated optimally to chemokine concentrations higher 
than those required for optimal CHME3 migration. This 
could be attributed to the fact that the chemokines used 
were of human origin, although recent experiments in this 
laboratory using rat MCP-1 with rat microglia showed no 
difference to those reported here for human chemokines 
in the numbers of cells migrating or the concentration 
required to produce optimal migration (data not shown). 
The rat and human MCP-1 both induced changes in the 
actin cytoskeleton of rat microglia. Therefore, species 
difference does not appear to contribute to this differing 
response in this particular chemokine.
Activated microglia are implicated in a number of 
CNS pathologies and are present in an activated state. The 
use o f immunostaining techniques on post mortem tissue 
has shown dense staining of microglia associated with 
amyloid deposits in Alzheimer’s disease (Dickson et al.,
1993; McGeer and McGeer, 1995) and microglial nod­
ules in human immunodeficiency virus encephalitis (Dick­
son et al., 1993). Activated microglia have also been 
observed in high densities in association with prion 
protein deposits in Creutzfelt-Jacob disease (Muhleisen et 
al., 1995). A review by Streit (1996) documented massive 
microglia infiltration into malignant rat glioma produced 
by intracerebral injection of glioma cells. This present 
study would suggest that centrally produced chemokines 
would be involved in microglia recruitment in these CNS 
pathologies and is not restricted to the pathogenesis 
of MS.
Our results show a dramatic change after chemo­
kine stimulation of microglia in their morphology and 
distribution of f-actin within 1 hr. Although cell migration 
cannot be attributed to f-actin changes alone, redistribu­
tion o f actin fibers and extension of pseudopodia are 
important events in cell locomotion, Chemokine signal­
ing through G protein-coupled receptors includes activa­
tion of the guanosine triphosphate-binding proteins Rac 
and Rho that are involved in regulation o f actin- 
dependent processes, i.e., formation of pseudopodia, 
ultimately leading to cell motility (Premack et al., 1996). 
Rho protein is well documented as a connector between 
membrane receptor interactions and regulation o f the 
cytoskeleton (Takai et al., 1995; Machesky and Hall, 
1996).
Because there is strong evidence of a role for 
chemokines in the pathogenesis of MS, we have shown 
here that microglia can respond to many of these signals 
in vitro, giving further support to the conclusion that 
chemokines produced at sites of inflammation, demyelina- 
ton, and tissue damage are able to promote the recruit­
ment of microglia. Further research in this laboratory in 
this area will concentrate on the effects chemokines have 
on the activation state of these cells that would comple­
ment the well-documented effects of other inflammatory 
cytokines on microglia.
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ABSTRACT  Matrix metalloproteinases (MMPs) are a family of zinc-dependent 
enzymes, capable of degrading proteins found in the extracellular matrix. MMPs 2 and 9 
are known to be produced by microglia, the resident macrophages of the central nervous 
system. The control of the secretion of these proteases and the activation of proenzymes 
by other proteases such as plasmin, as well as the balance between MMP secretion and 
the secretion of their natural inhibitors (TIMPs), have an important relevance in the 
pathogenesis of multiple sclerosis (MS). The in vitro control of MMPs 2 and 9, TIMPs 1 
and 2 , and urokinase-type plasminogen activator by microglia was examined in response 
to a panel of chemokines (chemotactic cytokines), using ELISA and zymography 
techniques. The chemokines MCP1 , M IPip, RANTES, IL-8 , and Fractalkine were all 
found significantly to increase the secretion of MMPs and TIMPs by a hum an foetal 
microglial cell line, CHME3, after 24 h stimulation. The chemokines tested, MCP1, 
M IPip, and Fractalkine, were also shown to increase MMP9 secretion by primary 
isolated ra t brain microglia in vitro. MCP1 , M IPla/p, and RANTES significantly 
decreased the secretion of uPA into culture supernatants in ELISA experiments. These 
findings suggest an important potential role for the involvement of chemokines in the 
breakdown of the blood-brain barrier and also the destruction of myelin basic protein in 
MS. GLIA 28:183-189, 1999. © 1999 Wiley-Liss, Inc.
INTRODUCTION
Microglia represent the primary immune effector 
cells of the adult central nervous system (CNS) and are 
often the first cell type to respond to CNS injury, 
displaying a wide range of immunologic activities. They 
are thought to contribute directly to a number of CNS 
pathologies, including Alzheimer’s disease and mul­
tiple sclerosis (MS), by production of proinflammatory 
cytokines, chemokines, free radicals, and proteases.
Matrix metalloproteinases (MMPs) are proteolytic 
enzymes involved in remodelling of the extracellular 
matrix and are implicated in the pathogenesis of MS 
because of their detection in MS brain tissue (Cuzner et 
al., 1996) and in the CSF of patients with MS (Miyagi-
shi et al., 1995). MMPs are suggested to play a role in 
the influx of inflammatory cells into the CNS, disrupt 
the blood-brain barrier, and have been shown to de­
grade myelin in vitro (Chandler et al., 1995; Gijbels et 
al., 1993), suggesting th a t these enzymes may contrib­
ute to myelin destruction in vitro.
MMPs, a t least 14 of which have been characterised 
to date, are divided into three subgroups, gelatinases, 
stromelysins, and collagenases (Chandler et al., 1997),
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and are expressed as inactive zymogens, which are 
activated by autocatalysis or cleavage by membrane- 
type MMPs or plasmin. Following activation, their 
activity is tightly controlled by complexes formed with 
specific tissue inhibitors of metalloproteinases or TIMPs 
and also by a 2-macroglobulin (Woessner, 1991). There 
are a t least four TIMPs to date, and they bind to MMPs 
in a 1 :1  ratio.
Urokinase-type plasminogen activator (uPA) cleaves 
plasminogen to its active form, plasmin, which in turn 
is able to cleave pro-MMPs. This forms another level of 
control of proteolysis along with the expression of MMP 
inhibitors and regulation a t the gene level. uPA has 
been previously detected in the culture medium of ra t 
microglia (Nakajima et al., 1992), and modulation of its 
secretion was observed by treatm ent with interleukin -1  
and lipopolysaccharide.
MMPs 2, 9 (gelatinases), 3 (stromelysin), and 7 
(collagenase) have been previously detected in plaques 
or cerebrospinal fluid (CSF) of patients with MS, and 
activated T cells (Biddison et al., 1997), astrocytes 
(Chandler et al., 1997), brain endothelial cells (Hark- 
ness et al., 1998), and microglia have been shown to 
express a wide range of MMPs both in vitro and ex vivo 
(Colton et al., 1993; Gottschall et al., 1995; Yamada et 
al., 1995). uPA is also associated with many neuropa­
thologies, including MS, as well as an involvement in 
normal physiological functions (Cuzner and Opdenak- 
ker, 1999).
MMP secretion by activated microglia may facilitate 
their ability to move toward and accumulate a t sites of 
inflammation or tissue damage in response to chemoat- 
tractants such as chemokines, as well contributing to 
the demyelination. Chemokines are a superfamily of 
chemotactic cytokines, which can be divided into four 
subgroups depending on the presence and position of 
conserved cysteine residues and are known as the CC, 
CXC, C, and CX3C chemokines. The CC chemokines 
include monocyte chemoattractant protein 1 (MCP1), 
macrophage inflammatory proteins l a  and 0  (MIPIa 
and -0 ), and RANTES. The most well-characterised 
CXC chemokine is IL-8 , and the only C chemokine 
discovered to date is lymphotactin. Chemokines play an 
important role in the attraction of leukocytes to areas of 
inflammation and infection and also are important in 
trafficking and homing of lymphocytes (Baggiolini, 1998) 
The hum an chemokines, MCP1, M IPIa, MIP10, 
RANTES, IL-8 , and IP-10, have previously been shown 
to cause the in vitro migration of ra t brain microglia 
(Cross and Woodroofe, 1999). A recently discovered 
CX3C chemokine called Fractalkine (also called neuro- 
tactin) was found to be expressed on the surface of 
microglia and is up-regulated in brain inflammation 
(Pan et al., 1997). Fractalkine has more recently been 
suggested to be most dominantly expressed by neurons 
with receptors for Fractalkine being expressed by mi­
croglia, suggesting this chemokine to be a source of 
communication between neurons and microglia (Harri­
son et al., 1998; Nishiyiori et al., 1998) It is now 
well-documented tha t chemokines have a role to play in
autoimmune disease of the CNS from studies on CNS 
tissue (Simpson et al., 1998; McManus et al., 1998) and 
CSF from MS patients (S0rensen et al., 1999), and from 
work on the animal model of MS, experimental allergic 
encephalomyelitis (EAE) (Berman et al., 1996; Ranso- 
hoff et al., 1996; Miyagishi et al., 1997). The specific 
chemokines identified in MS and/or EAE lesions in­
clude MCP1, M IPlo/0 , RANTES, and IP-10. Chemo­
kines have been shown to modulate the production of 
MMP9 expression by peripheral blood lymphocytes in 
vitro (Johnatty et al., 1997). Thus, understanding of the 
regulation of these proteases by chemokines in CNS cell 
types may lead to a further understanding of the 
pathogenesis of MS.
In this study we report th a t the expression of MMPs 
by ra t microglia and the human foetal microglial cell 
line CHME3 (Janabi et al., 1995) is modulated by 
chemokines in vitro and also that uPA and the inhibi­
tors of metalloproteinases, TIMPs, are modulated by 
chemokines in the CHME3 microglial cell line.
MATERIALS AND METHODS 
Isolation o f M icroglia
Microglia were isolated using a “rosetting” method as 
described by Hayes et al. (1988) and placed into culture 
in 24-well plates.
Cell Culture
Rat microglia and a human foetal microglial cell line, 
CHME3 (Janabi et al., 1995; a gift from Prof. M. 
Tardieu, Universite Paris Sud, France), were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM; Life 
Technologies, U.K.) supplemented with 10% heat- 
inactivated foetal calf serum (Life Technologies, U.K.), 
100 IU/ml penicillin, and 100 pg/ml streptomycin (Life 
Technologies). DX3 cells (a human cutaneous mela­
noma cell line) were cultured in the same medium as 
CHME3 cells under the same conditions, and the 
supernatant was collected and used as a positive con­
trol for MMP2 and -9 secretion in zymography experi­
ments.
Cell Stim ulation
CHME cells were seeded into 24-well plates a t a 
concentration of 1 X  105/well and cultured in serum 
containing medium for 24 h. The cells were then 
washed and transferred to macrophage serum-free 
medium (SFM; Life Technologies) for 2 h. Primary 
microglia were seeded at a density of 2  x 1 0 5/well and 
maintained in culture for 3-7 days prior to transfer to 
SFM. CHME3 cells were then stimulated in duplicate 
with 300 pi of human chemokine (MCP1, M IPIa, 
MIP1 0 , RANTES, IL-8 , or Fractalkine) hTNFa, or 
hIL- 1 0  for 24 h. Rat microglia were stimulated with ra t
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Fig. 1. MM P2 m odulation  in  CH M E3 cells b y  chem okines. E LISA  re su lts  show one of th ree  
rep re sen ta tiv e  experim ents. ^S ignificant in crease  above control levels (P  <  0.05).
MCP1; the ra t cytokines TNFa, IL-ip, and IFNy; or the 
hum an chemokines M IPip and fractalkine under the 
same conditions. Chemokines (except ra t MCP1 and 
Fractalkine, purchased from Peprotech, U.K.) were a 
kind gift from Prof. D Taub (National Institutes of 
Health, Bethesda, MD). Culture supernatants were 
then harvested, centrifuged to remove cell debris, and 
either loaded onto gelatin substrate SDS gels for electro­
phoresis or collected and stored a t — 20°C until re­
quired.
Zymography
Cell supernatants were separated on SDS-polyacryl- 
amide (7.5%) gels containing gelatin substrate to ana­
lyse MMP2 and -9 production. After electrophoresis, 
gels were washed in distilled water containing 2 % 
Triton X-100 for 1 h, then incubated in incubation 
buffer (50 mM Trizma base, 0.2 M NaCl, 5 mMCaCl2, 
pH 7.4) for 18 h and stained with Coomassie blue. Gels 
were then destained in 30% methanol containing 10% 
glacial acetic acid, and clear bands of protein degrada­
tion were visualised. Bands seen on gelatin gels were 
confirmed as metalloproteinases by addition of 10 mM 
EDTAto the incubation buffer to inhibit enzyme activity.
TIMP/MMP/uPA ELISA
Chemokine modulation of MMP2, MMP9, TIMP1, 
TIMP2, and uPA secretion by CHME3 cells following 
stimulation with chemokines was quantified using Bio- 
trak  ELISAs for MMPs and TIMPs (Amersham Interna­
tional, U.K.) and a uPA ELISA kit (Alpha Laboratories, 
Eastleigh, Hants, U.K.) according to the manufactur­
e r’s instructions. Samples were assayed in duplicate, 
and the significant differences from control values were
calculated by a one-way ANOVA on each individual 
experiment followed by a multiple range test for each 
chemokine concentration. P values of <  0.05 were 
considered significant.
RESULTS
ELISA
ELISA experiments were only carried out on CHME3 
cells, because only human kits were available and there 
was no cross-reactivity between rat MMPs or TIMPs 
and the human antibodies supplied in the kits. CHME3 
cells were found to secrete MMP2 constitutively by 
ELISA (Fig. 1). Use of an ELISA kit tha t detects 
pro-MMP9 as well as MMP9 bound to TIMP1 gave 
negative results (not shown) in two experiments, sug­
gesting tha t only the active form of MMP9 was present 
24 h after stimulation, as shown by zymography (see 
Fig. 3c,d). The chemokines tested, MCP1, M IPip, 
RANTES, IL-8 , and Fractalkine, all significantly in­
creased MMP2 production above control, unstimulated 
values in ELISA experiments at all concentrations 
tested, in a t least two of three repeat experiments. 
Constitutive secretion of MMP2 ranged between 9 and 
29 ng/ml/105 cells At the highest concentration of 
chemokine used (50 ng/ml), there was an approximate 
1 .2 - 6  fold increase for all chemokines tested in all three 
experiments. TIMP2 production was also significantly 
increased above control levels by all the chemokines 
tested in a t least two of three experiments (with the 
exception of IL-8  a t 20 ng/ml and RANTES at 10 ng/ml 
giving significant increases above control levels in ju st 
one of three experiments) with an approximate two- to 
fivefold increase a t the highest concentration of chemo­
kine (50 ng/ml) in three of three experiments. Figure 2a 
shows one of three representative experiments. Consti­
186 CROSS AND WOODROOFE
a 70
control 10 20 50 10 20 50 10 20 50 1
MCP 1 M IPIa MIPip
Stimulant (ng/ml)
0 20 50 10 20 50
RANTES |U.e
10 20 SO
Fractalkine
control 10 20 50 10 20 50 10 20 50 10 20 50 10 20 50 10 20 50
MCP1 M IPIa MIPip RANTES IL-8 Fractalkine
Stimulant (ng/ml)
Fig. 2. a :  T IM P2 m odulation  in  CH M E3 cells by  chem okines. E LISA  re su lts  show  one o f  th re e  
re p re se n ta tiv e  experim en ts. *S ignificant increase  above contro l levels ( P  <  0.05). b : T IM P1 m o d u la tio n  in  
CH M E3 cells by  chem okines. E LISA  re su lts  show  one of th re e  experim en ts . *S ign ifican t in c rease  above 
control levels CP <  0.05).
tutive expression of TIMP2 was between 10 and 
25 ng/ml/105 cells. TIMP1 production was significantly 
increased above unstimulated levels by the chemokines 
MCP1, M IPip, and Fractalkine at all concentrations 
tested in a t least two of three experiments. IL-8  gave a 
significant increase in TIMP1 secretion in only one of 
three experiments at 20 and 50 ng/ml, and RANTES 
caused a significant increase in TIMP1 secretion in only 
one of three experiments for each of the cencentrations 
tested. Interexperimental variation was marked, and 
constitutive levels of TIMP1 secretion ranged between 
24.7 and 71 ng/ml. Figure 2b shows the results of one of 
three experiments.
Gelatin Substrate Zymography
Gelatin zymography was used to detect changes in 
MMP2 and -9 production in CHME3 cells and primary 
ra t microglia; MMP9 could not be measured by ELISA, 
because there were no commercial kits available to 
measure ra t MMPs. Primary ra t microglia stimulated 
with rTNFa (10 ng/ml), rIL-ip (10 ng/ml), and rIFNy 
(10 IU/ml; not shown) caused an increase in both MMP2 
and MMP9 production. When stim ulated with ra t 
MCP1 or the hum an chemokines M IPip (Fig. 3a) or 
Fractalkine (Fig. 3b) a t concentrations of 10, 20, and 
50 ng/ml, MMP2 increased slightly or remained the
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Fig. 3. G ela tin  zym ography on su p e rn a ta n ts  from  r a t  m icroglia 
(a,b) a n d  CH M E3 cells (c,d) s tim u la te d  w ith  chem okines. T he u p p e r 
a rro w h ead  ind ica tes M M P9 an d  th e  low er arro w h ead  M M P2. E ach  
zym ogram  rep re sen ts  one o f th re e  re p e a t experim en ts, a : L a n e  1: 
S u p e rn a ta n t  from  cell line DX3 (positive control to  show  M M P2 an d  
-9). L a n e  2: C ontro l su p e rn a ta n t  (u n stim u la ted  m icroglia). L a n e s  
3 -5 : S u p e rn a ta n ts  from  cells s tim u la te d  w ith  M IP ip  a t  10 ,20 , an d  50
ng/m l, respectively, b : L a n e  1: DX3 su p e rn a ta n t. L a n e  2: C ontrol 
su p e rn a ta n t. L a n e s  3 -5 : S u p e rn a ta n ts  from  cells s tim u la te d  w ith  
F ra c ta lk in e  a t  10, 20, a n d  50 ng/m l, respectively, c : L a n e  1: C ontrol 
(u n stim u la ted ) CH M E3 su p e rn a ta n t. L a n e s  2 -4 : S u p e rn a ta n ts  from  
cells s tim u la te d  w ith  M C P1 a t  10, 20, an d  50 ng/m l, respectively, 
d : L a n e  1: C ontro l C H M E3 su p e rn a ta n t. L a n e s  2 -4 : S u p e rn a ta n ts  
from  cells s tim u la te d  w ith  IL-8 a t  10 ,2 0 , an d  50 ng/m l, respectively.
same as control levels, and MMP9 production was 
markedly increased. Stimulations with cytokines and 
chemokines all caused a comparable increase in gelati­
nase band intensity. Rat microglia have been previ­
ously shown to respond to hum an chemokines in chemo­
taxis experiments in vitro (Cross and Woodroofe, 1999).
The chemokines tested, MCP1 (Fig. 3c), M IPla/p, 
RANTES, IL-8 (Fig. 3d), and Fractalkine, were all 
shown to cause an increase in both MMP2 and MMP9 
in CHME3 cells, and these were increased by compa­
rable amounts by the different chemokines. TNFa at 1 
and 10 ng/ml afso increased MMP2 and -9 above control 
levels, although the effects were not seen using IL-ip at 
the same concentrations (not shown). Bands were dem­
onstrated to be metalloproteinases by the addition of 
EDTA to the incubation buffer in some of the gels. 
Gelatin gels were stained blue throughout, and the 
bands of degradation normally observed did not appear 
(not shown).
uPA ELISA
Urokinase secretion in unstimulated and MCP1-, 
M IPIa-, MIPip-, and RANTES-stimulated CHME3 
supernatants was assessed by ELISA. The mean, un­
stimulated level of uPA from three individual experi­
ments was 1.1 ng/ml, and this was significantly reduced 
in three of three experiments by all of the chemokines 
tested a t 50 ng/ml (Fig. 4). uPA secretion was also 
significantly reduced by MCP1 stimulation at 20 ng/ml.
DISCUSSION
The presence of MMPs has been under much investi­
gation in a number of CNS disease states, including 
stroke (Todor et al., 1998), MS (Anthony et al., 1997), 
Alzheimer’s disease (Yamada et al., 1995), and brain 
tumours (Freidberg et al., 1998). We have investigated 
the secretion of MMPs, TIMPs, and uPA by microglia 
and the influence of chemokines and other inflamma­
tory cytokines on their secretion. Our results show that 
all the chemokines tested were able to up-regulate 
CHME3 cell secretion of MMP2 and TIMPs 1 and 2 in 
ELISA experiments and up-regulated MMP2 and -9 in 
cultured ra t microglia. This may suggest a  potential 
role for chemokines in the regulation of breakdown of 
the blood-brain barrier and demyelination in MS as 
well as their role in chemotaxis of inflammatory cells, 
including microglia, in vitro (Cross and Woodroofe, 
1999) and their postulated role in the recruitment of T 
cells and resident microglia to areas of inflammation 
and tissue damage. MMPs produced by microglia could 
contribute to the formation of the plaque in MS by 
proteolysis of myelin and also by aiding migration of 
microglia through the extracellular matrix in response 
to chemoattractants produced at the site of inflamma­
tion. Baseline levels of TIMP1 were higher than TIMP2 
in CHME3 cells, although both were constitutively 
expressed by resting cells in culture after 24 h. Pagen- 
stecher et al. (1998) found tha t MMP gene products and 
TIMP gene products coincided with sites of inflamma­
tion and tissue damage in EAE and suggested a “dy­
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Fig. 4. Secretion  o f u rok inase-type  p lasm inogen  ac tiv a to r  by  CHM E3 cells, show ing dow n-regu la tion  of 
uPA  in  th e  su p e rn a ta n t  o f cells s tim u la te d  w ith  chem okines. ELISA  resu lts  show th e  m ean  o f th re e  
in d iv idual experim en ts. ^S ignificant decrease  below contro l levels (P  <  0.05).
namic state” in which the levels of each of these 
proteins and their interaction may determine the ex­
tent of the inflammatory lesion. Although the levels of 
MMPs and TMPs cannot be compared directly in these 
experiments owing to the nature of the ELISA specifici­
ties (i.e., the ELISA for MMP2 measures both free 
proenzyme and that bound to the inhibitor but not 
active enzyme), preliminary experiments in our labora­
tory show the presence of MMP2 in culture superna­
tants after just 2 h in culture, whereas TIMP1 was not 
detectable a t this time, suggesting tha t there may be a 
time lag in the secretion of the inhibitor. This would 
allow initial MMP activity, which is then regulated by 
TIMP secretion as well as other factors involved in 
activation of proenzymes. Further experiments are in 
progress to investigate this. The up-regulation of both 
gelatinases and TIMPs by chemokines may be a regula­
tory mechanism to limit and tightly control extracellu­
lar matrix breakdown. It has also been shown (Hay- 
akawa et al., 1992) that TIMP1 has cell growth- 
promoting activity and therefore could be beneficial to 
remyelination of axons. It is also likely that the plas­
minogen activator cascade will fit into this model, by 
exerting an effect on the extent of pro-MMP activation. 
Plasminogen activators are involved in the tightly 
regulated cascade as they cleave plasminogen to plas­
min, which activates pro-MMPs and also degrades 
several components of the extracellular matrix alone 
(Vassalli and Pepper, 1994). CHME3 cells were shown 
to secrete constitutively a urokinase-type plasminogen 
activator, and all the chemokines tested significantly 
reduced the amount of uPA in the supernatant when 
cells were stimulated for 24 h with chemokine a t a 
concentration of 50 ng/ml. This may he due to an 
increase in the number of uPA receptors on the cell 
surface or an increase in the binding affinity of uPA for
its receptor. Ongoing research in this laboratory will 
examine this further and should determine the effects, 
if any, of chemokines on plasminogen activator recep­
tors.
Several protease inhibitors have been shown to have 
an effect on EAE. An inhibitor, D-penicillamine, was 
found to decrease gelatinase A and B activity in CSF 
from patients with multiple sclerosis or optic neuritis 
and also reduced mortality and morbidity in mice 
developing acute demyelination in EAE (Norga et al., 
1995). The metalloproteinase inhibitor Ro31—9790 was 
found to prevent disease onset when given to ra ts  a t the 
same time as induction of EAE (Hewson et al., 1995). 
The inhibitors of MMPs are important considerations 
in the treatm ent of MS, but it is becoming clear th a t the 
molecules that up-regulate the MMPs, such as the 
chemokines, are also important targets for potential 
therapies to restore the balance of MMP and TIMP 
activities. This study provides a base for further re­
search, which should include inhibition of chemokine- 
stimulated gelatinase production by microglia, using 
chemokine and/or MMP inhibitors.
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